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8 | Chapter 1
Until the discovery of the AB0-bloodgroups in the early 1900s blood transfusions were a 
high-risk procedure: more than 50% of the recipients of blood died. Th e discovery of the 
AB0-bloodgroups followed by the development of citrate as anticoagulant to prevent clotting 
of blood enabled the start of transfusion medicine. Both World Wars and other disasters in 
the 20th century had a large impact on further development and structural organization 
of transfusion medicine. Before the introduction of centrifugation techniques in the 1960s 
whole blood transfusions were used. Since blood component transfusion of red blood cells, 
platelet concentrates and plasma became possible over time, red blood cell transfusions 
became gradually considered as a safe therapy for blood loss and other causes of anaemia. 
For decades a threshold of 6.2 mmol/l (10.0 g/dl) was used empirically as a transfusion 
trigger. In the 1970s the possibility of transfusion-induced immune suppression and in the 
1980s the risk of transfusion transmitted infections (eg. human immunodefi ciency virus or 
hepatitis) resulted in a more critical attitude towards blood transfusions and attention for 
the risk of blood transfusions [1]. Subsequently studies on evidence-based blood transfusion 
management were designed and surveillance registrations of side eff ects of blood transfusions 
were started; a process which is still ongoing. 
 Nowadays every year about 75 millions of blood units are collected and transfused 
worldwide, thereby yearly saving thousands of lives, facilitating more complex surgery and 
making transfusion of diff erent blood components indispensibale for the treatment of many 
diseases [2]. Th e development of modern transfusion medicine represents one of the greatest 
achievements of medicine in the 20th century.
 Of all donated units, 60-70% is transfused in surgical settings, in intensive care units 
or in acute situations. In the Western World yearly 50-70 per 1.000 patients receive a blood 
transfusion per year [3,4], while at the age of 80 years approximately one in fi ve persons has 
been transfused [5]. It is expected that with aging, more complex surgery and increasing 
treatment options for hemato-oncological diseases the demand for allogeneic blood 
transfusions will increase. 
 Red blood cell (RBC) units are prepared by removing the plasma from the whole 
blood (with a volume of 450-500 ml) collected from voluntary donors. To maintain cell 
viability during storage, as replacement of plasma, an additive solution is used. RBC units 
have a volume ranging between 250-300 ml and have a hematocrit of 55-65%, equal to 
135-180 ml of erythrocytes. Transfusion of one unit of RBC increases the hemoglobin (Hb) 
concentration of the recipient by approximately 0.6 mmol/l (1.0 gr/dl). Obviously this 
increase shows a huge variation depending on patient’s clinical condition, weight and height 
and the conditions of RBCs in the unit [6]. Th e rationale of blood transfusion is to increase 
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oxygen transport capacity by increasing the Hb concentration aiming an adequate tissue 
oxygenation. To compensate for anemia the body has adaptive systems such as an increase of 
the cardiac output, redistribution of the blood fl ow and increase of the 2,3-diphosphoglycerate 
(2,3-DPG) in red blood cells, which causes a shift  to the right of the oxygen dissociation 
curve [7,8]. If these compensatory mechanisms fail, the patient’s outcome without red blood 
cell transfusions can be fatal. In children an increase in mortality was found when the Hb 
concentration fell below 2.5 mmol/l (4.0 g/dl) [9]. A retrospective cohort of adult surgical 
patients refusing blood transfusions for religious reasons showed only a small risk of death 
of 1.3% when preoperative Hb concentration was more than 7.5 mmol/l (12.0 g/dl), while 
the risk of death increased to 33.3% when the preoperative Hb concentration was less than 
3.8 mmol/l (6.0 g/dl). Th is risk of death increased most in anemic patients with cardiovascular 
diseases and older age [10]. However, despite ample sophisticated research the precise margin 
between benefi cial and deleterious eff ects of allogeneic blood transfusions, their mechanisms 
and the exact threshold for transfusions of blood components on morbidity and mortality 
are still not well defi ned. Clinical and laboratory studies in transfusion medicine are still 
ongoing to solve these important questions.
Th e Risks of Allogeneic Blood Transfusions
Th e safety of blood transfusions is optimal, although will never be maximal and there 
will always be risks. In well-resourced countries blood is collected from voluntary donors. 
Th ey undergo a risk profi le by a health questionnaire, which aims to identify any potential 
risks as well for the donor as for the recipient. Due to stringent donor selection, improved 
mandatory tests and close surveillance of new emerging infections the risk of transfusion-
transmissible infections is very low. Th erefore in well-resourced countries the concern 
regarding adverse transfusion eff ects shift ed to non-infectious complications. With the aim 
to show transfusion safety at one hand and at the other hand to get insight in transfusion 
complications, in several countries the adverse reactions and events associated with blood 
transfusions are reported in national surveillance systems. Since 2003 the Dutch Foundation 
for Hemovigilance, Transfusion Reactions In Patients, (TRIP) collects all information about 
transfusion-associated reactions in the Netherlands. In 2009 2.384 transfusion reactions 
were reported to TRIP. Th at year the national (and only) blood supply organisation in the 
Netherlands, the Sanquin Blood Supply Foundation, delivered 699.720 blood products 
(559.976 RBC units, 49.354 platelet units and 90.390 plasma units). Th is means an average 
incidence of transfusion reactions of 3.4 per 1.000 blood components [11]. Th e incidence of 
more serious events was 98 (0.14 per 1.000 blood components). Transfusion reactions can 
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be divided into non-immune-mediated and immune-mediated reactions. Th e incidences of 
these reactions are summarized in Table 1. 
Non-Immune Mediated Transfusion Reactions
Non-immune mediated transfusion reactions involve transmission of infectious agents 
(bacteria, viruses, parasites or prions) and complications such as transfusion-associated 
circulatory overload (TACO) and hemosiderosis.
Table 1 | Incidences of Adverse Eff ects of Allogeneic Blood Transfusions







  Hepatitis B
  Hepatitis C 
  Parvo B19
  Parasites
  Prions
RBC 1:1.000; platelets 1:2.000







Transfusion-associated circulatory overload (TACO) 2-8:100
Iron-deposition; hemosiderosis Starts aft er >20 units RBCs
Immune-mediated
Acute hemolytic transfusion reactions
Delayed hemolytic transfusion reactions








Transfusion-associated graft  versus host disease (TA-GVHD) <1:1.000.000 
Post-transfusion purpura (PTP) <1:1.000.000
Transfusion-related acute lung injury (TRALI) 1:1.000-5.000
Transfusion-transmitted infections through bacteria are mainly caused by contamination of 
blood products from skin-commensal bacteria derived from the donor’s puncture site. Occult 
bacterial infections in the donor rarely cause blood-borne infections [12]. Th e incidence of 
bacterial contamination estimates 0.4% of RBC transfusions, while transfusion-associated 
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sepsis (TAS) occurs in 1 per 250.000 RBC transfusions [13]. Platelet concentrates are more 
prone for bacterial contamination, because they are stored at a higher temperature than RBCs 
(20-24oC versus 2-6oC). Approximately 1 per 2.000 platelet concentrates is contaminated 
by bacteria. In the literature, bacterial contamination accounts for 10-18% of transfusion-
related fatalities [13]. In 2009, total 43 cases of bacterial contamination were reported to 
TRIP, only one of them caused TAS due to a blood product which was contaminated [11]. 
Because routine bacterial culture of platelet products may miss some contaminants, more 
sophisticated detection techniques or pathogen-inactivation methods are in development to 
further reduce bacterial contamination of blood products [14]. 
 Due to genomic amplifi cation testing, transfusion-transmission of human 
immunodefi ciency virus (HIV) or hepatitis viruses has declined over the last decades. 
Th e estimated residual risk for transfusion-transmitted HIV infection is 1 per 7.8 million 
donations, for hepatitis B infection 1 per 800.000 donations and for hepatitis C infection 1 
per 3 million donations [15]. In 2009 in the Netherlands 6 post-transfusion viral infections 
were reported to TRIP, of them one case of hepatitis B infection could be directly related 
to blood transfusions [10]. Prestorage leukocyte-depletion of blood transfusions can reduce 
the transmission of leukotrophic viruses, such as cytomegalovirus (CMV) and Epstein-
Barr virus (EBV). Since the implementation of leukocyte-depleted blood transfusions, 
no infections due to transmission of these viruses have been reported in the Netherlands 
[11]. Due to depression of the hematopoiesis Parvovirus B19 infection can be deleterious 
in patients with hemolytic anemia, immunocompromised patients and pregnant women 
because transmission to the foetus. Transmission of Parvovirus B19 is not common and is 
prevented by selection of donors with neutralizing antibodies, these B19-safe blood products 
are indicated for patients at risk [16]. Due to increased travelling more viruses and parasites 
are imported to non-endemic areas. Transfusion-transmission of import pathogens, such as 
West Nile virus (WNV), Chikungunya virus, malaria and Chagas disease (endemic in South 
and Central America caused by the parasite Trypanosoma cruzi), is prevented by stringent 
donor screening and testing on indication [17]. In the Netherlands there are as yet no reports 
of transfusion-transmitted infections from import viruses or parasites.
 Since the 1990s there is concern about transfusion-transmission of prions leading to 
variant Creutzfeld-Jakob disease (vCJD). Th e incidence of vCJD is mainly concentrated in 
the United Kingdom where more than 75% of the known cases of vCJD have been recorded 
[18]. Th ree probable cases (1.7% of all cases of vCJD) have been reported in the United 
Kingdom in patients who had received blood products from donors who later developed 
vCJD [19]. As a preventive measure donors who resided until 1985 in the United Kingdom 
12 | Chapter 1
for more than six months are refused as blood donors in the Netherlands. To date no 
transfusion-related transmission of vCJD is known in the Netherlands [11].
 Besides transfusion-transmittable infections, an important non-immune mediated 
transfusion complication is transfusion-associated circulatory overload (TACO). TACO 
refers to pulmonary edema aft er transfusion of blood products. Recipients with renal 
or cardiac diseases and older patients are more susceptible for TACO, which is a serious 
underreported complication of blood transfusions. A retrospective analysis in elderly 
patients who underwent orthopedic surgery revealed an incidence of 2% aft er red blood 
cell transfusions and this could be up to 8% dependent on co-morbidity and age, with a 
fatality rate varying between 5 to 20% [20]. Because TACO is an underreported transfusion 
complication, the exact incidence is not known. Th e treatment of TACO consists of volume 
reduction with eventually ventilatory and/or circulatory support. More important is to 
prevent the risk of TACO by a restrictive transfusion strategy or the use of diuretics in 
patients with underlying cardiac and/or renal disease or elderly patients. Discrimination 
between TACO and transfusion-related acute lung injury (TRALI) can be diffi  cult.
 Hemosiderosis is inevitable in patients who chronically receive blood transfusions 
over years. Each RBC unit contains about 200 mg of iron, while from daily food only 1-2 
mg iron is absorbed from the intestines. Each year adds 5-8 gram iron to the body stores of 
chronically transfused patients. Th e deposition of iron results in damage to the heart, liver 
and endocrine organs. Two-thirds of the patients with transfusion-related hemosiderosis die 
from heart failure [21]. Iron chelation therapy is advised aft er 20 units of RBCs or when the 
concentration of ferritine exceeds 1.000 mcg/l and the patient requires repeated transfusions 
with a life expectancy of more than 1 year. 
Immune-Mediated Transfusion Reactions
Most reported transfusion reactions are immune-mediated [11]. Th ese reactions are oft en 
distinguished in acute and delayed haemolytic transfusion reactions, febrile febrile non-
hemolytic transfusion reactions, allergic transfusion reactions, transfusion-associated graft  
versus host disease, post-transfusion purpura and transfusion-related acute lung injury.
 Current estimates show that acute hemolytic transfusion reaction (AHTR) occur in 
1 per 18.000 transfused blood units and the mortality rate ranges between 1 per 600.000-
1.800.000 units. AHTR develops within 24 hours aft er transfusion and is due to intravascular 
and/or extravascular destruction of erythrocytes [22]. Incorrect blood transfusion due to 
ABO-incompability is the main cause of fatal AHTR, which can occur in patients with high 
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antibody titres aft er administration of only 5-20 ml of blood [23]. In the Netherlands 60 cases 
of various kinds of incorrect blood transfusions were reported in 2009; fortunately none of 
these reactions led to death [11]. Delayed hemolytic transfusion reactions (DHTR) occur 
24 hours to 28 days aft er blood transfusion and are caused by boosted RBC allo-antibodies 
in patients sensitized by previous blood transfusions or pregnancy. Th ese antibodies are 
too weak to be detected by the compatibility testing prior to transfusion. In the literature, 
DHTRs occur in 1 per 2.500-4.000 RBC transfusions and mostly these reactions have a 
mild course; however fatal DHTRs can occur [24]. In the Netherlands 8 cases of DHTRs are 
reported to TRIP in 2009; while 753 newly diagnosed antibodies aft er blood transfusions 
were reported [11]. 
 Febrile non-hemolytic transfusion reactions (FNHTR) are the most common 
adverse eff ect of blood transfusion. FNHTR is defi ned as a raise in body temperature of 2°C 
or more which occurs within 2 hours aft er a blood transfusion. FNHTR has an incidence 
of between 1 to 7% and one of the causes is a reaction between antibodies of the recipient 
against incompatible human leukocyte antigens (HLA) from the donor. Th is reaction 
is largely prevented by leukocyte-depletion of cellular blood products. Other identifi ed 
causes are a response of recipient’s leukocytes to cytokines in blood from the donor or 
accumulation of pyrogenic mediators during storage of blood products [25]. Observational 
studies documented since the implementation of leukocyte-depleted blood transfusions a 
signifi cant reduction of almost 50% in the incidence of FNHTRs [26,27]. In 2009, 35% of the 
reported transfusion reactions were due to FNHTR, which is stable since the start of TRIP 
in 2003 [11]. 
 Mild allergic transfusion reactions are common as well (1-3% of blood transfusions) 
and are mostly self-limited. Although severe anaphylactic transfusion reactions are rare, with 
an estimated incidence of 1 per 20.000-47.000 transfusions. In 2009, 69 cases of anaphylactic 
reactions were reported in the Netherlands [11]. Causes of allergic or anaphylactic reactions 
are hardly unravelled. Although IgA-defi ciency associated with anti-IgA antibodies in the 
recipient who is transfused with IgA-containing blood products is oft en presumed, this cause 
of severe anaphylactic reactions is seldom identifi ed. Despite IgA-defi ciency with presence 
of IgA-antibodies having a high incidence of 1:1.200; IgA-antibodies have been found in 
less than 20% of suspected cases with severe allergic reactions [28]. As a preventive measure 
patients these patients should receive washed blood transfusions or blood products from 
IgA-defi cient donors and should be transfused under appropriate prophylactic conditions. 
 Graft  versus host disease (GVHD) is a common complication of hematopoietic stem 
cell transplantation. GVHD has an incidence of approximately 50% and its presentation can 
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be varying from temporary inconvenience to serious and life-threatening, while transfusion-
associated graft  versus host disease (TA-GVHD) is extremely rare and has a mortality 
rate over 90%. Since the start of TRIP in 2003 no case of TA-GVHD is reported in the 
Netherlands [11]. Immunocompromised patients are at increased risk of TA-GVHD and 
in immune competent recipients TA-GVHD can occur when an HLA homozygous donor 
shares one haplotype with the patient. Th e viable lymphocytes in the blood product then 
respond to the foreign host HLA antigens [29]. TA-GVHD is prevented by irradiation 
of blood products to patient populations at risk. Leukocyte-depletion of blood products 
reduces the risk of TA-GVHD, but is considered inadequate for prevention.
 Another extremely rare complication with only one reported case since 2003 in the 
Netherlands is post-transfusion purpura (PTP), which is characterized by the development 
of severe thrombocytopenia occurring 1-24 days aft er an allogeneic blood transfusion [11]. 
PTP can develop in patients who are sensitized (by previous transfusion or pregnancy) to a 
human platelets antigen (HPA) [30]. Most patients with PTP recover in approximately two 
weeks, although PTP can result in severe bleeding. In emergency the fi rst choice of treatment 
in PTP is with high-dose intravenous immunoglobins. Patients with a documented history 
of PTP are advised to receive cellular blood components that are antigen-negative for the 
platelet antibody.
 A leading cause of transfusion-associated mortality is transfusion-related acute lung 
injury (TRALI), which is estimated to occur aft er 1:1.000 to 5.000 blood transfusions with an 
estimated mortality rate of 5-10% [31]. Since the start of registration of transfusion reactions 
by TRIP the reported cases of TRALI raised from 7 in 2003 to 21 in 2008, which is mainly 
the result of awareness of physicians [11]. TRALI is a serious life-threatening condition and 
is probably still underreported. According to an international agreed defi nition, the onset of 
TRALI is within 6 hours aft er blood transfusion [32]. Th e pathophysiology of TRALI has 
not been completely clarifi ed yet and is the fi nal result of a cascade of neutrophil priming, 
activation and endothelial damage [33]. One of the causes is passively transfused anti-
leukocyte antibodies in the donor’s plasma, which bind to antigens on patient’s neutrophils 
and initiate priming and activation with release of cytokines, proteases and free oxygen 
radicals. Neutrophil sequestration in the lung is fi nally leading to endothelial damage and 
capillary leakage. Such antibodies, mostly directed against HLA class I and II or human 
neutrophil-specifi c antigens (HNA), are mainly found in multiparous female donors [34]. As 
a preventive method since end 2007 in the Netherlands, fresh frozen plasma is only derived 
from non-transfused male donors. Since this implementation the reported cases of TRALI 
was reduced from 21 to 12 in 2009 [11]. Besides leukocyte antibodies there is circumstantial 
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evidence that other insults such as bio-active lipids accumulating in stored erythrocytes, 
CD40 ligand in platelet products and cytokines involved in infections can prime neutrophils 
to adhere to the vascular endothelium [34]. Consequently, TRALI occurs more oft en in 
patients in whom leukocytes are already primed due to an underlying condition associated 
with pro-infl ammatory mediators in which other factors can act as a second hit [35]. Th e 
clinical presentation of TRALI can be very similar to TACO [35,36]. It has been suggested 
that markers in plasma as elevated pro B-type natriuretic peptide (pro-BNP) levels may be 
helpful to discriminate TACO from TRALI [37]. Other possible diff erences between both 
underreported serious transfusion reactions are summarized in Table 2. 
Table 2 | Possible Diff erences between Transfusion Related Acute Lung Injury (TRALI) and 
Transfusion Associated Cardiac Overload (TACO)
Symptoms TRALI TACO
Onset of symptoms <6 hours Mainly <6 hours
Respiratory symptoms Dyspnea Dyspnea
Central venous pressure Normal Increased
Pulmonary wedge pressure Normal Increased
Fluid balance Positive or negative Positive
X-ray thorax Bilateral infi ltrates Bilateral infi ltrates with signs of fl uid overload
Echocardiography Normal ejection fraction Decreased ejection fraction
B-type natriuretic peptide Low or normal High
TRALI, AHTR and TAS were the leading causes of reported transfusion-associated 
mortality in the UK and USA [38]. However, besides these clinically manifest transfusion 
reactions, several studies observed that allogeneic blood transfusions lead in selected clinical 
circumstances to higher morbidity and mortality compared to non-transfused patients with 
the same conditions. If a relationship with transfusions would be causal, the fatality rate of 
these occult complications would greatly exceed the hitherto reported rates by surveillance 
registries. Th ese unsolved questions opened in diff erent clinical settings new and more 
evidence-based and multi-disciplinary clinical research, in particular in patients undergoing 
cardiac surgery or staying in the intensive care unit (ICU), because these patients receive 
large amounts of blood products. 
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Allogeneic Blood Transfusions in Cardiovascular Disease and in Cardiac Surgery
Due to a more critical oxygen delivery to the myocardium, patients with cardiovascular disease 
are less tolerant to anemia than others. Blood transfusions for  anemic patients with ischemic 
heart disease are intended to improve oxygen delivery to the myocardium and thereby the 
patient survival [39,40]. Cohort studies in patients with cardiovascular diseases, documented 
that at one hand anemia was associated with an increase in mortality and at the other hand 
that RBC transfusions may cause more congestive heart failure [41,42]. In a large cohort of 
78.974 patients older than 65 years with acute myocardial infarction, patients with lower 
hematocrit (Ht) levels had a higher 30-day mortality rate and RBC transfusions signifi cantly 
reduced the mortality rate in patients with a Ht level of less than 30% at admission [43]. 
In contrast, a post hoc analysis derived from three large cardiovascular studies showed that 
patients with an acute coronary syndrome who had received RBCs had (aft er adjustment for 
other predictive factors) signifi cant higher 30-day mortality than non-transfused patients 
[44].
 Coronary artery bypass graft  (CABG) surgery is a frequently performed intervention 
to re-vascularise the myocardium. Worldwide more than 800.000 patients are undergoing 
cardiac surgery annually. In the Netherlands, with 16.000.000 inhabitants, approximately 
17.000 patients (38% of them are valve replacements) are undergoing cardiac surgery every 
year [45]. Th e current mortality and morbidity rate aft er cardiac surgery is low and cardiac 
surgery has become a routine procedure also for older patients with more co-morbidities. 
Although the number of patients that receive blood transfusions and the numbers of 
transfused blood products became lower in time, patients undergoing cardiac surgery 
still receive more blood transfusions compared to most other surgical settings. Due to 
hemodilution and consumption of coagulation factors and platelets in the extracorporal 
circuit patients undergoing cardiac surgery can develop severe bleeding complications. 
Despite blood-sparing developments, reducing the need of blood transfusions, cardiac 
surgery still consumes a large proportion of RBC transfusions, estimated approximately 20% 
of the total blood supply [46]. 
 In cardiac surgery preoperative as well as postoperative anemia are important 
prognostic factors for outcome. A pre-operative Hb level below 6.2 mmol/l (10.0 g/dl) is 
associated with higher mortality rate compared to patients with higher Hb values [47]. It 
has been observed that preoperative anaemia is associated with increased risk of stroke or 
kidney failure [48,49]. Furthermore, the nadir of the Hb concentration during cardiac surgery 
is related with worse adverse outcome [47] and massive blood loss is associated with an 8-fold 
increase in mortality [50].
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Maybe infl uenced by diff erent clinical risk factors, such as age, co-morbidity and preoperative 
Hb values the transfusion rates for CABG used to show great variability between hospitals 
with a mean number of transfused units varying between 0.4 to 6.3 units per patient [51,52]. 
Several observational studies showed that the peroperative administration of RBCs was the 
most constant factor associated with mortality and morbidity and was dose-dependently 
associated with postoperative infections and higher mortality [53,54]. In a prospective study 
in cardiac surgery, 4.8% of patients who did not receive RBCs, suff ered from postoperative 
infections contrasting with 29% in patients who received 6 or more RBC units [55]. Not only 
short-term (30-and 90-day) mortality was infl uenced by transfusion of RBCs, also 1-year, 
5-and 10-year postoperative mortality was found to be increased in transfused compared 
to non-transfused patients undergoing the same type of cardiac surgery [56-59]. However all 
these studies were retrospectively designed and provide by no means proof of a causal role of 
allogeneic RBC transfusions on postoperative morbidity and mortality aft er cardiac surgery, 
where many other factors infl uence the outcome. 
 Patients undergoing cardiopulmonary bypass develop systemic infl ammatory 
reactions. Its magnitude and the capacity for reversal may determine outcome. Generation 
of infl ammatory mediators may be associated with more complex and longer surgery, 
whereas these patients receive also larger amounts of blood transfusions. It is postulated that 
allogeneic blood transfusions could play an additional role (second-hit) in the development 
of postoperative complications. 
Anemia and Blood Transfusions in the Intensive Care Unit 
Aft er cardiac surgery, patients generally stay at an intensive care unit (ICU) for as long 
as mechanical ventilation and cardiac inotropic drug support is needed. Anemia is oft en 
encountered in the ICU in surgical patients and is of multifactorial origin. Multiple blood 
sampling, blood losses due to gastro-intestinal tract bleeding or surgical reasons are the main 
reasons [60]. Daily multiple blood sampling amounts on average 41 to 66 ml at medical-
ICUs and up to 377 ml/day at cardiothoracic ICUs [61-63]. Th e amount of blood loss drawn 
for diagnostic sampling turned out to be the most signifi cant predictor for the receipt of 
blood transfusions [64]. Besides, hemodilution by abundant intravenous infusions, decreased 
RBC production due to iron-defi ciency and inappropriate erythropoietin-response due to 
infl ammatory mediators in critically ill patients, reduced RBC survival and increased (drug-
induced) hemolysis may contribute further to postoperative anemia in ICU patients [65-67]. 
 Lacking evidence-based transfusion triggers, anemia is oft en corrected with RBC 
transfusions. Several large observational studies investigated the incidence of anemia and the 
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trends of blood transfusions therapy at the ICU. In the USA an observational multicenter 
study comprising 4.892 patients across 284 ICUs found that more than 60% of the patients 
developed an Hb value less than 7.5 mmol/l (12.0 gr/dL), of which 44% received one or 
more RBCs. Low Hb value, without evidence of active blood loss, was in 90% the reason 
to transfuse with RBCs. In particular older patients and patients with a longer ICU-stay 
were at risk for transfusions [68]. In 1995, 85% of patients staying longer than 1 week at 
the ICU received a mean of 9.5 RBC units per patient [69]. Despite several blood-sparing 
developments this transfusion practice hardly changed in the following ten years [68]. A 
prospective observational study in several ICUs in Europe comprising 3.534 patients found 
comparable results [70]. Approximately 29% of the patients reached a Hb value of less than 
6.2 mmol/l (10.0 gr/dl) with a transfusion rate of 37%. Of the patients with an ICU-stay 
longer than 7 days, 73% had received RBC transfusions. Overall mortality was almost twice 
as high in patients who received allogeneic RBC transfusions compared to patients who were 
not transfused. 
 In critically ill patients, blood transfusions have been associated with mortality, 
ventilator-associated pneumonia, acute respiratory distress syndrome (ARDS) and 
bloodstream infections [71-75]. Besides RBC transfusions, also fresh frozen plasma and 
platelet units were reported to contribute to complications at the ICU [76,77]. However, 
these patients represent heterogeneous patient population with complex illnesses. Studies 
performed in more homogenous patient cohorts, such as in 666 patients with major 
burn injury revealed that the number of RBCs was associated with mortality and the risk 
of infection increased with each unit of blood transfused [78]. In a large study in 9.539 
trauma patients, blood transfusions within the fi rst 24 hours were associated with systemic 
infl ammatory response syndrome (SIRS) and mortality [79]. 
 In the past, RBC transfusions were administered according to an arbitrary Hb trigger 
of 6.2 mmol/l (10 gr/dl) [80]. Th e Transfusion Requirements in Critical Care (TRICC) trial 
compared for the fi rst time a restrictive transfusion strategy (maintaining hemoglobin level 
between 4.3-5.6 mmol/l [7.0-9.0 gr/dl]) with a liberal transfusion strategy (maintaining 
hemoglobin level level of more than 6.2 mmol/l [10.0 gr/dl]). Th e liberal strategy group 
had compared to the restrictive strategy group no benefi t in 30-day and hospital mortality. 
Moreover pulmonary edema and ARDS occurred more oft en in the liberal group [81]. Also 
subgroup analysis in patients with coronary artery disease revealed similar 30-day mortality 
in restrictive and liberal transfusion strategy groups [82]. Th ese fi ndings changed the 
transfusion policy of red blood cells in the ICU completely. In contrast with this randomized 
controlled trial, a retrospective observational single-center study in 2.393 patients found an 
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association with a hematocrit level less than 25% upon admission to the ICU and 6-month 
and 1-year mortality [83]. Patients at ICU represent a very heterogeneous population with 
various complex pathology. Th erefore it is diffi  cult to determine the eff ects of anemia and 
blood transfusions in this population. To unravel an association between blood transfusions 
and outcome, research in more matched patient populations is important. 
Clinical Relevance of Transfusion-Related Immunomodulation 
In the 1970s, it was discovered that pre-transplantation blood transfusions improved a 
subsequent renal allograft  survival [84]. It was presumed that a similar immune suppressive 
transfusion eff ect could lead to impaired cancer surveillance enhancing cancer recurrence aft er 
curative surgery and to susceptibility for postoperative infections [85-87]. Many observational 
studies reported that allogeneic blood transfusions were indeed associated with increased 
bacterial infections in patients undergoing abdominal surgery. Th ese possible adverse eff ects 
of blood transfusions, which are not registered in national surveillance systems, are referred 
as transfusion-related immunomodulation (TRIM). Th e presumed magnitude of TRIM 
would be much larger than the recognized adverse transfusion reactions reported to the 
national surveillance systems [88].
 Th e existence and possible mechanisms of TRIM are not yet fully discovered. Many 
factors might contribute to TRIM. Allogeneic leukocytes and (leukocyte-derived) soluble 
mediators in blood products are considered as most important [89]. Th rough fi ltration the 
number of allogeneic leukocytes in donated blood can be reduced by more than 99.9% with 
a residual leukocyte count of less than 1x106/L. Leukocyte-depleted (or leukocyte-reduced) 
blood transfusions were applied since the 1980s to reduce non-hemolytic febrile transfusion 
reactions, HLA allo-immunisation and CMV transmission in patients at risk. In early 2000s 
in several European countries and in Canada universal leukocyte-depletion of allogeneic 
blood transfusion was implemented. In the Netherlands in 2002 universal leukocyte-
depletion for blood transfusions was introduced as precautionary measure assuming to 
prevent viral infections and vCJD. Th e benefi ts of universal leukocyte-depletion are still 
controversial.
 To investigate the clinical eff ects of TRIM several studies have been performed 
comparing leukocyte-containing with leukocyte-depleted blood products in diff erent, 
mainly surgical, clinical settings. In particular patients undergoing cardiac surgery form a 
more homogeneous population and are at risk to receive large amounts of blood transfusions. 
In 1998 a Dutch randomized controlled trial in patients undergoing CABG, with or without 
valve replacement, compared standard buff y-coat depleted RBCs (containing 20-30% of 
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the donor leukocytes) with by fi ltration leukocyte-depleted RBCs [89]. Patients receiving 
more than 3 units RBCs had a signifi cant reduction in postoperative infections and 60-day 
mortality if transfused with leukocyte-depleted RBCs. Another Dutch study, published in 
1999, found in patients who received non-leukocyte-depleted blood transfusions during 
cardiac surgery an increase in concentrations of infl ammatory mediators [90]. Th e fi ndings 
from both studies suggest that allogeneic blood transfusions during cardiac surgery could 
play a role in postoperative outcome by contribution to an infl ammatory response. Th is 
opened a new fi eld in transfusion medicine: the causes and eff ects of TRIM, especially in 
cardiac surgery. 
SCOPE OF THIS THESIS
Th e predominant research question is whether and how the presence of leukocytes in 
allogeneic blood transfusions have a clinical deleterious eff ects in cardiac surgery patients. 
Th ese questions form the basis of this thesis evaluating clinical adverse transfusion eff ects, 
their nature and possible mechanisms of leukocyte-containing blood transfusions in cardiac 
surgery. For this purpose we conducted a randomized controlled trial (RCT) to confi rm 
the results found in subgroup analysis in a former study. For this study, patients undergoing 
complex cardiac surgery, who are more extensively transfused, were selected. Aft er confi rming 
an adverse role of allogeneic leukocytes in red blood cell transfusions, we aimed to identify 
mechanisms how transfusion-related factors could infl uence the outcome aft er cardiac 
surgery. 
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ABSTRACT
Background: Leukocytes in allogeneic blood transfusions are believed to be the cause of 
immunomodulatory events. A few trials on leukocyte removal from transfusions in cardiac 
surgery have been conducted, and they showed inconclusive results. We found in a previous 
study a decrease in mortality rates and number of infections in a subgroup of more heavily 
transfused patients. 
Methods: Patients (n=496) undergoing valve surgery (with or without CABG) were 
randomly assigned in a double-blind fashion to receive standard buff y coat-depleted (PC) or 
prestorage, by fi ltration, leukocyte-depleted erythrocytes (LD). Th e primary end point was 
mortality at 90 days, and secondary end points were in-hospital mortality, multiple organ 
dysfunction syndrome, infections, intensive care unit stay, and hospital stay. 
Results: Th e diff erence in mortality at 90 days was not signifi cant (PC 12.7% versus LD 
8.4%; odds ratio [OR], 1.52; 95% confi dence interval [CI], 0.84 to 2.73). Th e in-hospital 
mortality rate was almost twice as high in the PC group (10.1% versus 5.5% in the LD group; 
OR, 1.99; 95% CI, 0.99 to 4.00). Th e incidence of multiple organ dysfunction syndrome in 
both groups was similar, although more patients with multiple organ dysfunction syndrome 
died in the PC group. LD was associated with a signifi cantly reduced infection rate (PC 
31.6% versus LD 21.6%; OR, 1.64; 95% CI, 1.08 to 2.49). In both groups, intensive care 
unit stay and hospital stay were similar, and postoperative complications increased with the 
number of transfused units. 
Conclusions: Mortality at 90 days was not signifi cantly diff erent; however, a benefi cial eff ect 
of LD in valve surgery was found for the secondary end points of in-hospital mortality and 
infections. 
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 INTRODUCTION
Despite blood-sparing developments, blood transfusions still play a pivotal role in many large 
operations. Because of advances in transfusion medicine, allogeneic blood transfusions carry 
minimal risks for transmission of diseases. However, as it has been shown that allogeneic 
blood transfusions impair the immune response against cadaver kidney graft s [1], there 
is concern that blood transfusions could also suppress the recipients immune response 
against cancer and infections [2,3]. Th ese eff ects are oft en referred to as transfusion-related 
immunomodulation (TRIM) [4]. Many factors in transfusions might contribute to TRIM, 
but leukocytes and soluble factors mediated by leukocytes in blood transfusions are considered 
of possible importance [5,6]. Th e depletion of leukocytes by fi ltration of blood products has 
been applied for many years to reduce human leukocyte antigen (HLA) alloimmunization 
and cytomegalovirus transmission for patients at risk. A limited number of clinical studies 
investigated whether leukocyte-depleted erythrocyte concentrates diminish TRIM [6]. 
Th e only prospective, randomized controlled trial (RCT) that compared the recurrence of 
colorectal cancer aft er perioperative transfusions with leukocyte-depleted versus buff y coat-
depleted erythrocytes found no benefi t [7]. Th e eff ect of leukocyte-depleted erythrocytes 
on postoperative infections aft er abdominal surgery has been studied in fi ve RCTs, with 
confl icting results [8-12].
 Generally, in complex cardiac surgery, more erythrocyte concentrates are transfused 
than in abdominal surgery [13]. Two RCTs on cardiac surgery have been performed, and they 
showed inconclusive results on the incidence of postoperative infections [14,15]. Two other 
studies were not focused on cardiac surgery [16,17]. In one study, a nonsignifi cant benefi cial 
diff erence of leukocyte-depleted erythrocytes in severe infections was found [16]; the other 
found no decrease in antibiotic usage, their parameter for infections [17]. We observed in 
one RCT comparing leukocyte-depleted versus buff y coat-depleted erythrocytes in patients 
undergoing coronary artery bypass graft ing (CABG), with or without valve replacement, a 
signifi cant reduction in postoperative infections only in the patients receiving 4 or more units 
[15]. Unexpectedly, in this study, a reduced mortality rate in the group receiving leukocyte-
depleted erythrocytes was found. Th is diff erence was due to the near absence of death by 
multiple organ dysfunction syndrome (MODS) in the patients receiving leukocyte-depleted 
erythrocytes. Th ese results were the reason to initiate a prospective double-blind, 2-center 
RCT to detect possible diff erences in postoperative complications. Th is trial was performed 
in adults undergoing cardiac valve surgery (with or without CABG) because these patients 
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do have a high probability of receiving 4 or more erythrocyte units and have an increased risk 




A prospective, randomized, double-blind controlled trial was conducted between June 
1999 and May 2001 in adult patients older than18 years undergoing valve surgery (with or 
without CABG) in 2 university hospitals (Academic Medical Center and Leiden University 
Medical Center) in Th e Netherlands. Th e ethics review boards of both hospitals approved 
the trial protocol. Th e local trial coordinator collected written informed consent. Patients 
with a medical indication for leukocyte-depleted erythrocytes (LDs) and patients who had 
received blood transfusions within the previous 3 months were ineligible. When blood 
for compatibility testing of the participating patients was sent to the hospital transfusion 
service, the technicians randomly assigned the patients by opening a sealed and numbered 
envelope. Th e patients were randomly assigned into 2 groups: when there was an indication 
for transfusions, one group received buff y coat-depleted packed cells (PCs), which was at 
that time the standard product in Th e Netherlands, and the other group received prestorage 
by fi ltration of LDs. Th e patients, surgeons, anesthesiologists, and the trial coordinators were 
blinded to the random assignment, as the technicians placed uniform study labels on the 
description on the erythrocyte bags. In the hospital electronic information system, a code 
was used during the study period to hide the random assignment. 
 For the assessment of the preoperative risk of the patients, the score model described by 
Parsonnet was applied [18]. Surgical and anesthetic procedures were performed according to 
the standards of the hospitals. Th e hospitals used similar transfusion triggers for erythrocytes, 
plasma, and platelets. Not all patients underwent induced hypothermia (29° to 33°C). In 
one hospital, aprotinin was used in some patients; this hospital had a medium-care ward. 
Prophylactic antibiotics were given to all patients for 48 hours. Aft er surgery, the patients 
were monitored at the intensive care unit (ICU); they were discharged from the ICU when 
there was no more need for inotropes and intubation. 
Blood Products
PCs were prepared by centrifugation of whole blood at 3000 rpm for 10 minutes within 
20 hours aft er withdrawal. Buff y coat and plasma were removed, and erythrocytes were 
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reconstituted with 100 mL saline-adenine-glucose-mannitol. Th e average leukocyte content 
was 0.7 ± 0.4×109 per unit. Th e average hemoglobin content was 59 ± 5 g/unit. LDs were 
prepared before storage within 24 hours aft er withdrawal by passage of the buff y coat-
depleted erythrocytes through a leukocyte fi lter (Cellselect-Optima, NPBI International-
Fresenius HemoCare). Th e average leukocyte content was 0.15 ± 0.02×106 per unit and the 
average hemoglobin content was 54 ± 4 g/unit. Th e quality controls of the blood products 
were according to the requirements of the blood product specifi cations in Th e Netherlands. 
Platelet concentrates were prepared from pooled buff y/coats and were all leukocyte-depleted 
by fi ltration (less than 1x106 leukocytes per product) before storage. 
Data Collection
Preoperative and postoperative clinical and laboratory data and transfusion data were 
registered daily and collected by the local trial coordinator from the patient records and 
the hospital electronic information systems. Th e scoring of organ dysfunction was assessed 
retrospectively on the basis of the daily records. We used parameters for organ dysfunction as 
described by Knaus et al [19]. MODS was defi ned as the failure of less than 2 organ systems. 
Infections were scored according to the criteria of the Centers for Disease Control and 
Prevention [20]. Causes of in-hospital mortality were obtained from the hospital patient 
records, report of mortality at 90 days from the referring cardiologist, or the general 
practitioner. 
End Points and Statistics
Th e primary end point of the study was mortality at 90 days aft er surgery. Secondary end 
points were incidence of in-hospital mortality and the causes of death, incidence of MODS, 
infections during the hospital stay, duration of ICU-stay, and hospitalization. An independent 
safety committee monitored the interim results of the primary end point. 
 Based on the results of the subpopulation in a previous study [15], the trial was 
designed to detect a signifi cant diff erence in mortality between both trial arms of 10% (15% 
versus 5%). To reach statistical signifi cance (p<0.05) and a power of 90%, 210 evaluable 
patients were needed in each arm. To compensate for non-evaluable patients, the target 
number of included patients was 500. 
 Patients were stratifi ed by the type of surgery (valve with or without CABG) and 
by hospital. Within each of these strata, a straightforward randomization was performed 
by using a fi xed block size (n=24) to ensure a balance between the randomization groups. 
Th e fi nal analysis incorporated the stratifi cation structure (2χ2) when estimating the relation 
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between the randomization variable and the various outcomes. Th e analysis for all end points 
was on an intention-to-treat basis. All patients were analyzed according to the original 
random assignment, and no patients were re-assigned. Based on the results of the previous 
study [15], subgroup analysis was performed according to transfusions. For comparison of 
qualitative parameters, the Fisher’s exact test or χ2 test was used, and for comparison of 
quantitative parameters, the t test or Mann-Whitney U test was used. Odds ratios (ORs) and 
95% confi dence intervals (CIs) were used to compare the diff erences of mortality, infections, 
and MODS, calculated according to the Mantel-Haenszel procedure. Th e CI obtained by the 
Mantel-Haenszel procedure is based on a normal approximation. ICU-stay, hospital-stay, and 
duration of MODS were analyzed by means of the Student’s t test. Multivariate analysis of 
the risk factors was performed with the use of an enter/backward logistic regression model. 
For statistical analysis, the SPSS program was used. 
RESULTS
In total, 496 patients were enrolled in the study. Twenty-two patients were excluded for 
various reasons: 8 withdrew consent before the surgery, 6 cancelled surgery, 3 had no valve 
replacement performed, 3 had received blood transfusions in the past 3 months, and 2 died 
before the operation. In each arm, 237 patients were evaluable for the primary end points. 
Two patients (both randomly assigned into the LD group) died during the initial operation. 
Th ese 2 patients were ineligible for the analysis of the secondary end points. Th ree patients 
(all of them randomly assigned into the PC group) died in a second operation (performed 
more than 24 hours later); these patients remained in the study for the secondary end points. 
As shown in Table 1, both groups were comparable with respect to baseline characteristics, 
with an exception for the storage time of the erythrocytes. Based on their Parsonnet-score, 
the patients in both trial arms are considered to be at high-risk (mean ± SD: 13.5 ± 8.3). 
Th e majority (58.2%) of the patients received 4 or more erythrocyte units (mean ± SD: 
6.1 ± 6.6). Forty-two (8.9%) of the patients did not receive any transfusion. Four (0.8%) 
patients received both types of blood products; these patients remained in their original 
randomization arm. 
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Table 1 | Baseline Characteristics 
PC (n=237) LD (n=237)
Age, years   66.6 ± 12.5    65.3 ± 14.7
Hospital A/B, n 126/111 130/107
Female 102 (43.0) 113 (47.7)
Myocardial infarction  30 (12.7)  29 (12.2)
Hypertension  60 (25.3)  68 (28.7)
Diabetes mellitus  33 (13.9)  22 (9.3)
Heart failure  48 (20.3)  59 (24.9)
Parsonnet score
  0 to 4
  5 to 9
  10 to 14
  15 to 19
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Values are mean ± SD or number (%). * p<0.05
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Table 2 | Intention-to-Treat Analysis 
PC LD OR (95% CI)
Mortality at day 90 30 (12.7) 20 (8.4) 1.52 (0.84 to 2.73)
In-hospital mortality 24 (10.1) 13 (5.5) 1.99 (0.99 to 4.00)*
  Causes of death
   During initial operation
   MODS
   Cardiac events










  No. infections
  Type of infections
   Respiratory tract
   Urinary tract
   Wound
   Bacteremia















1.64 (1.08 to 2.49)*
MODS 49 (20.7) 48 (20.4) 1.07 (0.67 to 1.68)
Values are number (%). * p<0.05
Intention-to -Treat Analysis
As shown in Table 2, in total, 50 (10.5%) patients died within the fi rst 90 days aft er surgery. 
Th e total mortality rate at day 90 was higher in the PC group than in the LD group (12.7% 
versus 8.4%, respectively). Th is diff erence was not signifi cant (OR, 1.52; 95% CI, 0.84 to 
2.73; p=0.16). In the hospital, 37 (7.8%) patients died; in the PC group the in-hospital 
mortality rate was almost twice as high as in the LD group (10.1% versus 5.5%, respectively; 
OR, 1.99; 95% CI, 0.99 to 4.00; p=0.05). 
 In 128 of 4 72 patients (27.1%), 137 postoperative infections were diagnosed. In the 
PC group, 75 (31.6%) of 237 patients had infections, as did 53 (22.6%) of 235 patients in 
the LD group (OR, 1.64; 95% CI, 1.08 to 2.49; p=0.02). In total, 97 (20.6%) patients had 
MODS in the postoperative period. In both trial arms, there was a similar incidence of MODS 
(20.7% in PC versus 20.4% in LD group). Th e duration of MODS in days (mean±SD) was 
also not diff erent in both groups (6.3 ± 8.8 in PC versus 6.1 ± 8.0 in LD; p=0.98). 
 ICU stay in the PC group was 5.6 ± 7.2 (mean ± SD) days and 5.5 ± 7.3 days in the 
LD group (p= 0.88). Th e median ICU stay in both groups was 3 days. Th e postoperative 
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hospital stay was 13.8 ± 10.7 days and 13.3 ± 13.7 days in the PC and LD groups, respectively 
(p=0.66). Th e median duration of the hospital stay in both groups was 10 days. 
Analysis According to Transfusion
In both groups, the mortality rate at 90 days was higher in patients who had received ≥4 U: 
PC, 19.9% versus LD, 12.4%; OR, 1.82; 95% CI, 0.94 to 3.52; p=0.08 (Table 3). Th e causes 
of death aft er discharge in both groups were predominantly cardiac. Both for mortality at day 
90 and in-hospital, there were no deaths in the non-transfused patients. In the patients who 
received 1 to 3 U, there was no diff erence in mortality rates between both groups. Th e in-
hospital mortality rate increased markedly with transfusion of 4 or more units (Table 4) (PC, 
17.6% versus LD, 8.3%; OR, 2.43; 95% CI, 1.16 to 5.12; p=0.02). In both groups, most of 
the patients with in-hospital death had MODS. Mortality rate associated with MODS was 
higher in the PC than in the LD group (Table 2). 
Table 3 | Mortality at Day 90 According to Number and Type of Transfusions 
No. Mortality at day 90
PC LD PC LD OR 95% CI (p)
Total 237 237 30 (12.7) 20 (8.4) 1.52 0.84 to 2.73 (0.16)
No. of transfusions
0  21 (8.9)  21 (8.9)  0 0
≥1 216 (91.1) 216 (91.1) 30 (13.9) 20 (9.3) 1.63 0.90 to 2.98 (0.11)
1 to 3  85 (35.9)  71 (29.9)  4 (4.7)  2 (2.8)
≥4 131 (55.3) 145 (61.2) 26 (19.9) 18 (12.4) 1.82 0.94 to 3.52 (0.08)
Table 4 | In-Hospital Mortality Rates According to Number and Type of Transfusions 
No. In-Hospital mortality 
PC LD PC LD OR 95% CI (p)
Total 237 237 24 (10.1) 13 (5.5) 1.99 0.99 to 4.00 (0.05)
No. of transfusions
0  21 (8.9)  21 (8.9)  0  0
≥1 216 (91.1) 216 (91.1) 24 (11.1) 13 (6.0) 2.00 0.99 to 4.02 (0.05)
1 to 3  85 (35.9)  71 (29.9)  1 (1.2)  1 (1.4)
≥4 131 (55.3) 145 (61.2) 23 (17.6) 12 (8.3) 2.43 1.16 to 5.12 (0.02)
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Most patients with in fections were in the group receiving 4 or more units (Table 5) (PC, 
44.3% versus LD, 28.7%; OR, 1.93; 95% CI, 1.17 to 3.20; p=0.01). Th e types of infections 
are shown in Table 2. In both groups, the number of transfused erythrocyte concentrates was 
correlated with the incidence of MODS; however, this was not diff erent between the groups 
(Table 6). 
Table 5 | Postoperative Infections According to Number and Type of Transfusions 
No. Infections
PC LD PC LD OR 95% CI (p)
Total 237 235 75 (31.6) 53 (22.6) 1.64 1.08 to 2.49 (0.02)
No. of transfusions
0  21 (8.9)  21 (8.9)  2 (9.5)  1 (4.8)
≥1 216 (91.1) 214 (91.1) 73 (33.8) 52 (24.3) 1.61 1.06 to 2.47 (0.03)
1 to 3  85 (35.9)  71 (30.2) 15 (17.6) 11 (15.5)
≥4 131 (55.3) 143 (60.9) 58 (44.3) 41 (28.7) 1.93 1.17 to 3.20 (0.01)
Table 6 | MODS According to Number and Type of Transfusions 
No. MODS
PC LD PC LD OR 95% CI (p)
Total 237 235 49 (20.7) 48 (20.4) 1.07 0.67 to 1.68 (0.79)
No. of transfusions
0  21 (8.9)  21 (8.9)  2 (9.5)  2 (9.5)
>1 216 (91.1) 214 (91.1) 47 (21.8) 46 (21.5) 1.05 0.65 to 1.68 (0.85)
1 to 3  85 (35.9)  71 (30.2)  5 (5.9)  6 (8.5)
≥4 131 (55.3) 143 (60.9) 42 (32.1) 40 (28.0) 1.24 0.73 to 2.11 (0.42)
Multivariate Analysis
 For the primary end point and the secondary end points, the following preoperative and 
peroperative risk factors were analyzed: Hospital, sex, age, Parsonnet score, type of surgery, 
duration of cardiopulmonary bypass and aortic-cross clamping, randomization arm, and 
number of erythrocyte transfusions. For mortality at day 90, Parsonnet score (p=0.001), 
the number of erythrocyte transfusions (p<0.001), and sex (p=0.04) were signifi cant 
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prognostic factors; for in-hospital mortality, the number of erythrocyte transfusions 
(p<0.001), Parsonnet score (p=0.01), sex (p=0.03), and the randomization arm (p=0.01) 
were signifi cant prognostic factors (Table 7). For postoperative infections, the number of 
erythrocyte transfusions (p<0.001) and randomization arm (p=0.02) were signifi cant 
prognostic factors. For MODS, only the number of erythrocyte transfusions (p<0.001) was 
signifi cant prognostic factor. 
Table 7 | Multivariate Analysis for Mortality at Day 90 and In-Hospital Mortality Rates 
Mortality at day 90 In-Hospital mortality
p
No.erythrocyte transfusions < 0.001 < 0.001
Parsonnet score 0.001 0.01
Sex 0.04 0.03
Randomization arm 0.16 0.01
Type of surgery 0.07 0.12
Hospital 0.12 0.85
Age 0.24 0.28
Duration of cardiopulmonary bypass 0.22 0.42
Duration of aortic cross-clamping 0.77 0.91
DISCUSSION
In th is study, a large group of patients undergoing complex cardiac surgery were enrolled. 
Th ese patients were heavily transfused with erythrocyte concentrates, which were randomly 
allocated between standard PCs and LDs. Th e overall mortality rate within the fi rst 90 
days aft er surgery was 10.5% and the in-hospital mortality rate was 7.8%. Th ese rates were 
comparable with other studies in valve surgery [21,22]. In agreement with others [23], we 
found that most of the patients who died aft er discharge from the hospital died from cardiac 
causes. Th is was similar between both trial arms. We observed a high rate of rethoracotomy 
in this study with a diff erence between the hospitals: 7% in hospital A (256 patients) and 
20% in hospital B (218 patients). A possible explanation is the policy of administration of 
aprotinin in one hospital. Th e use of aprotinin was equally distributed in both trial arms. 
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Th e major fi ndings of this study were: 1) a nonsignifi cant diff erence for the primary outcome 
of the study, mortality at 90 days (12.4% versus 8.4%); 2) an in-hospital mortality rate 
in the PC group (10.1%) that was almost twice as high as that in the LD group (5.5%), 
largely caused by deaths associated with MODS; and 3) a signifi cantly higher incidence of 
postoperative infections in the PC group (31.6%) compared with the LD group (22.6%). 
Th e incidence of MODS was not diff erent, nor was the ICU stay or hospital stay between the 
groups. Th is lower in-hospital mortality rate in the LD group, as well as the strong relation 
with the number of transfusions, extends the results of the previous study [15]. Th is earlier 
study was primarily designed to evaluate the eff ect of leukocyte-depleted erythrocytes on 
alloimmunization and infections but revealed an unexpected diff erence in mortality rates 
in patients transfused with PCs. In a similarly designed study in patients with CABG (with 
infections as primary end point), a nonsignifi cant diff erence in mortality rate was observed; 
however, total mortality rate was low [14]. In 2 other randomized studies performed in 
diff erent patient groups, the subgroup analyses of cardiac surgery patients failed to show a 
benefi cial eff ect of LD on mortality rate [16,17]. 
 Th e present study in high-risk cardiac surgery was primary designed to detect possible 
diff erences in mortality rates. Patients who received 1 to 3 U showed a similar mortality rate 
between both trial arms, whereas the diff erence was favourable for LD when 4 or more units 
were transfused. However, the diff erence in mortality rate at 90 days did not reach statistical 
signifi cance between the 2 study populations. Based on results of 60-day mortality in the 
previous study [15], the present study was powered to detect a diff erence in mortality rate of 
10%. We observed a smaller diff erence in mortality rates between the groups, in particular 
that caused by cardiac mortality aft er discharge, which was equal in both trial arms. 
 Th e reduction in postoperative infections in favour of LDs was solely present in 
patients who received 4 or more units. It has been shown that transfusion of whole blood 
during surgery is associated with prolonged impairment of macrophages and natural killer 
cell function. Th is eff ect appears to be dependent on the dosage of leukocytes or on the 
leukocyte-aggregates in the transfused concentrates [11]. 
 Th is is the fi rst prospective trial in which the development of MODS in relation 
to blood products was studied. Overall incidence of MODS was 20.7%; this was highly 
associated with the number of transfusions but not with the randomization groups. Th e 
mortality rate associated with MODS was higher in the PC group compared with the LD 
group; whether the benefi cial eff ects of LD on MODS-related survival and to postoperative 
infections remains unclear and must be investigated further. 
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LD transfusions are widely implemented in Western Europe and Northern America. Th e 
clinical benefi ts other than prevention of HLA alloimmunization and cytomegalovirus 
transmission have been diffi  cult to demonstrate [6]. Taking previous studies [6] into account, 
leukocytes appear to be particularly important as a risk for infections when larger numbers of 
erythrocyte concentrates are administered. In this study, a large, homogeneous and multiple 
transfused patient group was enrolled. We demonstrated in this population that LDs result 
in a decrease in postoperative infections and in-hospital mortality rates. Th erefore, our study 
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ABSTRACT 
Background: In two randomized trials in cardiac surgery we observed that leukoreduced 
allogeneic red blood cell (RBC) transfusions (LR) compared with standard buff y-coat-
depleted RBC transfusions (BCD) resulted in lower rates of postoperative infections and 
mortality. 
Methods: To unravel whether this comprises two independent side eff ects or could be 
related complications of allogeneic leukocytes, we performed a re-analysis on the patients 
of these two trials. 
Results: For all analyses, homogeneity tests were shown not to be signifi cant. Data on 
characteristics of postoperative infections, nature of microorganisms, number of transfusions 
and causes of death in both studies were subjected to an integrated analysis. In both studies 
combined, 1085 patients had been assigned to prestorage leukoreduced RBCs (LR, n=542) 
or standard buff y-coat-depleted RBCs (BCD, n=543). Postoperative infections were 
signifi cantly higher in the BCD group [BCD: 34.2% vs. LR: 24.0%, common odds ratios 
(COR): 1.65, 95% confi dence interval (CI): 1.27-2.15], whereas the species of cultured 
microorganisms and the type of the infections were similar in both randomization arms. 
Mortality with the presence of infections in the postoperative period was signifi cantly higher 
in patients receiving BCD compared with LR (BCD: 5.5% vs. LR: 2.2%, COR: 2.59, 95% 
CI: 1.31-5.14), whereas mortality without infections in the postoperative period was similar 
in both arms (BCD: 3.9% vs. LR: 3.1%, COR: 1.24, 95% CI: 0.65-2.38). Th e only cause 
of death that diff ered signifi cantly between BCD and LR was the combination of multiple 
organ dysfunction syndrome with infections in the postoperative period.  
Conclusions: Th is re-analysis shows that transfusion of leukocytes containing RBCs during 
cardiac surgery may be associated with more infections with fatal outcome. Th is should be 
confi rmed in a larger extended analysis or a prospective study.
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INTRODUCTION
Th e outcome of patients undergoing cardiac surgery is closely related with the development 
and the severity of postoperative complications such as systemic infl ammatory response 
syndrome (SIRS), multiple organ dysfunction syndrome (MODS) and infections [1,2]. 
Moderate SIRS oft en develops aft er cardiac surgery and usually resolves with supportive care. 
However, severe SIRS can evolve to MODS, which may cause mortality, dependent on the 
number of failed organs [3].
 Although in supportive care of cardiac surgery allogeneic blood transfusions are 
commonly used, these may act as a two-edged sword. On the one hand, patients with 
coronary artery disease compensate less for anemia and need a higher hemoglobin transfusion 
trigger [4-6]. On the other hand, allogeneic blood transfusions may be associated with more 
complications [7,8]. Several studies on intensive care unit (ICU) patients and cardiac surgery 
showed a dose-dependent relationship between allogeneic blood transfusions and the 
development of postoperative infections [9-11] and hospital mortality [12,13].
 A meta-analysis of the three fully published [14-16] studies in cardiac surgery revealed 
an increased short-term postoperative mortality aft er transfusions containing allogeneic 
leukocytes as compared with transfusions of blood leukoreduced by fi ltration [17]. However, 
in diff erent surgical settings a meta-analysis for postoperative infections demonstrated no 
clear evidence in favour of leukoreduced blood transfusions [18].
 We conducted two randomized controlled trials (RCTs) [14,16] in cardiac surgery 
and observed in both studies a transfusion dose-dependent increase of postoperative 
infections as well as a higher mortality rate associated with MODS aft er the transfusion of 
standard, buff y-coat-depleted red blood cells (RBCs) compared with RBCs leukoreduced 
by fi ltration. We wondered whether postoperative infections and mortality might refl ect 
diff erent mechanisms or a common mechanism induced by allogeneic leukocytes. For this 
purpose we re-analysed the original data of patients who participated in two RCTs for the 
nature of infections and the infl uence of these infections on the course of postoperative 
outcome.
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MATERIAL AND METHODS
Both studies were double-blinded, prospective RCTs. In both studies, the ethical review 
boards of the hospitals approved the trial protocols, and the local trial coordinators obtained 
informed consent from the patients. Th e design and outcome of both studies are described 
elsewhere in detail [14,16]. Study 1 was a single-center study conducted between 1992 and 
1994 [16]. Patients undergoing coronary artery bypass surgery (CABG), valve surgery or 
a combination of both were randomized into three study arms: leukoreduced RBCs were 
either prepared prestorage from freshly drawn blood or were fi ltered aft er storage prior to 
transfusion. For the current analysis, we only included the patients who received prestorage 
leukoreduced RBCs (LR, n=305) and those who received buff y-coat-depleted RBCs (BCD, 
n=306) because these products were the common products used in both studies. Study 2 
was conducted between 1999 and 2001 in two hospitals and included patients undergoing 
valve surgery with or without CABG (14). In this study, buff y-coat-depleted RBCs (n=237) 
were compared with prestorage fi ltered RBCs (n=237). In both studies, all patients received 
prophylactic antibiotics postoperatively for 24 hours in patients undergoing CABG and 
48 hours in patients undergoing valve surgery. Postoperatively the patients were monitored 
at the ICU until there was no need for positive inotropes and intubation. Surgical and 
anesthetical procedures were according to the standards of the hospital in both studies.
Blood Products and Transfusions
Th e blood products and the quality control of blood products for both hospitals in the two 
studies fulfi lled the requirements and the specifi cations of the Dutch standards for blood 
banks. Within 24 hours of withdrawal BCD-RBCs were prepared by centrifugation of 
whole blood at 3000 g for 10 min. Buff y coat and plasma were removed, and RBCs were 
reconstituted with 100 ml saline-adenine-glucose-mannitol. Th e average leukocyte count 
was in the fi rst study 0.8 ± 0.5×109 per unit and in the second study 0.7 ± 0.4×109 per 
unit. Prestorage fi ltration of RBCs (LR) was performed within 24 hours aft er collection 
of blood by passage through a leukocyte fi lter. In both studies the same fi lter (Cellselect-
Optima, NPBI International-Fresenius HemoCare, Th e Netherlands) was used. Th e 
residual leukocyte count in the fi ltered units was measured in study 1 using Nageotte 
counting chamber, revealing a leukocyte count of [mean ± standard deviation (SD)] 1.2 
± 1.4×106 per unit. In study 2, fl ow cytometry was used for quality control, more reliably 
detecting low leukocyte numbers. By this method the mean (±SD) residual leukocytes in 
the fi ltered units was 0.15 ± 0.02×106 per unit. All platelet concentrates in both studies 
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were prestorage leukoreduced by fi ltration. In both studies, there were no by-study-defi ned 
transfusion triggers. Th e decision to transfuse blood products was based on local policies, 
hemoglobin level (less than 8-8·5 g/dl), platelet count (less than 100×109/l), blood loss and 
bleeding disorders. In one centre participating in study 2 more patients received aprotinin 
for prevention of blood loss.
Mortality
In study 1, mortality was a secondary endpoint and was registered until day 60 postoperatively; 
in study 2, mortality at 90 days aft er surgery was the primary endpoint. For both studies, 
death at 60 days was monitored and used for this analysis. Th e cause of death in both studies 
was retrieved from the patient hospital records or from the referring cardiologist or general 
practitioner.
Postoperative Infections
In both studies infections in the postoperative period had been a secondary endpoint and 
were recorded according to the criteria of Center for Disease Control and Prevention [19]. 
In both studies the following infections were scored: respiratory tract infection (defi ned 
as positive sputum culture and/or pulmonary infi ltrate on the radiograph), urinary tract 
infection (defi ned as positive urine culture with clinical signs of urine tract infection), 
wound infection (defi ned as positive wound culture and/or local symptoms) and bacteremia 
(defi ned as positive blood culture and fever). All information on infections and the 
identifi ed microorganisms was collected by the trial coordinators from the patient records or 
electronically from the hospital computer system.
Multiple Organ Dysfunction Syndrome (MODS)
In study 1 MODS was not an endpoint. In this study, the causes of death were registered 
and MODS was diagnosed as cause of death by the treating physicians. In study 2 MODS 
was a secondary endpoint. Th e scoring of organ dysfunction was assessed by the local trial 
coordinators on the basis of the daily records according to a model described elsewhere [20]. 
Th e dysfunction of the following organ systems were scored: respiratory dysfunction (defi ned 
as respiratory frequency ≤5/min or ≥49/min, arterial PaCO2 ≥6.65 kPa, AaDO2 ≥46.7 kPa, 
or longer than 72 hours dependency of mechanical ventilation), cardiovascular dysfunction 
(defi ned as heart frequency ≤54/min or ≥ 150/min, mean arterial pressure ≤ 49 mmHg, serum 
pH ≤7.24 in combination with PaCO2 ≤6.52 kPa, or dependency of positive inotropes), 
renal dysfunction (defi ned as urine production ≤ 479 ml per 24 hours or ≤159 ml per 8 
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hours, creatinine concentration ≥3.4 mg/dl, blood urea nitrogen concentration ≥50 mg/
dl, or dependency of dialysis), hematological dysfunction (defi ned as white blood cell count 
≤ 1.0×109/l, platelet count ≤20×109/l, or hematocrit ≤0.20) and insuffi  ciency of the central 
nervous system (defi ned as Glasgow Coma Score ≤6). MODS was defi ned as the failure of 2 
or more organ systems.
Statistics
Th ese extended analyses were performed on intention-to-treat basis. Breslow-Day and 
Tarone’s homogeneity tests were performed to verify that combined analyses were valid. 
Data were expressed as mean ±SD, number or percentage when appropriate. For comparison 
of qualitative parameters, the Fisher’s exact test or χ2 test was used, and for the comparison 
of quantitative parameters, the t-test or Mann-Whitney U-test was used. To analyse the 
diff erences, common odds ratios (COR) with 95% confi dence intervals (95% CIs) were 
calculated using the Mantel-Haenszel estimation. Multivariate analysis of the risk factors 
was performed using logistic regression model. Th e survival was analysed with Kaplan-Meier 
curves. All p-values are two tailed. All analyses were performed in SPSS (SPSS Inc., Chicago, 
IL, USA).
RESULTS
In Table 1 the patient characteristics of both studies are summarized. Patients included in 
study 2 underwent CABG combined with valve surgery and were at higher risk with respect 
to age, gender, type of surgery and duration of surgery; this was refl ected in longer ICU stay 
and hospital stay compared with study 1. In both studies more than 90% of the included 
patients received one or more RBC transfusions. Th ree patients in the LR group received 
solely BCD products, and in both groups 27 patients received both types of blood products. 
In the current analysis these patients remained in their original randomization arm. Th e 
homogeneity tests for all analyses were not signifi cant.
 In the BCD group 186 patients (34.2%) and in the LR group 130 patients (24.0%) 
had an infection. In total, 80 patients (7.4%) died, 51 patients (9.4%) in the BCD group 
and 29 patients (5.4%) in the LR group. Th e CORs for infections (COR: 1.65, 95% CI: 
1.27-2.15, p<0.01) and for mortality (COR: 1.84, 95% CI: 1.15-2.96, p=0.01) showed 
signifi cant diff erences between BCD and LR.
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Th e most frequent type of infection was respiratory tract infection (48.7%) followed by 
urinary tract infection (33.2%), bacteremia (12.3%) and wound infection (11.1%). In the 
BCD group nine patients (4.8%) had two or more infections and in the LR group seven 
patients (5.4%). In the deceased patient group, respiratory tract infection was the most 
common type of infection (33.8%) followed by bacteremia (16.3%), urinary tract infection 
(8.8%) and wound infection (2.5%). Th e distribution of the types of infections was similar in 
both randomization groups (Table 2). Th ere were more patients with more than 1 infection 
in the BCD group associated with mortality.
 From 33 patients (17.7%) in the BCD group and 25 patients (19.2%) in LR group 
cultures revealed no microorganisms. Th e homogeneity test between the studies for type 
of microorganisms (p=0.49) was not signifi cant. In the BCD group in 45 patients (24.2%) 
more than one microorganism was cultured. Th e isolated microorganisms in the BCD 
group were predominantly Haemophilus infl uenzae (16.8%), Staphylococcus aureus (16.8%) 
and Escherichia coli (15.4%). In the LR group, in 29 patients (22.3%) more than one 
microorganism was cultured. Th e most isolated microorganisms in this group were E. coli 
(23.1%), H. infl uenzae (18.5%), Enterobacter species (13.8%) and S. aureus (13.1%). Th ere 
were more gram-negative (75.1%) than gram-positive (22.4%) microorganisms cultured in 
patients with infections. Th e cultured microorganisms in patients with infections and in 
deceased patients were not diff erent between the randomization groups.
 In Table 3 the causes of death are shown. Th e most common cause of death in the 
BCD group was MODS combined with infections in the postoperative period; this was 
signifi cantly higher than that in the LR group. In the LR group cardiac complications 
(without MODS or infections) were the most common causes of death. Mortality, either 
from infections or other causes, tended to increase the more RBCs patients received (Table 
4). Th e extent of the association between RBCs dose and mortality was not diff erent between 
the trial arms for deaths not caused by infections but was signifi cantly greater in the BCD 
arm compared with LR for deaths caused by infections (p=0.01 overall and p=0.02 if 8 or 
more units were transfused).
 Th e association between infections in the postoperative period and mortality was 
analysed in a multivariate logistic regression model with pre-operative and per-operative risk 
factors. Th e following risk factors were found to be independently associated with mortality: 
cardiopulmonary bypass time (p<0.001), age at surgery (p=0.001), infections (p=0.004), 
type of surgery (p=0.012) and the randomization arm (p=0.03). Gender (p=0.07), 
study (p=0.99) and aortic clamping time (p=0.16) showed no independent association. 
Infections (p=0.43) and type of surgery (p=0.12) lost their signifi cant association with 
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mortality when the number of erythrocyte transfusions was added to the model (p<0.001). 
Cardiopulmonary bypass time (p=0.01), age at surgery (p=0.005) and the randomization 
arm (p=0.03) remained independently associated with mortality.
Table 4 | Mortality, with and without Infection in the Postoperative Period Related to the 







BCD/LR BCD LR COR (95%CI)
p
BCD LR COR (95% CI)
p
0 33/41 0 0 0 0
1-3 208/188 2 (1.0) 1 (0.5) 1.82 (0.16-20.2)
1.0
3 (1.4) 3 (1.6) 0.90 (0.18-4.53)
1.0
4-7 188/198 7 (3.7) 2 (1.0) 3.79 (0.78-18.5)
0.10
8 (4.3) 4 (2.0) 2.16 (0.64-7.28)
0.25
>8 114/115 21 (18.4) 9 (7.8) 2.66 (1.16-6.09)
0.02
10 (8.8) 10 (8.7) 1.01 (0.40-2.53)
1.0
Total 543/542 30 (5.5) 12 (2.2) 2.59 (1.31-5.14)
0.01
21 (3.9) 17 (3.1) 1.24 (0.65-2.38)
0.49
p-values are calculated for diff erences between the randomization arms; BCD=Buff y-coat reduced red blood 
cells; LR=Leukoreduced red blood cells;COR=Common odds ratios
Th e survival curves of patients with and without infections in the postoperative period are 
shown in Figure 1. Th e survival of patients without infections was not diff erent between the 
randomization groups (p=0.28), and most deaths in this group occurred in the fi rst 20 days 
aft er surgery. Most of the deaths in patients with infections occurred later; the diff erence 
between BCD and LR was mainly because of more deaths in the BCD group aft er an interval 
of 20 days or longer aft er surgery (p=0.09).
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Figure 1 | Th e 60-day survival in aft er cardiac surgery in patients with or without infections in 
the postoperative period. Survival without infections was not diff erent between BCD and LR 
(p=0.28). Diff erence in survival with infections between BCD and LR was mainly observed aft er 
20 days (p=0.09).
DISCUSSION
To evaluate the role of leukocytes in blood products administered during cardiac surgery, 
three fully published RCTs [14-16] and two abstracts [21,22] are available. In four of the fi ve 
studies, RBCs leukoreduced by fi ltration were associated with lower mortality. However, 
the exact mechanism associated with increased mortality has not been unravelled yet [23]. 
In all studies, postoperative infections had been evaluated as an independent endpoint with 
contradictory results. Th e current re-analysis was undertaken to explore whether infections 
in the postoperative period contributed to mortality in patients undergoing cardiac surgery 
aft er transfusion of leukocyte containing RBCs. Th is approach could be helpful to identify 
the possible role of infections in survival of patients receiving leukocytes containing RBCs. 
For this re-analysis we used the data of two previously published studies [14,16]. Th ese studies 
were undertaken in cardiac surgery; however, there were also diff erences between the studies. 
Th erefore, we tested the homogeneity of the results from both studies before analysing the 
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data. Because there were no signifi cant diff erences between the studies in all homogeneity 
tests, we reported the results from the combined analysis.
Our fi nding that the mortality rate was increased in patients with the presence of infections 
in the postoperative period aft er cardiac surgery was in agreement with others [24]. Th e 
possible relationship between leukocytes containing RBCs and mortality associated with 
postoperative infections has not been described before. Mortality associated with or without 
infections increased with the number of units of RBCs transfused in both randomization 
arms. However, the diff erence in mortality between those receiving BCD or LR was more 
marked in patients receiving 8 or more units of RBCs, which suggests that transfusion-related 
immunomodulation may either be dose related or be more clinically signifi cant in sicker 
patients. Because no diff erences in type of infections or type of microorganisms between 
BCD and LR were present, this points to an overall more reduced host resistance aft er non-
leukoreduced RBC transfusions. No specifi c suspectibility for particular microorganisms, as 
has been suggested in an animal model, was seen [25]. Patients dying without infections did 
so mainly in the fi rst 20 days aft er surgery, whereas patients with infections oft en died later. 
Th is was refl ected in the growing diff erence in mortality between BCD and LR beyond 20 
days. Th is is in agreement with other observations on a possible long-standing suppression 
of the innate immune system caused by leukocytes containing RBCs [26,27]. Patients with 
infections in the postoperative period appear to have a higher mortality associated with 
MODS when they receive leukocytes containing RBCs instead of leukoreduced RBCs. Th is 
diff erence in mortality associated with infections could be explained by increase of pro-
infl ammatory mediators by production or release induced by leukocytes containing RBCs. 
It has been shown that transfusion of RBCs in cardiac surgery leads to higher concentrations 
of pro-infl ammatory mediators and is associated with more postoperative infections [28]. It 
is possible that such a postoperative infl ammatory response (which could lead to MODS 
and a worse outcome) is more pronounced in patients receiving leukocytes containing 
RBCs compared with leukoreduced RBCs. More studies are necessary to investigate the 
role of allogeneic blood transfusions in the pathophysiology of postoperative infl ammatory 
responses and organ dysfunction.
 Th ere are several restrictions in this analysis. First, this is not a new RCT but an 
extended analysis of two double-blind RCTs conducted in diff erent patient populations. Th e 
RCTs were designed to investigate the potential eff ect of leukocytes containing RBCs in a 
highly transfused patient group. In the second study only patients undergoing valve surgery 
(with or without CABG) were included. Th is group was older, underwent longer surgery 
and stayed longer in ICU and in hospital. Th is high-risk patient group was selected because 
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the fi rst study indicated the greatest deleterious eff ects of leukocytes containing RBC 
transfusions in the more heavily transfused patients who underwent valve surgery combined 
with CABG, which was confi rmed in the second study. Second, the studies had diff erent 
endpoints. Th e fi rst published study found no diff erence in alloimmunization (primary 
endpoint). Th e secondary endpoints (postoperative infections and mortality) were higher 
in patients transfused with leukocytes containing RBCs compared with patients transfused 
with leukoreduced RBCs. Th ese diff erences were associated with the number of RBC 
transfusions. Th e second study found a non-signifi cant diff erence for mortality at 90 days 
(the primary outcome). However, in patients transfused with leukocytes containing RBCs, 
in-hospital mortality was twice as high and postoperative infections (secondary endpoints) 
were signifi cantly higher compared with patients transfused with leukoreduced RBCs. For 
this re-analysis these outcomes were not double-checked or adjudicated by independent 
investigators. Th ird, both studies had been performed 7 years apart. Between the fi rst study 
conducted in 1992-1994 and the second in 1999-2001, surgical procedures, application 
of aprotinin and transfusion practice changed, although cardiac surgery patients remained 
at risk to receive a large number of blood products. Fourth, the fi rst study did not score 
MODS as an independent outcome but only as a cause of death. Th erefore, exact incidence 
and severity of MODS in all participating patients is not known. Also, detailed data on pre-
operative risk status of the patients were not recorded in the fi rst study. Furthermore, the data 
had been collected in the same way by the same investigators in the same country. All these 
factors could have infl uenced this extended analysis. However, their infl uence aff ects both 
randomization arms equally because randomization had resulted in a balanced distribution 
of patients in both studies.
 In summary, this extended analysis suggests a possible common pathway to 
postoperative death because of a higher incidence of presence of infections in the postoperative 
period associated with mortality, which might be elicited by long-standing immune 
suppression as a result of the presence of leukocytes in allogeneic blood transfusions. It is 
necessary to confi rm these fi ndings, preferentially by similar analysis on patients enrolled in 
all fi ve RCTs conducted in cardiac surgery or (if possible) by a prospective study in countries 
that have not implemented universal leukoreduction.
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ABSTRACT
Allogeneic blood transfusions are dose-dependently associated with postoperative 
complications. Leukocytes present in blood components may play a role in these eff ects, 
referred to as transfusion-related immunomodulation (TRIM). Of 19 randomised controlled 
trials of the eff ect of allogeneic leukocytes in transfusions, 13 looked into the eff ect of 
leukocyte-containing red blood cells (RBCs) in the surgical setting on the occurrence of 
postoperative infections and/or mortality. In contrast to confl icting outcomes of the trials in 
other settings, in cardiac surgery there is evidence that leukocyte-containing RBC increase 
postoperative complications associated with mortality. Th e studies performed in cardiac 
surgery show less heterogeneity than studies in other surgical interventions and had been 
conducted either in one or a few participating centres. In this review we discuss possible 
explanations for these results in cardiac surgery (as opposed to other settings), which may 
relate to clinical as well as transfusional factors. We suggest that leukocyte-containing 
transfusions during and aft er cardiac surgery add a second insult to the cardiopulmonary 
bypass procedure induced systemic infl ammatory response.
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INTRODUCTION
Transfusion-related immunomodulation (TRIM) refers to immune suppression aft er blood 
transfusion, currently presumed to be mediated by allogeneic leukocytes. In the 1970s, 
observational studies revealed better survival of kidney graft s in previously transfused 
patients compared with non-transfused patients [1]. Concern for wider consequences of such 
a transfusion eff ect on cancer growth and immunity against infections resulted in hundreds 
of publications [2]. However, the underlying reasons for transfusion likely confounded the 
patient outcomes. Only randomised controlled trials (RCTs) circumvent this. Recently 
two meta-analyses of available RCTs on the role of peri-operative leukocyte-containing 
transfusions were published [3,4]. As little new information emerged since the publication of 
these two overviews, there is no need for an update of a systematic review [5]. In this review 
we discuss these RCTs and focus on the particular clinical circumstances of cardiac surgery 
that may enhance susceptibility to TRIM.
Selection Criteria
For this review we used MedLine (1980-May 2008), searching the terms “leukocyte-reduced, 
leukocyte-depleted, fi ltered (red blood cell or erythrocyte) blood products”, “haemoglobin 
trigger, transfusion dose”, “transfusion-related immunomodulation” or “pre-transplant blood 
transfusion.” Only randomised controlled trials, (systematic) reviews and meta-analyses with 
clinical endpoints were selected. We excluded studies restricted to leukocyte-depletion of 
platelet components, or comparing in-vitro parameters. Publications of RCTs, re-analyses 
and follow-up publications of the original cohort were evaluated for information on 
transfusion products, transfusion dosage, and proportion of transfused patients. We also 
searched the references of the selected publications to fi nd relevant abstracts or commonly 
referenced key publications. We found one meta-analysis of 7 studies comparing a liberal 
versus restrictive transfusion policy based on the hemoglobin (Hb) trigger in adults [6] and 
4 similar studies in children [7-10]. Sixteen RCTs compared leukocyte-depleted red blood 
cells (RBC) with those containing leukocytes of which 14 RCTs (two still in abstract form) 
investigated transfusions administered for surgery or trauma [11-24]. One RCT evaluated 
all hospital patients [25] and one was conducted in human immunodefi ciency virus (HIV) 
positive patients [26]. In prospective kidney transplant recipients, we found three RCTs 
investigating the eff ect of a blood transfusion on graft  outcome [27-29]. 
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RCTs Comparing Restricted with Liberal Transfusion Policy
Seven hemoglobin (Hb)-trigger studies comprising 1.703 patients used non-leukocyte-
depleted RBCs. Th e meta-analysis by Carson et al shows that a restrictive transfusion trigger 
entails no more mortality than a liberal transfusion trigger [6], rather the opposite was found 
(OR: 0.80; 95% CI: 0.63-1.02). Th is outcome was infl uenced by one large RCT in 838 
patients, staying at an intensive care unit (ICU), in which patients were either transfused 
to maintain the Hb value between 7 and 9 g/dl (restrictive) or above 10 g/dl (liberal). 
Patients assigned to a restrictive trigger received an average of 2.6 units of RBCs compared 
with 5.6 units in the liberal group. Mortality at 30 days, the primary outcome measure, was 
not signifi cantly diff erent between the groups: 18.7% versus 23.3% (OR: 0.80; 95% CI: 
0.61-1.04) in favour of the restrictive trigger. In subgroups of patients younger than 55 years 
of age and those with a lower APACHE (Acute Physiology And Chronic Health Evaluation) 
risk score, mortality was signifi cantly lower in the restrictive group than in the liberal group: 
5.7% versus 13% (p=0.02) and 8.7% versus 16.1% (p=0.03), respectively [30].A similar study, 
using leukocyte-depleted RBC products in 637 paediatric ICU patients, confi rmed that a 
lower transfusion trigger substantially reduces the number of transfused patients and the 
number of units transfused without a negative clinical eff ect [7]. Multi-organ-dysfunction-
syndrome (MODS), the primary endpoint of this study, developed in 12% of the children 
in both groups. It is tentative to speculate that leukocytes in blood products may have 
contributed to higher mortality in low-risk adults who had been liberally transfused [30]. 
Another 3 Hb-trigger studies had been conducted in neonates and infants and also used 
leukoreduced transfusions. Th e results raised concern about the safety of a lower Hb on brain 
damage in children undergoing cardiac surgery [8], or in very low birth weight premature 
infants [9,10]. 
RCTs on Leukodepletion of Red Blood Cell (RBC) Products 
To date, 19 RCTs investigated clinical eff ects of allogeneic leukocytes in RBC products 
[11-29]. Th ese studies in diff erent clinical settings compared pre-or post (bedside)-storage 
fi ltered leukocyte-depleted RBCs (less than 106 leukocytes per unit) with various standard 
components, e.g. whole blood or RBCs in plasma or additive solution, with or without 
buff y-coat. Oft en the number of residual leukocytes was not stated. Patient and transfusion 
characteristics, study designs and the main results of these trials are summarized in Tables 1 
and 2.
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Studies on Immunosurveillance of Cancer
Only 2 RCTs, with 697 and 640 patients respectively, compared buff y-coat-poor RBC with 
fi ltered RBC on the cancer recurrence rate aft er colorectal surgery with curative intent. Both 
studies evaluated long-term outcome aft er at least 5 years follow-up and found no diff erence 
in colorectal cancer recurrence [12,17,31]. However, colorectal cancer is a weakly immunogenic 
tumour and the malignant cells can down-regulate expression of specifi c HLA-alleles and 
co-stimulatory molecules, allowing the tumour to escape an immune attack, whether or not 
the immune response is impaired by transfusions [32]. A possible TRIM eff ect of allogeneic 
leukocytes on surveillance of more immunogenic types of cancer remains undetermined. 
Studies Evaluating Postoperative Bacterial Infections
Twelve RCT’s on leukodepletion of blood transfusions in diff erent clinical settings 
evaluated postoperative infections as a primary or secondary endpoint [11-16,18-23]. Th ese 
studies varied as to single- or multi-centre design, clinical diagnosis, methods to document 
and report infections, and the proportion of transfused patients (range 14%-95%). In 
abdominal and cardiac surgery several studies were performed investigating postoperative 
infections, which revealed diff erent outcomes (Table 1). One RCT compared the eff ect of 
leukocyte-depleted and standard blood products in transfused trauma patients and reported 
no diff erence in occurrence of infections and acute lung injury (ALI) in an initial [18] and 
second re-analysis of these patients [33]. Recently, two meta-analyses of RCTs on leukocyte-
depletion of blood products have been published and these initiated a methodological 
discussion [3,4]. Applying intention-to-treat analysis, Vamvakas concludes that there is no 
association between leukocyte-containing transfusions and the incidence of postoperative 
infections [3]. Blumberg et al analysed only subgroups of transfused patients, excluding 36% 
of the patients, and concludes that there is a signifi cant and clinically relevant almost 50% 
reduction in postoperative infection rate aft er transfusion of leukocyte-depleted RBCs [4]. 
How such unequivocal conclusions could be reached was recently addressed in this journal 
[34]. Besides integration of studies that should not be integrated because of heterogeneity, 
the in- or exclusion of three recent publications (2 publications that appeared as abstracts 
and have not been published as complete studies in peer-reviewed journals [20,24]) were 
identifi ed as causes for the discordant results. Full publication of the 2 studies in abstract 
form has to be awaited in order to conclude on an eff ect of leukocyte-depleted RBCs on 
postoperative infections aft er various types of surgery. 
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Studies Evaluating Mortality
Short-term mortality was evaluated in 12 RCTs (Table 1). Under conditions of heterogeneity, 
Vamvakas found in a meta-analysis no overall adverse eff ect of leukocyte-containing 
products on short-term mortality (OR: 1.14; 95% CI: 0.89-1.45), with an exception in 
cardiac surgery (OR: 1.72; 95% CI: 1.05-2.81) [3]. As shown in Table 1, cardiac surgery 
patients received, in contrast to patients with other types of surgery, oft en more than three 
units of RBCs. Mortality aft er cardiac surgery is generally below 5%, however increases with 
complexity of the surgical intervention, increased blood loss, co-morbidity and older patient 
age to more than 10% [35]. In general extensively transfused cardiac surgery patients have 
more postoperative morbidity and mortality [36]. Platelet transfusions probably enhance 
both morbidity and mortality [37], but they are inextricably bound to larger numbers of 
RBC transfusions and more surgical bleeding.
 Four RCTs performed in cardiac surgery are published as full articles [19,21-23]. 
Two of these trials randomised the patients for three diff erent blood products. One 
compared buff y-coat-depleted (BCD)-RBCs with two fi ltered RBCs: fresh fi ltered RBCs 
before storage (FF) or stored fi ltered RBCs (SF) [19]. All products had a similar shelf-life 
of around 13 days. Th ere was a higher mortality (7.8%) in the group who received BCD-
RBCs as compared with 3.6% and 3.3% in those receiving FF or SF products respectively 
(p=0.015). Th is suggests that soluble mediators, still present in the SF products, caused no 
more adverse eff ects than FF-RBC, lacking leukocyte-derived soluble factors. In a subgroup 
analysis, the diff erence in mortality was present only in patients who received more than 
three RBC units. A second study using three types of blood products, assigned patients 
to fi ltered whole blood (stored <7 days before fi ltration), BCD-RBC or plasma-reduced 
RBCs. Short-term postoperative mortality was 0.5%, 2.9 % and 2.5% respectively, indicating 
no additional deleterious role of a higher number of leukocytes present in plasma-reduced 
RBCs as compared to BCD-RBCs [21]. In the study of van de Watering et al [19] the 
incidence of multiple-organ-dysfunction-syndrome (MODS) was not registered, however 
mortality due to MODS was the major cause of excess deaths aft er standard transfusions. We 
conducted another study in more complicated cardiac surgery with a higher probability of 
multiple RBC transfusions in order to explore the relationship with leukocyte-containing 
transfusions on MODS and mortality [22]. Surprisingly, the incidence of MODS (20%) was 
similar in the groups receiving standard BCD-RBC or pre-storage fi ltered RBC, however 
MODS as a cause of death occurred more oft en in patients who received BCD-RBC. 
Subgroup analysis showed that only patients who received more than 3 units suff ered higher 
mortality in the group receiving BCD-RBC. A fourth small study in 69 low-risk CABG 
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patients compared bedside-fi ltered RBCs (containing soluble leukocyte-produced factors) 
with the same unfi ltered RBC product [23]. Th ere was no diff erence in mortality between 
both randomization arms. Th is study was preliminary stopped because interim analysis 
showed less respiratory tract infections in the fi ltered group (p=0.048). Two other studies in 
cardiac surgery are still available only as abstracts, mentioning limited data [20,24]. 
 Th e observation that not the leukocyte load per transfusion [21], nor the soluble 
mediators released by leukocytes during storage [19], but rather the number of units 
transfused that entails the worse outcome [19,22], suggests that sicker patients in cardiac 
surgery requiring more RBC transfusions are more susceptible to TRIM. We analysed in 
more detail the causes of death in two RCTs in cardiac surgery [19,22]. Th is revealed that 
patients who received standard buff y-coat-poor RBCs, compared with before storage fi ltered 
leukodepleted RBCs, excessively died from a combination of infection and MODS (OR 
2.92; 95% CI 1.22-6.97; p=0.02). Short-term mortality (60-days) from infections alone and 
from MODS without infections or from bleeding or surgical complications was equal in 
both transfusion arms [38]. Long-term mortality aft er transfusions of buff y-coat-poor RBCs 
or leukocyte-depleted RBCs, has been published in two studies (both aft er colorectal cancer 
surgery) which observed no diff erence in survival aft er 7 and 8 years [17,39]. 
 Recently in an observational study Koch et al investigated the eff ects of peri-operatively 
transfusion of RBCs either stored less than 14 or more than 14 days in cardiac surgery [40]. 
In this study one-year mortality was higher in patients receiving RBCs stored more than 
14 days, however this association between storage time and mortality was only reported 
as unadjusted analysis. In the RCTs comparing buff y-coat-poor RBCs with leukocyte-
depleted RBCs mortality increased in more heavily transfused patients. Consequently small 
imbalances in heavily transfused patients may be an important confounder, this was also 
suggested in the correspondence aft er the publication of Koch et al [41]. Currently, taking 
several studies in cardiac surgery investigating the storage time of RBCs into account [42-
46], it is not possible to conclude that RBCs with limited storage time should be used 
particular in cardiac surgery patients. Because available databases used retrospectively in 
these studies investigated diff erent storage times and used diff erent blood products results 
from prospective studies have to be awaited.
Studies Outside Surgery and Trauma
Few studies on possible TRIM eff ects have been performed. Only one RCT addressed 
the eff ects of universal leukoreduction as a transfusion policy. For six months, in a tertiary 
hospital, 2.780 consecutive patients with a transfusion indication were randomised 
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between fi ltered and standard unmodifi ed RBCs [25]. No diff erence in mortality, use of 
antibiotics, or hospital stay was found. Th e study was criticized because of a high (20%) 
percentage of product violations, many patients receiving the wrong, not assigned, blood 
products. Considering that not all clinical diagnosis groups may experience negative eff ects 
of leukocyte-containing products, the results of this large study refl ect the absence of benefi t 
of universal leukoreduction of blood products in non-selected patient groups. 
 Th e VATS (Viral Activation Transfusion Study) was conducted aft er in-vitro and in-
vivo observations that allogeneic leukocytes stimulate HIV replication [26]. In this study, 
531 HIV-positive patients with a fi rst indication for transfusion were randomised between 
pre-storage fi ltered and unmodifi ed buff y-coat containing RBC transfusions. No diff erence 
in HIV-RNA level or in the number of CD4-positive cells was found between the study 
arms. Median survival time was 13 months in the fi ltered RBC group and 20.5 months 
in the group receiving the unmodifi ed RBC group. Th is diff erence was not signifi cant in 
intention-to-treat analysis, but aft er correction for various prognostic factors transfusion of 
unmodifi ed RBCs was associated with better outcome (RR 1.35; 95% CI 1.06-1.72) [26].
Studies on Pre-Transplantation Blood Transfusion
Pre-transplantation third-party blood transfusion reducing kidney graft  rejection has been 
investigated in only 3 randomised studies of diff erent design (Table 2) [27-29]. One study 
compared in 52 patients the eff ect of standard unmodifi ed RBCs compared with buff y-coat-
poor or washed RBC on the development of HLA antibodies and graft  survival. No diff erence 
in outcome was observed, but the leukoreduced products did not meet the standards (<106 
leukocytes/unit) and all products may have been equally eff ective [27]. In a multi-centre 
randomised study in 423 prospective cadaver kidney transplantation patients, a better 1-year 
(90 versus 82%; p=0.02) and 5-year (79 versus 70%; p=0.025) graft  survival was observed 
aft er 3 random pre-transplantation transfusions of unmodifi ed RBCs compared with 
no transfusions [28]. Also severe rejections were signifi cantly reduced in patients received 
RBCs. In a third multi-centre study, 144 patients were randomly assigned to one HLA-DR 
shared transfusion (n=49), one HLA-DR mismatched transfusion (n=48) or no transfusion 
(n=47). Blood transfusion consisted of unmodifi ed RBCs stored less than 72 hours. Th ere 
was no diff erence in graft  survival at 1 year (90, 92 and 92%) or at 5 years (79, 84 and 80%) 
respectively. Th e incidence of acute rejections in patients who had received an HLA-DR 
shared transfusion was not signifi cantly lower than observed in the other 2 groups (19 versus 
33%), but the study was not powered to detect possible diff erences of this order [29]. Th e 
results of this latter study do not confi rm previous observational studies, suggesting that
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pre-transplant transfusion from a donor sharing one HLA-DR antigen protects against graft  
rejection [47]. Th e three studies do not allow a combined analysis, because of heterogeneity 
in design, diff erent immunosuppressive protocols and blood products used. Although 
the largest study found a protective eff ect of TRIM on renal graft  survival [28], a smaller 
study designed on the presumed mechanism of allograft  induction by HLA-DR sharing 
blood transfusions was not supportive [29]. Lacking more confi rmatory studies an evidence 
based conclusion on graft -tolerizing eff ect of pre-transplant allogeneic leukocytes in blood 
products is as yet not possible. 
Possible Mechanisms of TRIM
Many factors, soluble and cellular, present in leukocyte containing blood products have been 
proposed to modulate the immune system [34].
 Leukocyte-containing RBCs contain viable and apoptotic leukocytes, erythrocytes, 
residual platelets depending on the type of product, and factors released by these cells during 
storage. Soluble immune response modifi ers accumulating during storage of blood products 
include elastase, histamine, soluble HLA, soluble Fas-ligand, TGF-β1 and pro-infl ammatory 
cytokines IL-1β, IL-6, and IL-8 [48]. In-vitro, soluble leukocyte derived factors from stored 
RBC products induce immediate up-regulation of expression of infl ammatory genes in 
third party leukocytes [49,50]. Interleukin-8 may be the cause of transient post-transfusion 
leukocytosis in critically ill patients, possibly by mobilisation of cells from the bone 
marrow [51]. In a multivariate analysis Heddle et al identifi ed the number of contaminating 
leukocytes and the storage duration of RBCs as the most signifi cant factors associated with 
febrile non-haemolytic transfusion reactions [52]. However, although investigated in just one 
RCT, stored and then fi ltered RBC, expected to contain leukocyte mediators, was associated 
with a similar reduction of postoperative mortality as pre-storage fi ltered blood, suggesting a 
causal role for leukocytes [19]. 
 Apoptosis of leukocytes begins immediately aft er blood withdrawal. Th e speed of 
leukocyte deterioration in RBCs during storage at 2-6oC varies and can be distinguished 
in functional lesions and gradual apoptosis and necrosis, fi rst of granulocytes, then 
monocytes, while lymphocytes can remain viable for more than 25 days. Apoptotic cells 
engage the phosphatidylserine (PS)/annexin V receptor on macrophages, inducing release of 
prostaglandin E-2 and TGF-β, factors suppressing macrophages and natural killer cells and 
impair the antigen-presenting capacity [53]. 
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Viable allogeneic leukocytes in blood components can act as responder cells or as stimulator 
cells inducing cellular immunity and antibody production in the recipient. A functional 
phosphorylation defect, described aft er 3-5 days storage, impairs protein synthesis of T cells 
upon signalling of the T-cell receptor and reduces the proliferative responder capacity of 
donor lymphocytes against recipient cells [54]. Aft er 10-14 days of storage, the capacity of 
donor antigen presenting cells to stimulate recipient T-helper cells is abrogated in-vitro by 
reduction of co-stimulatory molecules [55]. Aft er transfusions stored for a couple of days, 
a two-way interaction between donor and recipient cells is refl ected by the appearance of 
circulating proliferating lymphoblasts a few days aft er blood transfusion [56]. In general, 
donor DNA becomes undetectable one week aft er transfusion, but persistence of donor cells 
for years, even aft er transfusion of fi ltered and stored leukocyte depleted transfusions, has 
been described in approximately 25% of recovered trauma survivors [57]. Utter et al showed 
that trauma induced immune suppression and impaired the patient’s proliferative reaction 
against donor lymphocytes, which could establish donor microchimerism [58]. Th ese trauma 
survivors are apparently healthy and this long-term chimerism is unlikely an explanation for 
postoperative infections and short term mortality aft er cardiac surgery. 
 Despite convincing in-vitro and animal studies supporting TRIM, it is diffi  cult to 
demonstrate clinical counterparts of such eff ects aft er blood transfusion in humans. Dzik et 
al proposed the existence of two diff erent categories of TRIM eff ects: on the innate immune 
response and on the adaptive antigen-driven immune system, to separate the mechanism in 
surgery patients and transfusion-induced tolerance in organ transplantation [53]. Although 
there is increasing knowledge that the innate and adaptive immune systems do not act 
independently and are linked by (subsets of ) natural killer and dendritic cells [59], the clinical 
condition of a surgery patient compared to a patient in steady state disease may be crucial. 
 Tissue damage and other trauma such as burns, mechanical ventilation and 
hypovolemia generate products and expose structures of degraded tissue (e.g. heat-shock 
proteins, proteases) interacting with sensors (Toll Like Receptors [TRLs]) on macrophages 
leading to immediate release of stress hormones, infl ammatory cytokines and chemokines 
[60]. Besides release of cortisol, serotonin, TNF-α, IL-1 β, IL-6 and IL-8, the coagulation 
and complement systems are activated [61]. Th ese factors may cause a systemic infl ammatory 
response syndrome (SIRS) and are immediately counteracted by a compensatory anti-
infl ammatory response syndrome (CARS) [62]. An overwhelming SIRS causes a dormant 
state of cell metabolism, referred to as multiple-organ-dysfunction-syndrome (MODS) [63]. 
CARS has an immune paralysing eff ect and is characterised by anti-infl ammatory cytokines, 
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such as TGF-β1, IL-4 and IL-10 and inhibition of the IL-12-IFN-γ pathway, impairing 
natural defence against invading micro-organisms [64,65]. 
 Th e innate immune system in SIRS or CARS phase of the cascade stimulates or 
suppresses antigen presenting cells and may skew the adaptive immune response towards 
T-helper 1, T-helper 2 or to regulatory T-cells. Th e clinical condition of the patient receiving 
blood transfusions may determine to a large extent the type of TRIM eff ect.
Cardiac Surgery and the Infl ammatory Cascade
During cardiac surgery blood is exposed to the extra-corporeal circuit, hypothermia, 
ischaemia/reperfusion injury. Th ese insults are potent inducers of a stress response. Aft er 
cardiac surgery a post-perfusion SIRS occurs, with leukocytosis, capillary leakage, and organ 
dysfunction. SIRS usually resolves with adequate supportive therapy and most of the patients 
recover. However overwhelming SIRS can dominate CARS and progress to MODS, which 







Figure 1 | Mechanism of Blood Transfusions and Complications aft er Cardiac Surgery. 
Abbreviations Figure 1: SIRS=Systemic infl ammatory response syndrome; CARS=Compensatory 
anti-infl ammatory response syndrome; MODS=Multiple-organ-dysfunction-syndrome
 Sablotzki et al [67] measured the cytokine pattern up to 48 hours aft er CABG 
surgery in 24 patients who all recovered uneventfully. Aft er the start of bypass, soluble 
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IL-2 receptor, IL-2 and IL-12 decrease and incompletely restore themselves, respectively 
6-48 hours aft er surgery. Th e levels of IL-6 and IL-10, undetectable before surgery, increase 
at the end of bypass and reperfusion. Th e very high IL-10 peak fades away aft er 6 hours, 
while IL-6 remains high up to 48 hours. Such a cytokine pattern shows that cardiac surgery 
immediately evokes a biphasic cytokine response. Th is response includes platelet activation 
and macrophage de-activation with decrease of TLRs [68,69]. Activated platelets cause semi-
maturation of dendritic cells, which produce IL-10 [70]. Th e fi rst day aft er cardiac surgery 
there is a profound reduction in dendritic cells with impaired IL-12 and IFN-γ production, 
depressing T-helper-1 and natural killer cells, inhibiting the immune response against 
microbial invasion [68,69]. 
 In 114 patients undergoing cardiac surgery Fransen et al [71] found an association 
between allogeneic blood transfusions and postoperative increase of concentrations of 
infl ammatory mediators. Furthermore, patients developing MODS aft er cardiac surgery 
oft en show a higher and longer increase of pro-infl ammatory factors from the fi rst post 
surgical day onwards and in particular high IL-8 and IL-6 are early predictors for non-
survival aft er cardiac surgery [72].
 Allogeneic blood transfusions are given at diff erent times during and aft er cardiac 
surgery. Any intervention by biological response modifi ers during an already existing 
infl ammatory cascade, which include leukocyte-containing RBC transfusions, can be 
inappropriately timed and lead to increased morbidity and mortality. It is possible that by 
leukocyte-containing RBC transfusions to patients with an activated infl ammatory response, 
this further imbalances the SIRS-CARS equilibrium in favour of SIRS. Th is (second-hit) 
response may exacerbate a pro-infl ammatory stimulus leading to aggravation of MODS and 
could fi nally result in death (Figure 1).
CONCLUSIONS
Allogeneic leukocyte-containing RBC transfusions may have immunomodulatory eff ects 
that are presumed benefi cial for organ transplantation, but harmful for surveillance of cancer 
and for resistance to postoperative infections. Th is concept initiated hundreds of studies, and 
19 randomised controlled trials in various clinical conditions. However, important questions 
remain as to the nature and magnitude of clinical benefi ts and complications ascribed to 
TRIM, its mechanism and the putative causal factors in allogeneic blood components. Th e 
clinical counterpart of transfusion-induced eff ects on the cellular immune system is diffi  cult 
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to demonstrate. Th is may be the result of diff erences in the composition of leukocyte-
containing RBC transfusions used in the various trials and whether blood transfusions 
are administered to patients in a steady state or during an activated or suppressed innate 
immune response. A TRIM eff ect due to leukocyte-containing RBCs has yet only been 
shown in cardiac surgery patients. Th ese patients oft en need multiple transfusions, which 
are administered during an activated (anti)-infl ammatory cascade. Leukocyte-containing 
blood transfusions interfering in this cascade by induction of an additional infl ammatory 
insult as well as by immunomodulatory eff ects may disturb a delicate balance, leading to fatal 
complications in patients at risk.
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ABSTRACT
Background: To investigate whether the higher incidence of postoperative complications in 
cardiac surgery aft er transfusion of leukocyte-containing red blood cells can be related with 
infl ammatory mediators. 
Methods: Analysis of infl ammatory markers IL-6, IL-10, IL-12 and procalcitonin in patients 
participating in a randomized trial comparing leukocyte-depleted (LD-RBC) with leukocyte 
containing, buff y-coat-depleted, red blood cells (BCD-RBC).
Setting: Two university-affi  liated hospitals in the Netherlands.
Subjects: 346 patients undergoing cardiac valve surgery with a complete series of pre-and 
postoperative blood samples.
Results: Th ere were no diff erences in the cytokines and procalcitonin concentrations upon 
arrival at ICU between both study arms. In subgroups, patients transfused with 0-3 RBC 
transfusions showed similar cytokine concentrations in both study arms, whereas patients 
with 4 or more RBC transfusions had signifi cantly higher IL-6 concentrations in the 
BCD-RBC group. Patients who developed postoperative infections and multiple-organ-
dysfunction-syndrome (MODS) showed, respectively, increased concentrations of IL-6 and 
IL-12 in the BCD-RBC group. Th e interaction tests between infections and non-infections 
were also signifi cant for IL-6 and for MODS and non-MODS for IL-12. Multivariate 
analysis showed that high IL-6 concentration with MODS and both high IL-6 and IL-10 
concentrations with hospital mortality. 
Conclusions: Allogeneic leukocyte-containing blood transfusions compared with leukocyte-
depleted blood transfusions induce dose-dependent signifi cantly higher concentrations of 
pro-infl ammatory mediators in the immediate post-operative period aft er cardiac surgery. 
High concentrations of IL-6 are strong predictors for development of MODS; whereas both 
IL-6 and IL-10 are associated with hospital mortality. Th ese fi ndings suggest that leukocyte-
containing RBCs interfere with the balance between postoperative proinfl ammatory 
response, which may further aff ect the development of complications aft er cardiac surgery. 
Allogeneic Leukocytes and Infl ammatory Markers in Cardiac Surgery | 83
INTRODUCTION
Cardiac surgery is associated with tissue trauma, ischemia-reperfusion injury and blood 
surface contact. Th ese conditions induce systemic eff ects and release of infl ammatory 
mediators, which are presumed to play a role in the development of postoperative 
complications such as systemic infl ammatory response syndrome (SIRS), multiple-organ-
dysfunction-syndrome (MODS) and infections [1,2]. Moderate SIRS oft en develops aft er 
cardiac surgery and usually resolves with supportive care. However severe SIRS can evolve to 
MODS, which cause higher morbidity and mortality aft er cardiac surgery [3,4].
 During cardiac surgery, despite blood-saving developments, allogeneic red blood cells 
(RBCs) are oft en transfused. Allogeneic RBC transfusions are dose-dependently associated 
with increased risk of postoperative infections and mortality aft er cardiac surgery [5-9]. 
However, it is not clear whether this relationship is causal or what the possible mechanisms 
could be [10]. 
 In two randomized controlled trials in patients undergoing cardiac surgery we found 
a transfusion-dose dependent increased rate of postoperative infections and mortality 
(due to multiple-organ-dysfunction-syndrome) in the patient group receiving buff y-coat-
depleted red blood cells (BCD-RBCs) as compared to fi ltered leukocyte-depleted red blood 
cells (LD-RBCs) [11,12]. Th ese fi ndings suggest that allogeneic leukocytes in BCD-RBCs 
may have played a causal role, possibly by enhancement of the infl ammatory response aft er 
cardiac surgery. In this study we compare blood samples collected from patients randomized 
to either BCD-RBCs or to LD-RBCs. Th e aim of this laboratory analysis is to investigate 
a possible relationship between the presence of leukocytes in blood transfusions and some 
infl ammatory mediators with postoperative complications as morbidity and mortality. 
 We selected four key mediators that represent the infl ammatory response aft er 
surgery. Th e pro-infl ammatory cytokine IL-6 has been shown to be an early predictor for 
non-surviving patients in cardiac surgery and it has been previously reported that intra-
operative blood transfusions in cardiac surgery caused an increase of IL-6 levels [13,14]. IL-10, 
an anti-infl ammatory cytokine, has been found to be increased aft er per-operative allogeneic 
blood transfusions in orthopaedic surgery in association with prolonged hospital stay [15]. 
IL-12 refl ects activation and proliferation of lymphocytes and natural killer cells, which are 
relevant for the defence against nosocomial infections [16,17]. Procalcitonin has been shown 
to be an early marker for sepsis and bacterial infections aft er major surgery and has been 
found increased on the fi rst postoperative day aft er cardiac surgery in patients who developed 
organ dysfunction and severe complications [18].
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MATERIAL AND METHODS
Study Design
In a randomized controlled trial performed in two university hospitals in the Netherlands, 
aft er written informed consent was obtained, 474 patients undergoing cardiac valve surgery 
with or without coronary-artery-bypass-graft  (CABG) were randomized to receive BCD-
RBCs or LD-RBCs. Th e endpoints of the study were: postoperative infections, multiple-
organ-dysfunction-syndrome (MODS) and 90-days and in-hospital mortality. Th e local 
ethical committees of both hospitals approved the trial protocol. Th e design and outcome of 
the study has been described elsewhere in detail [12]. For the assessment of preoperative risk 
of the patients the score model described by Parsonnet was applied [19]. Anesthetical and 
surgical procedures were according to the standards of the hospitals. Following endotracheal 
intubation, patients were ventilated to normocapnia with an air-oxygen mixture. Heparin 
sulphate was administered before start of cardiopulmonary bypass at a dose of 3 mg/kg 
and subsequently at doses to maintain the activated clotting time above 400 seconds. Aft er 
arterial and venous cannulation, cardiopulmonary bypass was commenced using a membrane 
oxygenator (Baxter, Uden, the Netherlands). Aft er termination of cardiopulmonary bypass, 
heparin was antagonized by protamine sulphate at a 1:1 ratio. A nonpulsatile roller pump 
was used for all operations. Th e nonpulsatile fl ow rate at about 2.4 l/min/m2 were set to 
maintain arterial pressure. Patients were cooled to 27-30oC. For myocardial protection 
cardioplegia with cold crystalloids was administered. In one hospital, patients considered to 
be at high risk for bleeding received aprotinin. All patients received prophylactic antibiotics 
postoperatively for 48 hours. Postoperatively the patients were monitored at the intensive 
care unit (ICU) until there was no need for positive inotropes and mechanical ventilation.
Postoperative Complications
Postoperative infections were defi ned according to the criteria of Centers of Disease 
Control and Prevention (CDC) [20]. Th e following infections were scored: respiratory 
tract infection (defi ned as: positive sputum culture and pulmonary infi ltrate on the X-ray), 
urinary tract infection (defi ned as: positive urine culture with clinical signs of urine tract 
infection), wound infection (defi ned as: positive wound culture with clinical symptoms) and 
bacteremia (defi ned as: positive blood culture and fever). Th e development of postoperative 
organ dysfunction was assessed on the basis of the daily medical records at the ICU using 
the model described by Knaus [21]. Th e dysfunction of following organ systems were scored 
postoperatively: respiratory dysfunction (defi ned as: respiratory frequency <5/min or 
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>49/min, or arterial PaCO2 >50 torr [6.5 kPa], or AaDO2 >349 torr [46.5 kPa], or longer 
than 72 hours dependency of mechanical ventilation), cardiovascular dysfunction (defi ned 
as: heart frequency <54/min or >150/min, or mean arterial pressure <49 mm Hg, or serum 
pH <7.24 in combination with PaCO2 <50 torr [6.6 kPa], or dependency of positive 
inotropes), renal dysfunction (defi ned as: urine production <479 mL/24 hours or <159 
ml/8 hours, or creatinine concentration >3.4 mg/dl, or blood urea nitrogen concentration 
>50 mg/dl, or dependency of dialysis), hematological dysfunction (defi ned as: white blood 
cell count <1.0×109/l, or platelet count <20×109/l, or hematocrit <0.20) and insuffi  ciency 
of the central nervous system (defi ned as Glasgow Coma Score <6). MODS was defi ned as 
the failure of 2 or more organ systems. Th e trial coordinators collected all information on 
infections, MODS and hospital mortality from the patient records or electronically from the 
hospital computer system. 
Blood Products 
Th e blood products had been prepared and controlled according to the procedures of the 
Dutch blood banks. Within 20 hours of withdrawal, RBCs were prepared by centrifugation 
of whole blood at 3000 × g for 10 minutes. Buff y-coat and plasma were removed from donated 
blood and BCD-RBCs were reconstituted with 100 mL saline-adenine-glucose-mannitol 
(SAG-M). Th e average leukocyte count (±SD) in BCD-RBCs was 0.7 ± 0.4×109 per unit. 
LD-RBCs were prepared by prestorage fi ltration of RBCs within 24 hours aft er collection of 
blood. BCD-RBCs were subsequently fi ltered through a leukocyte fi lter (Cellselect-Optima, 
NPBI International-Fresenius HemoCare, the Netherlands) resulting in a mean residual 
leukocyte count in the LD-RBCs of 0.15 ± 0.02×106 per unit. All platelet concentrates were 
prestorage leukoreduced by fi ltration. Th e mean storage time of all transfused RBCs was 
calculated in days. 
Infl ammatory Markers 
Blood samples were taken pre-operatively, at the end of perfusion, upon admission to the ICU 
and in case of prolonged ICU-stay, in total two days during ICU-stay. Blood samples were 
immediately centrifuged and alliquotted, the serum was stored at -80oC. Th e concentrations 
of procalcitonin, IL-6, IL-10 and IL-12 were measured in all patients pre-operatively and 
at arrival at ICU; and in case of prolonged ICU-stay (longer than 2 days) additionally at 
day 1 and 2 of ICU-stay. All concentrations of the mediators were measured in duplicate 
using enzyme-linked immunoassay technique (PeliKline Compact, Sanquin Diagnostics, 
Amsterdam, the Netherlands). Th e lower detection limit was for all cytokines 5.0 pg/mL. 
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Procalcitonin was measured by an immunoluminometric assay (LumiTestPCT, Brahms 
Diagnostica, Berlin, Germany). Th e analytic sensitivity of the assay was 0.1 ng/mL.
Statistical Analysis
All patients with at least a pre-operative blood sample and a blood sample at arrival at ICU 
were analyzed in this study. Descriptive results of continuous variables were expressed 
as mean (±SD). Categorical variables were reported as frequency distributions (%). 
Complications were defi ned as postoperative infections, MODS or hospital mortality. 
For comparison of qualitative parameters Fisher’s exact test or χ2 test was used and for 
comparison of quantitative parameters t test or Mann-Whitney U test was used. Th e 
concentrations of the cytokines were expressed as the median with interquartile ranges 
(IQR) and were compared between randomization arms and correlated with complications. 
Diff erences between groups analyzed by the Mann Whitney U test were reported as odds 
ratios (OR) with 95% confi dence intervals (95% CI). Interaction test was performed to 
measure the relation between the randomization arms and the development of complications 
on the concentrations of cytokines. Multivariate analysis of the risk factors was performed 
using a logistic regression model to estimate the risk factors for each of the postoperative 
complications. For this purpose the following variables were included in the model: gender, 
type of surgery, Parsonnet-score, use of pre-operative statins, cardiopulmonary bypass 
time, use of peri-operative aprotinin and corticosteroids, randomisation arm, number of 
RBC transfusions, storage times of transfused RBCs. Th e risk factors from the univariate 
analysis for the composite postoperative complications with p<0.20 were entered into the 
model, the measured concentrations of IL-6, IL-10 and IL-12 at the arrival at ICU and the 
postoperative increase of leukocytes were forced into the fi nal model. For this analysis the 
concentrations of the cytokines, the Parsonnet-score and cardiopulmonary bypass time were 
transformed into quartiles. Th e storage time was divided into three groups: patients receiving 
only RBCs stored for less than 17 days, patients receiving only RBCs stored for 17 or more 
days and patients receiving RBCs with storage times less than 17 and 17 or more days. In 
the fi nal model the independent risk factors for infections, MODS and hospital mortality 
were analyzed separately in a stepwise elimination process. Th e exponent with odds ratios 
and 95% confi dence intervals were reported. All p-values were two-tailed and are reported 
more as a measure of strength of associations than probabilistic assessment. All analyses were 
performed by using SPSS version 15.0 for Windows (SPSS Inc., Chicago, USA). 
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RESULTS
Patient Characteristics
From the 474 evaluable patients randomized within the previously described study [12], due 
to logistic reasons (mostly this regarded procedures outside offi  ce hours) from 128 patients 
complete serial blood samples could not be collected or processed properly (from 106 patients 
no pre-or postoperative blood samples could be collected and from 22 patients no pre-and 
postoperative blood samples were collected). As shown in Table 1, the patient and transfusion 
characteristics of the 346 included patients were balanced between the BCD-RBC and LD-
RBC groups. In the BCD-RBC group signifi cantly more postoperative infections were 
found as compared to the LD-RBC group (p=0.02). In the cohort available for laboratory 
analysis the in-hospital mortality was not signifi cantly diff erent between both randomization 
arms (p=0.19). Th e incidence of MODS was similar in both randomization arms (Table 1). 
Th e patient characteristics of the subgroup of 54 patients with prolonged ICU-stay were 
also well balanced between both study arms (Table 1). Th ere were no diff erences in patient 
characteristics in the subgroups of patients with postoperative complications between both 
randomisation arms (data not shown).
Infl ammatory Markers on ICU-arrival
Th e pre-operative concentrations of all cytokines and procalcitonin levels were all below 
the detection limits. Th e concentrations of cytokines and procalcitonin at arrival at ICU 
were not associated with patient age, Parsonnet-score, use of pre-operative statines and peri-
operative aprotinin, duration of cardiopulmonary bypass and aortic clamping times and the 
analysis according to storage times of transfused RBCs. Patients who received corticosteroids 
peri-operatively had at ICU-arrival lower concentrations of IL-6 than patients who did not 
(median 70; interquartile range [IQR] 39-152 versus median 118; IQR 52-245 pg/ml, 
p<0.01); whereas the concentrations of IL-10 were at ICU-arrival higher in the patient 
group who received corticosteroids (median 54; IQR 14-93 pg/ml versus median 18; IQR 
6-76 pg/ml, p<0.01). Th e concentrations of procalcitonin were increased at ICU-arrival 
(median 0.16; IQR 0.13-0.21 ng/ml). A postoperative increase of the leukocyte count was 
observed at ICU-arrival in all patients (median 2; IQR 1.4-3.6×109/l). 
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Infl ammatory Markers and Randomization to Diff erent Blood Products
Between patients randomized to receive BCD-RBC or LD-RBC no diff erences were 
measured on arrival at ICU in the concentrations of IL-6, IL-10, IL-12 and procalcitonin. 
In the subgroup of patients receiving 0-3 units RBCs the concentrations of cytokines were 
not diff erent (Table 2). Th ere were 182 (52.6%) patients who had received 4 or more units 
RBCs: 84 (49.1%) patients in the BCD-RBC group and 98 (56.0%) patients in the LR-
RBC group. In this subgroup, only the concentration of IL-6 was signifi cantly higher in the 
BCD-RBC group as compared to the LD-RBC group (median 152; IQR 74-340 pg/ml 
versus median 96, IQR 61-249 pg/ml, p=0.02). Th e concentrations of IL-10 and IL-12 were 
at ICU-arrival not diff erent in the analysis according to the type of blood products and the 
number of RBC transfusions (Table 2).
 Th e concentration of IL-6 at ICU-arrival was higher in the BCD-RBC group than in 
the LD-RBC group in patients who developed postoperative infections. Th e concentration 
of IL-12 was higher in patients who developed MODS in the BCD-RBC group. Th e 
concentrations of procalcitonin, postoperative increase of the leukocyte count (data not 
shown) and IL-10 were not diff erent between BCD-RBC and LD-RBC groups, also not 
in subgroups with or without postoperative complications (Table 2). Th e interaction tests 
showed a signifi cant diff erence for IL-6 in the groups with complications and infections 
compared with non-complications and non-infections, respectively. Th e interaction test for 
IL-12 was signifi cant in the MODS group between non-MODS group (Table 2).
 In patients who had received 4 or more units of RBCs, 90 (49.4%) patients had 
postoperative complications: 49 (58.3%) patients in the BCD-RBC group and 41 (41.8%) 
patients in the LR-RBC group. Patients receiving 4 or more units RBCs and who developed 
complications had signifi cantly higher concentrations of IL-6 in the BCD-RBC group as 
compared to the LD-RBC group (median 258; IQR 124-367 pg/mL versus median 196, 
IQR 75-264 pg/ml, p=0.04). In the subgroup of patients receiving 4 or more units RBCs 
without complications, the concentrations of IL-6 levels were not diff erent between both 
study arms (median 90; IQR 52-159 pg/ml versus median 75, IQR 47-137 pg/ml, p=0.66). 
Th ere were no diff erences in the concentrations of IL-10 and IL-12 between both blood 
products according to number of transfusions in patients with and without transfusions 
(data not shown).
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Table 2 | Cytokine Concentrations at ICU-Arrival in Patients with and without Complications
BCD-RBC LD-RBC p p for interactionb
IL-6 (pg/ml)a
 All patients (n=346) 113 (50-250)  85 (45-228) 0.07
Transfusions: 0-3 RBCs (n=164)  77 (36-167)  72 (37-194) 0.64 0.14
>4 RBCs (n=182) 152 (74-340)  96 (61-249) 0.02
Complications: None (n=225)  71 (39-152)  72 (40-146) >0.90 0.04
Any (n=121) 198 (98-360)  183 (72-267) 0.10
Infections: No (n=262)  85 (40-184)  77 (45-212) 0.83 0.006
Yes (n=84) 190 (97-390)  99 (52-250) 0.03
MODS: No (n=284)  97 (47-190)  73 (41-188) 0.20 0.17
Yes (n=62) 258 (120-350) 237 (90-278) 0.23
Hospital mortality: No (n=324)  99 (47-215)  81 (44-217) 0.26 0.07
Yes (n=22) 303 (159-381) 206 (73-260) 0.06
IL-10 (pg/ml)a
 All patients (n=346)  25 (6-77)  25 (9-93) 0.35
Transfusions: 0-3 RBCs (n=164)  18 (6-56)  19 (9-94) 0.35 0.74
>4 RBCs (n=182)  43 (7-84)  33 (9-90) 0.75
Complications: None (n=225)  25 (6-66)  26 (10-82) 0.30 0.52
Any (n=121)  24 (7-91)  22 (7-115) 0.74
Infections: No (n=262)  26 (7-69)  26 (9-91) 0.40 0.92
Yes (n=84)  17 (6-85)  24 (10-110) 0.24
MODS: No (n=284)  25 (6-74)  25 (10-82) 0.29 0.68
Yes (n=62)  19 (9-128)  32 (6-165) >0.90
Hospital mortality: No (n=324)  24 (6-77)  24 (9-83) 0.34 0.71
Yes (n=22)  64 (10-123) 161 (62-210) 0.20
IL-12 (pg/ml)a
 All patients (n=346)  40 (23-64)  37 (23-58) 0.48
Transfusions: 0-3 RBCs (n=164)  36 (21-54)  31 (18-50) 0.66 0.82
>4 RBCs (n=182)  44 (26-87)  44 (27-64) 0.47
Complications: None (n=225)  34 (21-63)  34 (22-51) >0.90 0.22
Any (n=121)  48 (30-75)  45 (25-63) 0.29
Infections: No (n=262)  37 (21-64)  34 (21-51) 0.70 0.76
Yes (n=84)  51 (30-75)  49 (30-64) >0.90
MODS: No (n=284)  37 (21-64)  38 (23-58) 0.80 0.03
Yes (n=62)  50 (39-88)  36 (24-60) 0.02
Hospital mortality: No (n=324)  39 (22-64)  37 (23-58) 0.56 0.65
Yes (n=22)  55 (44-89)  38 (24-49) 0.10
 aData presented as median with 25th and 75th quartiles (IQR); bp for interaction test between the diff erences 
of cytokines in patients with and without complications; BCD-RBC, Buff y-coat depleted red blood cells; LD-
RBC, leukocyte-depleted red blood cells; MODS, multiple-dysfunction-syndrome.
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Multivariate Analyses of Risk Factors for all Postoperative Complications
Th e association between cytokine concentrations upon arrival at the ICU and subsequent 
development of postoperative complications was analysed separately for each complication 
(infections, MODS and hospital-mortality) in a multivariate logistic regression model. 
Based on the results of the univariate analysis for the postoperative complications (Table 3), 
the risk factors with a p<0.20 were included in the multivariate analysis. Th e multivariate 
analysis showed that all complications were independently associated with number of RBC 
transfusions (Table 4). Furthermore the concentration of IL-6 was independently associated 
with the composite of postoperative complications. Postoperative infections were also 
independently associated with the study arm in favour of LD-RBCs and the cardiopulmonary 
bypass time. MODS was also independently associated with IL-6 concentrations and the 
hospital mortality was independently associated with the Parsonnet-score and with the 
concentrations of IL-6 and IL-10.













Type of surgery (valve or valve+CABG) 0.05 0.15 0.69 0.30
Gender (male or female) 0.91 0.58 0.49 0.14
Pre-operative statin use 0.85 0.85 0.94 0.47
Parsonnet-score <0.001 0.003 0.04 <0.001
Randomization arm (BCD-RBC or LR-RBC) 0.10 0.01 0.64 0.16
Peri-operative corticosteroid use 0.16 0.79 0.96 0.29
Peri-operative aprotinin use 0.29 0.51 0.48 0.69
Cardiopulmonary bypass time (in minutes) 0.001 0.001 0.01 0.53
Number of RBC transfusions <0.001 <0.001 <0.001 <0.001
Storage time of transfused RBC units 
(< 17 days, > 17 days, or both)  0.01 0.02 0.01 0.07
BCD-RBC, Buff y-coat depleted red blood cells; LD-RBC, leukocyte-depleted red blood cells; MODS, 
multiple-organ-dysfunction-syndrome
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Kinetics of Cytokines in Patients with Prolonged ICU-stay
In this group of 346 patients, 54 patients had a prolonged ICU-stay of at least two days. 
From these patients from the end of perfusion until postoperative day 2 the kinetics of the 
cytokines IL-6, IL-10 and IL-12 were measured. Th ese patients had a higher age, had longer 
duration of surgery, received more blood transfusions and had higher hospital mortality 
than the whole study group of 346 patients (Table 1). Th e concentration of IL-6 increased 
at the end of perfusion and reached its peak upon arrival at ICU aft er which it declined. 
Th is peak was higher in patients who received BCD-RBC as compared to patients who 
received LD-RBC transfusions (median 188; IQR 111-330 pg/ml versus median 104; 
IQR 66-193 pg/ml, p=0.02). Th e increase of IL-10 preceded the increase of IL-6 and reached 
immediately aft er the end of perfusion signifi cantly higher concentrations in the LD-RBC 
group than in the BCD-RBC group (median 168; IQR 81-270 pg/ml versus median 94; 
IQR 19-234 pg/ml, p=0.05). Th e IL-10 concentrations had already decreased upon arrival 
at ICU. IL-12 concentrations only showed a transient rise upon the arrival at ICU and were 
similar in both study arms (Figure 1).
DISCUSSION
In a randomized study comprising 474 patients with high risk heart valve surgery with or 
without CABG we found leukocyte-containing transfusions (BCD-RBC) dose-dependently 
associated with more postoperative infections and higher in-hospital mortality compared 
to patients receiving leukocyte-depleted (LD-RBC) transfusions [12]. We assumed that 
infl ammatory mediators associated with transfusion of allogeneic leukocytes during cardiac 
surgery might play a role. We investigated for the concentrations of infl ammatory cytokines 
(IL-6, IL-10 and IL-12) and procalcitonin in patients undergoing cardiac valve surgery in 
relation with transfusion of BCD-RBCs or LD-RBCs. From 346 representative patients pre- 
and post-operative blood samples were available to investigate cytokine and procalcitonin 
levels aft er surgery. In the analysis of the total patient population we found no diff erences in 
the levels of the selected cytokines IL-6, IL-10 and IL-12 or procalcitonin upon arrival at the 
ICU. However, signifi cantly higher IL-6 levels at arrival at ICU were found in patients aft er 
transfusion of 4 or more units BCD-RBCs compared with LD-RBCs. Higher IL-6 and IL-
12 aft er leukocyte-containing transfusions were present in patients who developed infections 
and MODS respectively. IL-10 and procalcitonin were not associated with number and type 
of transfusions in patients with or without complications, although higher IL-10 levels were











































IL-10 concentrations during ICU-stay
IL-6 concentrations during ICU-stay
Figure 1 | Th e cytokines IL-6, IL-10 and IL-12 concentrations (pg/mL) in patients measured 
pre-operatively (PRE OP), at end of perfusion (END PERF), arrival at ICU (ICU ARRIVAL), 
at ICU-stay day 1 (ICU DAY 1) and day 2 (ICU DAY 2) in patients staying longer than 2 days 
at ICU. Th e comparisons are made between buff y-coat depleted red blood cells (BCD-RBC) and 
leukocyte-depleted red blood cells (LD-RBC).
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associated with hospital mortality in both randomisation arms. Th is is the fi rst study showing 
higher pro- infl ammatory markers aft er leukocyte-containing transfusions in cardiac surgery, 
in particular in subgroups later developing serious clinical complications.
 In several studies IL-6 concentrations have been found increased in association 
with a pro-infl ammatory response aft er cardiac surgery [22,23]. In these studies the possible 
relationship with allogeneic blood transfusions was not analyzed. Furthermore other studies 
found an association between allogeneic blood transfusions and postoperative morbidity and 
mortality [5-9], however these studies did not perform laboratory analysis. Only one study 
reported that blood transfusions contributed to the release of infl ammatory markers in cardiac 
surgery [13]. Th e purpose of the laboratory analysis was to evaluate a possible relationship 
between the concentrations of infl ammatory markers aft er cardiac surgery and leukocyte 
containing blood products and whether an association with postoperative complications, 
such as infections, MODS and hospital mortality could be found. Th e interaction between 
allogeneic blood transfusions and postoperative complications has been questioned in the 
literature [24], which has not been solved by our study, however our results suggest that 
stimulation of a pro-infl ammatory response by allogeneic leukocytes in transfusions enhances 
susceptibility for complications. To identify the relation between transfusion of type of 
blood products and the development of complications on the concentrations of cytokines 
we performed an interaction test. Th is showed that the diff erences in the concentrations of 
IL-6 and IL-12 in patients who developed infections and MODS, respectively, is related to 
the transfusion of leukocyte-containing blood products, while no diff erences were measured 
in the concentrations of IL-6 and IL-12 in patients without infections and MODS. Th e 
multivariate analysis in this patient cohort revealed that, besides the strong eff ect of the 
number of blood transfusions on all postoperative complications, an association existed 
between the type of blood product (BCD-RBC) and the development of postoperative 
infections. Th is was in accordance with clinical observations of detailed analysis of causes of 
deaths observed in two randomised studies [11,12], which revealed that the higher mortality 
in patients receiving BCD-RBCs was caused by a combination of infections and MODS. 
While death due to cardiac complications and non-infectious reasons were comparable in 
patients aft er BCD-RBC or LD-RBC transfusions [25].
 In contrast to prior reports, we found no diff erences in procalcitonin concentrations 
immediately aft er cardiac surgery predicting complications in patients [26]. On the other 
hand, our study confi rms that higher concentrations of IL-6 are associated with complications 
aft er cardiac surgery [27,28] and that higher IL-6 and IL-10 concentrations are related to 
mortality [29,30]. Furthermore we observed that the higher the number of transfusions, 
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the more outspoken diff erences in cytokine concentrations between randomisation arms 
emerged. We found in two randomized trials a transfusion-dose dependent association 
with postoperative infections and mortality with leukocyte-containing blood transfusions 
[11,12]. Our laboratory analysis suggest that the presence of leukocytes in blood transfusions 
are transfusion-dose dependent associated with the concentrations of some infl ammatory 
mediators, which could be further related with the development of more postoperative 
complications in highly transfused patients. 
 Additionally we evaluated the time course of the cytokine concentrations in 54 
multiple transfused patients with prolonged ICU-stay. In this more heavily transfused 
(median 7 units RBCs) subgroup with a prolonged stay in the ICU (longer than 2 days), at 
arrival at ICU, IL-6 levels were higher and IL-10 levels signifi cantly lower in patients who 
received BCD-RBCs as compared to LD-RBCs. Th e increased concentrations of IL-6, IL-
10 and IL-12 occurred immediately aft er cardiac surgery and generally decreased within 
24 hours. Th e anti-infl ammatory cytokine IL-10 was the fi rst to increase immediately aft er 
perfusion and was higher in LD-RBC group compared to BCD-RBC group. In both study 
arms the concentration of IL-10 decreased during ICU-stay. Th e increase of infl ammatory 
cytokine IL-6 was observed later and reached higher levels in the BCD-RBC group than in 
LD-RBC group. Th is pattern of waves of pro-and anti-infl ammatory cytokines seems typical 
for cardiac surgery and has been reported also in patients with uneventful recovery [13,29,30]. 
 Cardiac surgery causes an initially anti-infl ammatory response followed by a pro-
infl ammatory response leading to production and release of infl ammatory mediators 
[13,29,30]. Th e balance between these pro-infl ammatory and anti-infl ammatory responses 
determines the clinical course of the post-surgical systemic infl ammatory response. Th e 
higher pro-infl ammatory cytokine IL-6 and lower anti-infl ammatory cytokine IL-10 in 
the BCD-RBC group suggests that leukocyte-containing blood transfusions aggravate this 
pro-infl ammatory pattern, which is more pronounced than in the leukocyte-depleted blood 
transfusions. Th ese fi ndings support that leukocyte-containing allogeneic blood transfusions 
amplify an infl ammatory response in addition to an ongoing systemic infl ammatory 
response aft er cardiac surgery. Th is transfusion-related immunomodulation could enhance 
the development of postoperative adverse events, which may result in severe infections and 
aggravation of MODS. Th ese adverse events could infl uence recovery and could eventually 
lead to higher incidence of mortality. 
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CONCLUSIONS
Th is laboratory analysis derived from a large patient population undergoing cardiac surgery 
provides for the fi rst time detailed information about diff erences between leukocyte-
depleted and leukocyte-containing transfusion-related immune responses. Th e results 
supports that leukocyte-containing transfusions interfere with the balance between 
postoperative pro-and anti-infl ammatory responses towards the pro-infl ammatory direction. 
Th e complex balance between pro-infl ammatory and anti-infl ammatory mediators leading 
to postoperative complications is diffi  cult to discriminate based on our data. Additionally 
to blood transfusions, multiple factors may infl uence infl ammatory responses that could 
contribute to the development of postoperative complications. Future studies are needed 
to investigate the more long-term eff ects of allogeneic blood transfusions in cardiac surgery. 
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 Chapter 6
Mannose-Binding Lectin is Involved 
in Multiple-Organ-Dysfunction-
Syndrome aft er Cardiac Surgery: 
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ABSTRACT
Background: Serum levels of mannose-binding lectin (MBL), a recognition molecule of 
the lectin pathway of complement, are highly variable, based on genetic variation. Aft er 
cardiac surgery, extracorporeal circulation and ischemia/reperfusion injury initiate a 
systemic infl ammatory response, which can evolve to multi-organ dysfunction syndrome 
(MODS). Peroperative transfusions of allogeneic leukocytes contribute to infectious and 
infl ammatory complications. Th e present study investigates the role of MBL in relation to 
blood transfusions and complications following cardiac surgery. 
Methods: In cardiac surgery patients who participated in a randomised trial comparing 
leukoreduced with buff y-coat-depleted red blood cell transfusions, circulating MBL 
was measured pre- and post-operatively by ELISA. Data were related to the incidence of 
complications and to the transfusions the patients received.
Results: Patients with high pre-operative serum MBL levels (>400 ng/ml) show a signifi cant 
(52 ± 12%) decrease of serum MBL post-operatively, while patients with low serum 
MBL levels (<400 ng/ml) show a signifi cant increase of serum MBL levels aft er surgery 
(140 ± 106%), which was further enhanced by fresh-frozen plasma (FFP) transfusions. MBL 
levels were not associated with infections, sepsis, or death. Patients with MBL defi ciency 
(MBL <80 ng/ml) were protected against development of MODS (p=0.016), whereas FFP 
transfusion abolished this protection (p=0.048). 
Conclusions: Cardiac surgery is associated with MBL consumption, independent of the 
transfusion of allogeneic leukocytes. Patients with MBL defi ciency develop no MODS, 
unless they have been transfused with FFP, which is associated with MBL reconstitution. 
Th erefore, sustained MBL defi ciency may be a favourable status for patients undergoing 
cardiac surgery. 
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INTRODUCTION
Cardiac surgery associated with ischemia/reperfusion injury is oft en followed by a systemic 
infl ammatory response syndrome (SIRS). Moderate SIRS usually resolves with supportive 
care, although severe SIRS can evolve to multiple-organ-dysfunction-syndrome (MODS). 
Th e outcome of cardiac surgery is closely related with the severity of MODS and development 
of severe infections [1].
 One of the components of the infl ammatory response which is activated during 
cardiac surgery is the complement system [2,3]. Th e complement system can be activated by 
three pathways: the classical pathway, the alternative pathway and the lectin pathway. While 
the classical pathway is activated by antibodies and immune complexes, the lectin pathway 
can be triggered by binding of carbohydrates exposed on a wide range of micro-organisms 
to mannose-binding lectin (MBL) [4]. Polymorphisms in the MBL gene result in a wide 
range of functional MBL levels. Roughly 30% of the Caucasian population has reduced 
levels of MBL, due to single nucleotide polymorphisms in exon 1 of the MBL2 gene, and 
approximately 5-10% has a functional MBL defi ciency [5].
 MBL defi ciency in itself does not lead to clinical problems, but several studies have 
shown that MBL defi ciency confers an increased susceptibility for infections in immune-
compromised patients [6-9]. Th e role of MBL defi ciency on the development and outcome of 
SIRS and sepsis syndrome is controversial. Worse outcome in patients with sepsis is described 
[10,11]. However, in animal models, inhibition of the lectin pathway was shown to protect 
against ischemia-reperfusion injury and diminished neutrophil accumulation and cytokine 
release [12], and MBL-defi cient mice were protected against severe ischemia/reperfusion 
injury in various organ systems [13-16]. Th ese studies suggest that MBL defi ciency could have 
favourable eff ects on tissue injury following ischemia and reperfusion.
 In cardiac surgery, red blood cell transfusions dose-dependently increase the risk of 
morbidity and mortality. In randomized trials we observed that red blood cells containing 
leukocytes compared with fi ltered leukoreduced red blood cells were associated with 
increased postoperative infections and mortality with MODS [17]. Aft er complicated 
cardiac surgery, approximately 20-25% of the patients develop MODS and the combination 
of MODS and infections is associated with increased mortality [18]. However the role of 
blood component transfusions on activation of the complement system, especially on the 
lectin pathway, is not known. Cellular interactions of MBL have been described in vitro 
for several cell types. Interaction of polymorphonuclear leukocytes with ligand-bound 
MBL in vitro was shown to induce cell aggregation and superoxide production [19]. Direct 
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interactions between leukocytes and the complement system may provide an explanation 
for the benefi cial eff ect of leukocyte depletion in red cell transfusion. We hypothesize that 
MBL and the lectin pathway may contribute to complications aft er cardiac surgery, both via 
activation of the complement cascade and via cellular interactions. 
 In the present study, we evaluated the eff ect of cardiac surgery and blood transfusions 
on pre- and postoperative MBL levels and we assessed whether MBL levels were associated 




A randomized, double-blinded controlled trial had been conducted in two hospitals and 
included patients undergoing valve surgery with or without coronary artery bypass graft  
(CABG). Patients were randomized to receive (when needed) standard buff y-coat depleted 
or pre-storage leukoreduced red blood cells. Patient samples were collected aft er informed 
consent was obtained. Th e endpoints of the study were: postoperative infections, MODS 
and mortality (90-days and in-hospital). Th e design and clinical outcome of the study has 
been described elsewhere [17]. In this trial infections were defi ned according to the criteria 
of the Center for Disease Control (CDC) [20]. Th e following infections were taken into 
account: respiratory tract, urinary tract, sepsis and wound infections. Th e incidence and 
duration of organ dysfunction was described as defi ned by Knaus [21]. MODS was defi ned 
as failure of two or more organ systems. Th e blood products used in this study were prepared 
and controlled according to the Dutch standards for blood banks. 
 Blood samples were taken pre-operatively before the start of the surgical procedure 
and at admission on the ICU, immediately centrifuged, and the sera stored at -80oC. 
Measurement of MBL
Th e concentration of MBL was measured by sandwich enzyme linked immunosorbent assay 
(ELISA) as described previously [22]. In summary, 96-well ELISA plates were coated with 
mAb 3E7 (monoclonal anti-MBL antibody kindly provided by Dr. T. Fujita, Fukushima, 
Japan). Aft er blocking residual binding sites with PBS containing 1% BSA and washing, 
serum samples were diluted and incubated, followed by detection with digoxygenin (dig-) 
conjugated 3E7 and HRP-conjugated sheep Fab anti-Dig antibodies (from Roche Applied 
Science, Mannheim, Germany), respectively. Enzyme activity was developed using ABTS. 
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Th e optical density was measured using a microplate reader, and results were calculated on 
basis of a calibration line using pooled normal human serum with a known concentration of 
MBL. 
 To estimate the eff ect of the surgical procedure on the MBL serum concentration, the 
ratio of the post- and preoperative MBL serum level was calculated.
Statistics
Categorical characteristics among MBL groups were compared using cross-tables with 
calculation of p-values. Continuous variables were analyzed using Student t-test or, when 
appropriate Mann -Whitney test was used. Th e diff erences in MBL levels before and aft er 
surgery were analyzed by the Wilcoxon’s signed rank test. Spearman Rank correlation 
coeffi  cients were used for correlation. A logistic regression model was used to evaluate the 
eff ect of per-operative factors on the postoperative/preoperative MBL ratio. P-values <0.05 
were considered as statistically signifi cant. All analyses were performed in SPSS (SPSS Inc, 
Chicago, IL, USA). 
RESULTS
Patients Characteristics
Of the 474 patients included in the trial, serum for MBL determination was available from 
400 patients prior to surgery. From these 400 patients, postoperative MBL levels could be 




Pre-operative serum levels of MBL were highly variable as expected in the human population 
(range 15-3709 ng/ml; Table 1). In Figure 1A the post-/ preoperative MBL ratios are shown. 
Th e ratio of post-operative and pre-operative MBL concentration was negatively correlated 
with the pre-operative MBL concentration (R = -0.73, p<0.0001). Patients with high 
serum MBL levels before surgery (>400 ng/ml) showed an average decrease of 52 ± 12% 
of the serum MBL level aft er the procedure (range ratio 0.19-0.93; p < 0.0001, Figure 1B). 
In contrast, patients with low serum MBL levels before operation (< 400 ng/ml) generally 
showed an increase of serum MBL levels, as represented by a ratio signifi cantly higher than 
1 (p<0.0001, Figure 1B). 
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Patient number 400 194 206
Age (mean ±SD)   65.8 ± 13.9  66.5 ± 12.5 65.1 ± 15 0.36
Type of surgery (N (%))
 Valve 








Female (N (%)) 178 (44.5%)  85 (43.8%)  93 (45.1%) 0.84
Parsonnet score 13.8 ± 8.2 13.8 ± 8.6  13.8 ± 7.8 0.98
Blood transfusions during surgery†
 Red blood cells (mean units per patient ±SD)
 FFP (mean units per patient ±SD)
 3.2 ± 3.6
 3.2 ± 4.1
 3.4 ± 4.7
 3.6 ± 5.4
  3.0 ± 2.1
  2.8 ± 1.7
0.23
0.22
Patients without FFP transfusions (N (%))









Cardiopulmonary bypass time (minutes; mean ±SD) 140 ± 62 145 ± 66  136 ± 57 0.13
Aortic cross clamping time (minutes; mean ±SD)   96± 46  96 ± 47   96 ± 44 0.98







   75 ± 4.6
 50.2 ± 5.8
0.55
0.50
Infections (N (%)) 113 (28.3%)  66 (34.0%) 47 (22.8%) 0.02
MODS (N (%))  89 (22.3%)  45 (23.2%) 44 (21.4%) 0.72
Sepsis (N (%))  17 (4.3%)  10 (5.2%)  7 (3.4%) 0.46
Hospital mortality (N (%))  34 (8.5%)  23 (11.9%) 11 (5.3%) 0.04
Mean MBL (ng/ml) (mean ±SD)
 Pre-operative (N=400)
 Post-operative (N=330)
 837 ± 796
 453 ± 350
 820 ± 802
 449 ± 356
  854 ± 792










Pre-operative MBL <80 (ng/ml) (N (%))









* Patients were randomized to receive either buff y-coat-depleted red blood cells or leukocyte depleted red blood 
cells, when needed. † Units per patients transfused during surgery. Only patients who received red blood cells 
and FFP transfusions are included for calculation of mean and SD. 
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Figure 1 | Th e eff ect of plasma transfusion on levels of serum MBL in patients who undergo 
cardiac surgery. A. Ratios of post/pre-surgery MBL levels were plotted against pre-operative serum MBL 
levels in all patients (N=330). Th e dashed line indicates a serum MBL level of 400 ng/ml.  B. Mean ratios post/
pre-surgery MBL levels ± SD were calculated for patients above and below 400 ng/ml who did or did not receive 
FFP during the operation, as indicated. ** indicates statistical signifi cance. Ratios in all groups were signifi cantly 
diff erent from 1 (P<0.0001; Wilcoxon signed rank test). Th e diff erence between patients with serum MBL level 
below 400 ng/ml who did or did not receive plasma was tested with the Mann Whitney test (P=0.0039). 
Ratios of MBL levels were not diff erent between recipients of leukoreduced or buff y-coat 
depleted red blood cells. In both groups the MBL level decreased or increased with the same 
ratios determined by the preoperative MBL level (not shown). In contrast, FFP transfusions 
were associated with an additional increase of post-operative serum MBL in patients with 
a pre-operative MBL level below 400 ng/ml (median post/pre MBL ratio 1.25 versus 1.61, 
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p=0.0039; Figure1B), whereas FFP transfusion did not show an eff ect in patients with MBL 
levels above 400 ng/ml. 
 Following surgery, all patients displayed a dilution eff ect, as shown by a decreased 
serum total protein concentration (average ratio total protein post/pre-surgery =0.67 ± 0.08; 
range 0.46-0.86). However, this dilution factor was not correlated to post/pre-surgery MBL 
ratios, also not when patients with pre-MBL levels above 400 ng/ml were analysed only 
(R<0.1). 
 In a logistic regression model we further evaluated the contribution of various per-
operative factors on the post/pre-surgery MBL ratio. Th e type of surgery (p=0.23), duration 
of cardiopulmonary bypass (p=0.19), duration of aortic crossclamping (p=0.25), number of 
red blood cell transfusions (p=0.19), randomization arm (p=0.74) and the decrease in total 
protein concentrations (p=0.43) did not show a signifi cant eff ect on the post/preoperative 
MBL ratio. 
MBL Serum Levels and Complications of Cardiac Surgery
Following cardiac surgery 113 of 400 patients developed infections (28.3%), 89 patients 
developed MODS (22.3%), 17 patients had sepsis (4.3%) and 34 patients died (8.5%; 
Table 1). Infections and mortality were signifi cantly higher in patients receiving leukocyte-
containing transfusions than in patients randomized for leuko-reduced red blood cells 
(p=0.02 and p=0.04, respectively). Patients who developed MODS had a signifi cantly 
longer duration of cardiopulmonary bypass (median 148 versus 124 minutes; p=0.0002) 
and aortic crossclamping (median 98 versus 90 minutes; p=0.008).
 Since data as presented above show that the surgical procedure and plasma 
transfusions have an eff ect on serum MBL levels, the relation between serum MBL and 
complications of cardiac surgery were further evaluated based on pre-operative MBL levels 
in patients who did not receive plasma. Using an MBL level of 400 ng/ml as a cut-off  value, 
no signifi cant association could be identifi ed between higher or lower pre-operative MBL 
levels and infections, sepsis, MODS or mortality in the 224 patients who did not receive FFP 
transfusions (Table 2). However, patients with an MBL level below 80 ng/ml, indicating overt 
MBL defi ciency, did not develop MODS (Figure 2 and Table 2; p=0.016). Th e incidence of 
infections, sepsis and mortality was not signifi cantly diff erent in patients with pre-operative 
MBL serum levels below or above 80 ng/ml. 
 In total 176 patients received FFP transfusions. In patients with pre-operative MBL 
levels below 80 ng/ml, the FFP transfusions increased the risk for development of MODS 
until the same degree as for patients with preoperative MBL concentrations above 80 ng/ml 
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(Table 3; p=0.048). In patients with pre-operative serum MBL levels above 80 ng/ml or 
above 400 ng/ml, FFP transfusion did not show any eff ect on the development of MODS. 
Table 2 | Complications in Relation to Pre-operative MBL Levels in Patients who did not Receive 
Plasma
MBL (ng/ml)* All ≤80 >80 p-value§ ≤400 >400 p-value§
N† 224 18 206 93 131
Infection (%)‡ 25.0 22.2 25.2 1.0 28.0 22.9 0.43
Sepsis (%)‡  3.6 0  3.9 1.0  5.4  2.3 0.28
MODS (%)‡ 21.0 0 22.8 0.016 19.4 22.1 0.74
Mortality (%)‡ 6.3 0  6.8 0.61  7.5  5.3 0.58
*MBL level before surgery; †Number of patients in each category; ‡Percentage of patients who developed this 
complication; §P value (Fisher exact test; comparison between MBL-low and MBL-high patients); MODS = 
multiple-organ-dysfunction-syndrome
Figure 2 | Low serum MBL levels protect against MODS in patients who did not receive plasma 
during operation. Pre-operative serum MBL levels are shown in patients who did or did not 
develop MODS. Only patients who did not receive FFP were plotted. 
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Table 3 | Plasma Transfusion is a Risk Factor for MODS in Patients with Low Pre-operative MBL 
Levels 
MBL level (ng/ml)* No plasma (N)† % MODS‡ Plasma (N)† % MODS‡ p-value§
All 224 21 176 24 0.55
≤80  18 0  20 25.0 0.048
>80 206 22.8 156 23.7 0.90
≤400  93 19.4 7 1 25.3 0.45
>400 131 22.1 105 22.9 1.00
* MBL level before surgery; †Number of patients who did or did not receive plasma during the procedure; 
‡Percentage of patients who developed multi-organ dysfunction syndrome; §P value (Fisher exact test; 
comparison between patients who did or did not receive plasma)
CONCLUSIONS
In a randomised study in cardiac surgery patients we observed a lower incidence of 
postoperative infections and mortality associated with MODS aft er transfusion of fi ltered 
leukoreduced red blood cell transfusions compared with standard buff y-coat depleted 
red blood cells [17]. Pre-operative and postoperative blood samples had been taken for 
investigation of mechanisms, which could explain diff erences between both randomization 
arms, should these occur. Because in previous studies low MBL levels have been associated 
with infections and high levels with ischemia/reperfusion injury [6-12], both important 
complications of cardiac surgery, we hypothesized that leukocytes in red blood cell units 
may play a role by activation of the innate immune system via the lectin pathway. 
 Th e results of this study show that absence or presence of allogeneic leukocytes 
in erythrocyte products had no eff ect on MBL concentrations aft er surgery. In both 
randomisation arms, patients with higher (>400 ng/ml) pre-operative MBL levels show post-
surgical decrease by almost 50%. Although patients with preoperative MBL values below 
400 ng/ml increased their postoperative MBL levels, especially if FFP had been administered 
during the procedure. If the preoperative MBL value was above 80 ng/ml, preoperative and 
postoperative MBL values were not associated with postoperative infections, MODS or 
mortality. However, none of the 18 patients with MBL defi ciency below 80 ng/ml who did 
not receive per-operative FFP developed MODS. In contrast, the incidence of MODS in 20 
MBL-defi cient patients who received FFP was comparable with the incidence in patients 
with higher preoperative MBL concentrations. 
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Th is is, to the best of our knowledge, the fi rst study that reports MBL serum levels aft er 
cardiac surgery. In a previous study in a small number of 23 patients undergoing abdominal 
aneurysm aorta surgery, a postoperative decrease of approximately 40% of MBL was observed, 
whereas in a control group, undergoing biliary and pancreatic surgery, there was no eff ect on 
MBL levels aft er the operation [23]. In patients undergoing abdominal surgery for respectable 
esophagus carcinoma a clear increase of serum MBL was observed, with a slow kinetics 
starting on day 5 postoperatively [24]. In gastric surgery patients, no eff ect on post-surgery 
MBL levels was observed as assessed on day 3 [25]. Th ese variable results in patient cohorts 
undergoing diff erent surgical interventions, in studies with relatively small cohort sizes, 
indicate interplay of diff erent factors modifying the MBL serum level. In our large patient 
population undergoing cardiac surgery, we observed an increase as well as a decrease of MBL 
concentrations. Th e change in MBL concentration aft er surgery was signifi cantly associated 
with the patient’s MBL status prior to surgery. Because the MBL level in the population 
shows a wide range, which is genetically based, this relationship is easily missed when small 
groups of patients are evaluated. Th e measured decrease of 50% in the MBL concentration 
was somewhat overestimated because of postoperative hemodilution, refl ected by a decrease 
of the total protein concentration. In reverse, due to this hemodilution, the increase of 
MBL aft er cardiac surgery is somewhat underestimated. When calculation of MBL post/pre 
ratios was corrected for this hemodilution eff ect, we confi rmed a median 24% decrease of 
serum MBL levels (P<0.0001, not shown) in patients with pre-operative MBL levels above 
400 ng/ml, suggesting an independent cause for the decrease of serum MBL. 
 Th e reduction in serum MBL in patients with higher preoperative MBL levels is 
most likely the result of consumption by activation of the lectin pathway during surgery, 
presumably mainly by interaction of MBL with ischemic and injured tissue. Accordingly, 
MBL consumption was previously observed in patients undergoing aorta aneurism operation 
[23], a procedure also associated with extended ischemia, but not in patients undergoing 
other surgical interventions [23-25]. Th e fi nding that this decrease was not compensated in 
our cardiac surgery patients, neither by endogenous production nor by FFP transfusions, 
suggests a stronger MBL consumption in these patients than in patients with lower 
preoperative MBL levels. In patients with preoperative MBL concentrations below 400 ng/
ml we do not know whether (compensated) per-operative MBL consumption may occur, but 
aft er surgery endogenous production is increased and the level further increases aft er FFP 
transfusions. Th e latter observation, i.e. MBL reconstitution of MBL-defi cient patients upon 
FFP transfusion, has also been reported for patients undergoing aortic aneurysm repair [3]. 
It is well conceivable that MBL consumption is more effi  cient in patients with a high MBL 
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level before transplantation, since levels of MBL above 400 ng/ml are strongly associated 
with the MBL wildtype genotype and normal lectin pathway function, whereas MBL from 
low-MBL patients may show impaired interaction with ligand [26]. Further studies with 
sampling during the various phases in cardiac surgery are needed revealing the kinetics of 
MBL during surgery to explain the mechanisms of this dichotic MBL behavior. 
 In the present study no association was observed between pre- or post-surgery MBL 
levels and postoperative infections aft er cardiac surgery, in contrast to studies performed 
in immunocompromised patients showing an association of MBL defi ciency with increased 
risk of infections [6-9]. However, patients with an obvious MBL defi ciency before surgery 
were signifi cantly protected against the development of MODS. Only in these patients, 
FFP transfusions, resulting into (partial) reconstitution of the MBL status, reversed this 
protection against MODS. Th is is in agreement with observations in experimental renal 
and myocardial ischemia/reperfusion injury and septicaemia in rats and mice, which suggest 
that low MBL ameliorates ischemia/reperfusion injury and sepsis-induced organ damage 
[12,13,27,28]. Lower MBL levels have also been associated with less graft  loss in kidney 
transplantation in humans [22]. In the setting of aortic aneurism repair, one patient has been 
presented who was MBL defi cient and who did not respond to the surgical procedure with 
production of soluble complement activation products and cytokines, in contrast to all MBL-
suffi  cient patients who developed an evident infl ammatory reaction [3]. MBL may mediate 
an infl ammatory response via activation of the complement cascade and probably also by 
direct interaction with and activation of leukocytes [19]. However we observed a benefi cial 
eff ects of transfusion with leukoreduced red blood cells in cardiac surgery [17], no eff ects of 
allogeneic leukocytes could be observed in this study in postoperative MBL levels. Taken 
together, results now presented in our study support a role for MBL in the activation of the 
complement system and induction of a systemic infl ammatory response upon ischemia and 
reperfusion injury, which may evolve into multiple organ dysfunction. MBL defi ciency have 
probably a protective role in development of MODS, which disappears with transfusions of 
FFP and is not directly related with allogeneic leukocytes. 
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ABSTRACT
Background: Cost-eff ectiveness of leukodepleted erythrocytes (LD) over buff y-coat-
depleted packed cells (PC) is estimated from the primary dataset of a recently reported 
randomized clinical trial involving valve surgery (± CABG) patients.
Methods: Data on the patient level of 474 adult patients undergoing valve surgery (± CABG) 
who were randomized double-blind to LD or PC was used to calculate the healthcare costs 
and longevity per patient. Th e incremental cost-eff ectiveness ratio (ICER) in net costs per 
life-year gained was established from the healthcare perspective. Bootstrapping and cost-
eff ectiveness acceptability curves were used to determine the confi dence interval of the 
ICER.
Results: Th e longevity of patients in the PC and LD group was 10.6 and 11.4 years 
respectively. Relative to PC, LD yielded an estimated 0.8 (95% CI-0.27 to 1.84) life-year in 
baseline. Adjusted for age and gender diff erences health gains for LD are 0.4 life-year gained 
(95% CI-0.67 to 1.44]. Healthcare costs per patient averaged US$ 10163 per patient in the 
PC group and US$ 9949 in the LD group. Average cost-savings were US$ 214 (95% CI-1964 
to 1536) per patient. Acceptability curves constructed from bootstrap simulations showed 
a probability of being cost saving of 59% for universal leukodepletion from the healthcare 
perspective. Th e probability of adopting leukodepletion regardless the costs reaches 92.7%. 
LD in patients receiving 4 or more transfusions showed the highest cost-savings and health 
gains.
Conclusions: Leukodepletion of erythrocytes is a cost-saving strategy in cardiac valve 
(± CABG) patients. However, acceptability analysis failed to show a signifi cant diff erence 
with buff y-coat-depleted packed cells.
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INTRODUCTION
Th e clinical benefi t and application of leukodepletion of cellular blood products such 
as erythrocytes or platelets remains a strongly debated issue in transfusion medicine [1,2]. 
Observational and prospective clinical studies show results ranging from a positive clinical 
outcome to no eff ect. Observational “before-aft er” studies summarised in a meta-analysis 
suggested a reduction in risk of post-operative infections, but no decrease in mortality was 
observed [3]. 
 A meta-analysis of randomised clinical trials reporting on the eff ect of leukodepletion 
showed no eff ect on mortality across all included clinical settings. However, subgroup 
analysis for open heart surgery patients showed an increase in mortality for patients receiving 
standard RBCs instead of leukodepleted RBCs [4]. Recently a double-blind randomized 
clinical trial involving valve surgery (with or without CABG) patients found a reduction in 
infections and in hospital mortality as secondary endpoints. No signifi cant reduction of the 
primary endpoint mortality was observed aft er three months, the primary data on the patient 
level of this is used for the present cost-eff ectiveness analysis [5]. Only the secondary outcome 
hospital mortality was considered in the previously mentioned meta-analysis of randomised 
clinical trials.
 Up to date formal cost-eff ectiveness analyses on leukodepletion are scarce and 
are mainly derived from observational, retrospective data. However, the few studies 
that are available show a favorable economic profi le for selected clinical indications. For 
instance, utilizing observational clinical data in an economic model, leukodepletion of 
platelets appears to be cost-saving when applied in adult acute myelogenous leukaemia [6]. 
Furthermore, leukodepletion of platelets in acute myelogenous leukemia and lymphoma 
patients, and leukodepletion of whole blood in colorectal surgery showed lower hospital 
costs compared to unfi ltered blood products [7,8]. In CABG patients leukodepletion of 
erythrocytes was cost-saving [9]. Th e Canadian Co-ordinating Offi  ce for Health Technology 
Assessment concluded that universal leukodepletion would not be cost-saving but that 
selective leukodepletion, that is, applying it to all patients who had an established indication 
for its use (such as frequently transfused patients), might be cost-saving [10].
 In this study the cost-eff ectiveness ratio of pre-storage leukodepleted (by fi ltration) 
erythrocytes incremental to standard buff y-coat-depleted packed cells was established from 
the healthcare perspective for patients undergoing valve surgery with or without CABG 
using clinical outcomes and cost data per patient from a prospective randomized double 
blind clinical trial [5]. 
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MATERIAL AND METHODS
Patients, Design and Data Collection
Th e design of the clinical trial is described in detail by Bilgin et al [5]. Briefl y, a prospective, 
randomized, double-blind, controlled trial was conducted in 2 university hospitals in the 
Netherlands in adult patients >18 years undergoing valve surgery (with or without CABG). 
Patients with a medical indication for leukodepletion and patients who had received blood 
transfusions within the previous 3 months were ineligible. Th e patients were randomized into 
two groups: when there was an indication for transfusions, one group received buff y-coat-
depleted packed-cells (PC), which was at that time the standard product in the Netherlands, 
and the other group received pre-storage leukocyte-depleted (by fi ltration) erythrocytes 
(LD). Th e hospitals used similar transfusion triggers for erythrocytes, plasma and platelets. 
To all patients prophylactic antibiotics were given for 48 hours. Postoperatively the patients 
were monitored at the intensive-care-unit (ICU); they were discharged from the ICU when 
there was no more need for inotropes and intubation.
 Primary endpoint was the rate of mortality 90 days aft er surgery. Secondary 
endpoints were incidence of in-hospital mortality, the incidence of postoperative Multiple-
Organ-Dysfunction-Syndrome (MODS), infections, ICU and standard care stay. We used 
parameters for organ dysfunction as described by Knaus [11]. MODS was defi ned as the failure 
of >2 organ systems. Infections were scored according to the criteria of CDC (Centers for 
Disease Control and Prevention) [12]. Causes of in-hospital mortality were obtained from the 
hospital patient records, mortality at 90 days from the referring cardiologist or the general 
practitioner. Blood product use (erythrocytes, platelets and plasma) and prescriptions for 
antibiotics were registered. Th e analysis for all endpoints was on an intention-to-treat basis.
Cost-Eff ectiveness Analysis
Th e Incremental Cost Eff ectiveness Ratio (ICER) was expressed in net costs per life-
year gained. Net costs were estimated by subtracting average costs per patient in the PC 
group (CPC) from those in the leukodepleted arm in the trial (CLD). Table 1 lists the unit 
costs used to calculate the total costs from the trial data. To estimate the ICER for overall 
implementation of leukodepletion and only for cardiac surgery patients, excess costs of 
leukodepletion were calculated at two levels: Dutch Sanquin Blood Supply Foundations’ 
estimate for universal leukodepletion (baseline) and estimation for selective leukodepletion 
for cardiac surgery patients solely. Costs of ICU stay and standard care were obtained 
from the reference costs for Dutch pharmaco-economic analyses and corrected for blood 
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product use [13]. Costs of erythrocytes, fresh frozen plasma and platelets were obtained from 
Sanquin Blood Supply Foundation. Antibiotics costs were derived from the Dutch Price 
Index (Z-index, Th e Hague, Th e Netherlands) and corrected for the average discount for 
hospital pharmacies (-20%). As outlined in the introduction net cost (CLD-CPC =DC) 
were considered from the healthcare perspective. Incremental health gains were expressed 
in life-years gained (DE) and were derived by linking survival, derived from the mortality 
at day 90, to age and gender specifi c remaining life expectancies in the Netherlands (source: 
Statistics Netherlands, Heerlen, Th e Netherlands). To account for increased mortality in 
cardiac surgery patients survival was corrected by an annual excess death rate of 1% [14]. 
Because the study duration was less then one year, discounting of costs and monetary benefi ts 
was not necessary. Life-years gained were discounted at 3% (0% and 5% in the sensitivity 
analysis) according to international guidelines [15,16]. 
Table 1 | Unit Costs Used to Calculate Costs from Trial Data
Cost component Cost (US$) per unit Unit
Leukodepletion (baseline, universal) 20 RBC
Leukodepletion (selective) 36 RBC
ICU stay 1024 Day
Standard care stay 305 Day
Antimicrobial therapy Reference price Dose
RBCs 130.84 Unit
Fresh Frozen Plasma 164.45 Unit
Platelets 342.15 Unit
Clinical trials contain both costs and health information at the patient level and therefore 
inferences can be made for the confi dence interval around the point estimate cost-eff ectiveness 
ratio. However, being a ratio, standard statistics do not apply for the cost-eff ectiveness ratio 
and other approaches such as bootstrapping must be applied [17]. Bootstrapping as a non-
parametric approach avoids the diffi  culties related to distribution depended statistics and 
estimates an empirical sampling distribution for the cost eff ectiveness ratio [18]. In boot-
strapping a number of random cost and eff ect pairs equivalent to the number of observations 
in the original data set are taken with replacement from the original data set. Next, the 
bootstrap estimates for the mean costs and health eff ects of both the LD (  ) and 
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PC (  ) group are calculated, enabling to calculate the bootstrap estimate of the 
incremental cost eff ectiveness ratio (ICER*), given by:
=
 Repeating the bootstrapping process R times yields the empirical sample distribution 
of the cost eff ectiveness ratio, with the estimated mean cost eff ectiveness ratio    (we took 
R=5000), see Figure 1. Using the bootstrap replicates, an acceptability curve is constructed. 
In fi gure 1, for example, the percentage of bootstrap replicates below a given willingness to 
pay (line R) corresponds to the probability of acceptance for that specifi c willingness to pay. 
An acceptability curve is generated by plotting the percentage of bootstrap replicates below 
the willingness to pay line R, when varied from nought (points below x-axis) to infi nity 
(points right-hand side of y-axis). Th e acceptability curve is tending towards 1 minus the 
one sided p-value for the eff ect diff erence if the willingness to pay goes to infi nity (y-axis). 
Th e 95% confi dence interval for the cost-eff ectiveness ratio is determined by the 2.5% and 
the 97.5% probabilities of acceptance. Due to the precautionary principle it is unlikely that 
interventions with a negative impact on health will be implemented in blood transfusion 
medicine, regardless of the potential cost-savings. Th e acceptability curve can be adjusted 
for the precautionary principle by disregarding bootstrap replicates falling in the Southwest 
quadrant.
 Th e willingness to accept monetary compensation for health losses is greater (higher 
selling price of a life-year lost) than the willingness to pay for health gains [19]. Th e willingness 
to pay for blood transfusion safety is very high and due to political and societal pressure the 
willingness to accept monetary compensation for health losses is likely to approach infi nity. 
Th erefore, in the sensitivity analysis cost-eff ectiveness acceptability curves were constructed 
regarding bootstrap replicates with health losses regarded as unacceptable. For the cost-
eff ectiveness analysis the statistical package Splus was used.
Cost-Eff ectiveness of Leukodepletion | 121
Figure 1 | Empirical sample distribution of the incremental cost-eff ectiveness ratio (ICER) for 
leukodepletion incremental to buff y coat depleted RBCs (1000 bootstrap replicates shown). For 
a willingness to pay of 3500 US$/LYG (line R) the percentage acceptability is the percentage of 
replicates below line R.
RESULTS
Clinical Trial
In total 496 patients were enrolled in the study. Twenty-two patients were excluded for 
various reasons: 8 patients had withdrawn consent before the surgery, 6 because surgery was 
cancelled, 3 because only CABG was performed, 3 had received blood transfusions in the past 
3 months and 2 died before the operation. In each arm 237 patients were evaluable for the 
primary endpoints. Two patients (both randomized in the LD group) died during the initial 
operation. Th ese two patients were ineligible for the analysis of the secondary endpoints. Th ree 
patients (all of them randomized in the PC group) died in a second operation (performed > 
24 hours later), these patients remained in the study for the secondary endpoints. As shown 
in Table 2 both groups were comparable with respect to baseline characteristics, with an 
exception for the storage time of the erythrocytes. Th e majority (58.2%) of the patients 
received >4 units erythrocytes (mean ± SD: 6.1 ± 6.6). Forty-two (8.9%) of the patients 
did not receive any transfusion. Four (0.8 %) patients received both types of blood products, 
these patients remained in their original randomization arm.
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Table 2 | Baseline Characteristics and Primary and Secondary Endpoints
PC LD OR [95% CI]
Baseline characteristics
Age, year 66.6 ± 12.5 65.3 ± 14.7
Valve surgery + CABG 73 (30.8) 81 (34.2)
Units erythrocytes transfused 6.2 ± 7.1 5.9 ± 6.1
Storage time of the units, days 19.7 ± 5.4 17.4 ± 5.9*
Endpoints
Mortality at day 90 (primary endpoint) 30 (12.7) 20 (8.4) 1.52 [0.84 to 2.73]
In-hospital mortality 24 (10.1) 13 (5.5) 1.99 [0.99 to 4.00]*
Infections 75 (31.6) 53 (22.6) 1.64 [1.08 to 2.49]*
MODS† 49 (20.7) 48 (20.4) 1.07 [0.67 to 1.68]
*p≤0.05; values are numbers (%), †MODS indicates Multiple-Organ-Dysfunction-Syndrome.
As shown in Table 2, in total 50 (10.5%) patients died within the fi rst 90 days post-
operatively. Analyzed according to assignment in the PC group the total mortality at day 
90 was higher than in the LD group (12.7% versus 8.4% respectively). Th is diff erence was 
not signifi cant: OR=1.52; 95 % CI: 0.84-2.73, p=0.16. In the hospital 37 (7.8%) patients 
died, in the PC group the in-hospital mortality rate was almost twice as high as in the LD 
group (10.1% versus 5.5% respectively, OR=1.99, 95% CI: 0.99-4.00, p=0.05. In 128 of 472 
patients (27.1%) in total 137 postoperative infections were diagnosed. In the PC group, 75 
(31.6%) of 237 patients and in the LD group, 53 (22.6%) of 235 patients had infections 
(OR=1.64, 95% CI: 1.08-2.49, p=0.02). In total 97 (20.6%) patients developed MODS in 
the post-operative period. In both trial arms there was a similar incidence of MODS: PC: 
20.7% versus LD: 20.4%. Th e duration of MODS in days (mean ± SD) was also not diff erent 
in both groups (PC: 6.3 ± 8.8 versus LD: 6.1 ± 8.0, p=0.98). ICU-stay in the PC group 
was 5.6 ± 7.2 (mean ± SD) days and in the LD group 5.5 ± 7.3 days (p=0.88). Th e median 
ICU-stay in both groups was 3 days. Th e postoperative hospital stay was 13.8 ± 10.7 days and 
13.3 ± 13.7 days in the PC and LD group respectively (p=0.66). Th e median duration of the 
hospital stay in both groups was 10 days. 
Cost-Eff ectiveness Analysis
Th e remaining average life expectancies for the PC group and LD group utilizing 90 day post 
surgery survival rates are 11.4 and 10.6 year respectively, with a non-signifi cant diff erence 
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(DE) of 0.8 life-years gained in baseline (see Table 3). Costs of care and blood products 
(all price levels) were consistently lower for the LD group compared to the PC group, 
Table 4. Only costs of antibiotics were on average slightly higher in LD group. Th erefore, 
LD compared to PC displays negative net costs from the healthcare viewpoint (both the 
universal and the selective scenario), Table 3 and 4. However, the diff erence between the 
healthcare costs of PC and LD is not signifi cant. Since LD compared to PC shows negative 
net cost in combination with positive health gains, LD is formally labelled as a cost-saving 
strategy and the formal calculation of the ICER point estimate is not necessary and non-
informative.
Table 3 | Health Eff ects, Net-Costs and Cost-Eff ectiveness of Leukodepletion from the Healthcare 
Perspective







10.6 11.4 0.8 [-0.27 to 1.84]







10163 9949 -214 [-1964 to 1536]
Cost-eff ectiveness LD incremental to PC (ΔC/ΔE)
Cost-saving†
*LYG = life-years gained, †Confi dence interval not defi ned
Table 4 | Mean Costs per Patient
Cost component* PC (US$) LD (US$)
ICU-care 5725 5643
Standard care 2610 2585
Antibiotics 58 70
Blood products (baseline; 20 US$ excess LD) 1770 1651
Blood products (Healthcare selective; 36 US$ excess LD) 1770 1745
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From the empirical sample distribution of the ICER depicted in Figure 1 an acceptability 
curves is constructed, see Figure 2. Figure 2 demonstrates that leukodepletion has a 
probability of 59% to be cost-saving (no costs are accepted therefore the willingness to pay = 0, 
intercept of curve with y-axis). Furthermore, regardless of the costs of leukodepletion, i.e. 
the willingness to pay approaches infi nity, the probability is solely governed by the clinical 
outcome in the clinical trial, and therefore the probability is tending towards 92.7%. Th e 
acceptability curve doesn’t cross the 97.5% level of acceptability, therefore the health gains 
and net costs of LD are not signifi cant diff erent from PC for any given willingness to pay.
Figure 2 | Acceptability curve of leukodepletion constructed from 5000 bootstrap replicates. Th e 
92.7% probability line represents the probability of acceptance when the willingness to pay for a 
life-year approaches infi nity.
Sensitivity Analysis
Randomisation should ensure that there are no diff erences of patient characteristics in both 
treatment groups, however, non-signifi cant diff erences in age and gender could have an eff ect 
on the longevity point estimation from gender and age specifi c life expectancies. Th ough 
no diff erences between age and gender are apparent in both groups (Table 2), adjusting 
for age and gender reduces the health gains observed for leukodepletion considerably, see 
table 5. Th e health gains are reduced from 0.8 life-years gained in baseline to 0.4 life-years 
gained aft er adjustment for age and gender diff erences. Still, the point estimate for the ICER 
remains cost-saving.
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If leukodepletion is deployed selectively in cardiac surgery patients, the unit cost of 
leukodepletion rise compared to universal leukodepletion in our baseline (see above). Both 
the cost savings (Table 5) and therefore the probability of acceptance at a willingness to pay 
of 0 US$ (Figure 2) are less. LD remains a dominant intervention if the discount rate is raised 
to 5%, see Table 5.
Table 5 | Sensitivity Analysis: Health Eff ects, Net-Costs and Cost-Eff ectiveness of Leukodepletion 
for Diff erent Scenarios








Age and gender baseline adjusted





0.4 [-0.67 to 1.44]
Healthcare perspective 0% discount rate 13.6 15.0 1.4 [-0.29 to 3.15]
Healthcare perspective 5% discount rate 9.0 9.6 0.5 [-0.25 to 1.35]
0 to 3 transfusions 12.8 13.2 0.5 [-1.01 to 1.95]
4 or more transfusions 8.9 10.2 1.4 [-0.02 to 2.75]
Net-costs (ΔC) and costs for PC and LD 
(3% discount rate)
PC (US$) LD (US$) ΔC (US$) [95% CI]
Age and gender baseline adjustment 10163 9949 -214 [-1964 to 1536]
Healthcare, selective (36 US$ excess costs LD) 10163 10042 -121 [-1877 to 1636]
Patients with 0 to 3 transfusions 6000 5747 -253 [-960 to 455]
Patients with 4 or more transfusions 13532 12615 -917 [-3667 to 1834]
Cost-eff ectiveness (US$/LYG†) LD incremental to PC
Age and gender baseline adjustment Cost-saving‡
Healthcare 0% and 5% discount rate Cost-saving‡
Healthcare, selective Cost-saving‡
Patients with 0 to 3 transfusions Cost-saving‡
Patients with 4 or more transfusions Cost-saving [cost-saving to 4300]
*Discount rate 3% and excess costs of leukodepletion US$20, except where stated, †LYG = life-years 
gained,‡ Confi dence interval not defi ned
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Analysis of cost-eff ectiveness for diff erent levels of blood transfusions received reveals that 
patients receiving 4 or more transfusions benefi t more (increased cost savings and health 
gains) from leukodepletion. Still, in both scenarios LD is dominant to PC. Acceptability 
curves of LD for diff erent levels of blood transfused received shows that only the curve of 
patients receiving 4 or more transfusion crosses the 97.5% level of signifi cance, see Figure 
3. Th e confi dence interval for the cost-eff ectiveness for leukodepletion in patients receiving 
4 or more transfusions stretches from dominant to 4300 US$ per life-year gained (97.5 
percentile). Leukodepletion in patients receiving less than 4 transfusions seems to have a 
higher probability of acceptance compared to the baseline in a willingness to pay range of 
0 to 1000 US$ per life-year gained. However, constructing acceptability curves from only 
the bootstrap replicates with a positive health gain, shows that the maximum probability of 
acceptance of leukodepletion in patients receiving 0 to 3 transfusions is reduced from 83% 
to 60%. Disregarding bootstrap replicates with health losses has little eff ect on the baseline 
acceptability curve and the acceptability curve of leukodepletion for patients receiving 4 or 
more transfusions [19].
Figure 3 | Acceptability curves of leukodepletion for diff erent levels of erythrocyte transfusions 
constructed from 5000 bootstrap replicates. Eff ect of regarding bootstrap replicates with loss of 
health (ΔE<0) and cost savings (ΔC<0) unacceptable, is shown. 
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DISCUSSION
Leukodepleted erythrocytes over standard buff y-coat-depleted packed cells is a cost-
saving intervention in patients undergoing valve surgery with or without CABG from the 
healthcare perspective. However, the average cost-saving of US$214 per patient failed to 
show signifi cance in the acceptability analysis. It was expected that the cost of care would be 
less in the LD group, since there is a signifi cant diff erence between the PC and LD group in 
the risk of post-operative infections. All costs are lower in the LD group, except for the costs 
of antibiotics due to the prophylaxis in both groups. Health gains of LD incremental to PC 
are not signifi cant and are further reduced when adjusted for age and gender diff erences. 
However, the achieved health gains are in the range of the increase in life expectancy by 
CABG compared to medical therapy over 10-year follow up in patients with three vessel 
disease (5.7 months) [20,21]. Moreover, the estimated health gains greatly surpass the health 
gains estimated for implemented procedures in blood banking such as HIV NAT screening 
which yielded on average 16 hours per patient [22]. Th e threshold for pharmaco-economic 
acceptability has been published at US$50,000 per QALY gained in the USA [23]. 
However, the pharmaco-economic acceptance criteria and thresholds diff er between health-
care settings, societies and interventions. For instance, cost-eff ectiveness ratios in health care 
of approximately US$100,000 to US$1,000,000 per life-year gained are readily accepted 
for transplantation and intensive care settings in the developed world [24-26]. Most of the 
procedures to minimize allogeneic transfusion risks did not show cost-utility ratios below 
the current US$50,000 per QALY gained threshold for economic acceptability and were 
up to several million US$ per QALY or life-year gained for solvent detergent treatment of 
plasma, nucleic acid amplifi cation testing and HIV p24 antigen testing [27]. In the available 
meta-analyses cardiac surgery is the only clinical setting where leukodepletion has shown 
health benefi ts. Th e result of this analysis is only applicable for valve surgery patients (with 
or without CABG) and can’t be extended to other clinical settings. Pending additional 
randomised clinical trials, leukodepletion may be less cost-eff ective in other clinical settings.
Th e higher excess costs for selective leukodepletion only in cardiac surgery patients reduces only 
the probability of being cost-saving compared to universal leukodepletion. Leukodepletion 
in patients receiving 4 or more transfusion is more likely to be accepted than in baseline (all 
patients) or patients receiving less than 4 transfusions. Th is outcome is also supported by 
the conclusion of the Canadian Co-ordinating Offi  ce for Health Technology Assessment 
that leukodepletion could be cost-eff ective for patients receiving many transfusions [10]. In 
patients receiving less than 4 transfusions bootstrap replicates with cost savings and health 
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losses are important drivers for a high probability of acceptance, though being less preferable 
from the societal and political perspective. Disregarding bootstrap replicates with negative 
health eff ects had little eff ect on the baseline acceptability curve and the acceptability of 
leukodepletion in patients receiving 4 or more transfusions but decreased the probability of 
acceptance substantially for patients receiving less than 4 transfusions.
 Performing cost-eff ectiveness analysis alongside a clinical trial is a relatively young 
method under development in pharmaco-economics [17,18]. As with this clinical trial, clinical 
trials are unfortunately designed solely to determine clinical eff ects and not specifi cally 
designed for evaluating cost-eff ectiveness. Th erefore, in the design of this trial, variability in 
cost-data was not taken in to account in the power determination. Th is economic analysis 
was performed from the healthcare perspective, therefore only direct costs were considered. 
Th e preferred societal perspective includes indirect as well as direct costs. However, the 
impact of in-direct costs, such as productivity and leisure losses, would be limited in this 
analysis because of the relatively advanced age (mean 65 years) of the included patients and 
the severity of the underlying disease.
 Governed by society’s perception of blood transfusion risks [28], governments seem 
to be willing to allocate signifi cant budgets to improve transfusion safety. However, we have 
to keep in mind that if health budgets are fi xed, allocation of budgets to less favourable 
cost-eff ective strategies in healthcare, neglects potential other more cost-eff ective strategies 
with higher health gains. Leukodepleted erythrocytes applied in cardiac valve surgery with 
or without CABG compared to standard buff y-coat-depleted erythrocytes showed a (non-
signifi cant) moderate favourable economic profi le. More randomised clinical trials powered 
for health economics are needed to underpin or reject the suggested favourable economic 
profi le.
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ABSTRACT
Background: Studies in cardiac surgery have reported increased postoperative morbidity and 
mortality aft er allogeneic red blood cell (RBC) transfusions. Whether platelet and/or plasma 
transfusions are a marker for more concomitant RBC transfusions or are independently 
associated with complications aft er cardiac surgery is unknown.
Study design and methods: Data from two randomized controlled studies were combined to 
analyze the eff ects of platelet and/or plasma transfusions on postoperative infections, length 
of stay in the intensive care unit (ICU), all-cause mortality and mortality in the presence or 
absence of infections in the postoperative period.
Results: Aft er adjusting for confounding factors, plasma units and not RBC transfusions 
were associated with all-cause mortality. Leukocyte-containing RBC transfusions and 
platelet transfusions were associated with mortality occurring in the presence of or aft er 
infections. Number of (leukocyte-containing) RBC transfusions was also signifi cantly 
associated with postoperative infections and with ICU-stay for 4 or more days.
Conclusion: Although it is diffi  cult to separate the eff ects of blood components, we found 
that in cardiac surgery peroperative plasma transfusions are independently associated with 
all-cause mortality. Leukocyte-containing RBC transfusions and platelet transfusions are 
independently associated with mortality in the presence of infections in the postoperative 
period. Future transfusion studies in cardiac surgery should concomitantly consider the 
possible adverse eff ects of all the various transfused blood components. 
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INTRODUCTION
Patients undergoing cardiac surgery are at increased risk for bleeding, because of 
thrombocytopenia secondary to hemodilution, platelet dysfunction and consumption of 
platelets in the extracorporal circuit. In addition, intra-operatively anticoagulant medication 
is administered to these patients. To improve hemostasis, platelets and fresh-frozen plasma 
(FFP) are oft en transfused in the peri-operative and postoperative periods. However, neither 
the effi  cacy nor the safety of platelet and plasma transfusions has been demonstrated.
 Retrospective studies in cardiac surgery have shown that allogeneic red blood cell 
(RBC) transfusions are associated with an increased risk of postoperative infections and 
mortality in a dose-dependent manner [1-4]. In two randomized controlled trials (RCTs) of 
patients undergoing cardiac surgery [5,6], we found an increase in postoperative infections 
and mortality related to the number of transfused RBCs. Postoperative infection and 
mortality were signifi cantly higher in patients receiving buff y-coat-depleted (BCD) RBCs 
than in patients receiving leukocyte-reduced (LR; fi ltered) RBCs, which suggested a role of 
allogeneic leukocytes in provoking postoperative infections and mortality. However, patients 
receiving multiple RBC transfusions oft en receive platelets and plasma transfusions as well. 
Whether platelet and plasma transfusions contribute to such postoperative complications or 
are just a surrogate marker for the need for a higher number of RBC transfusions is unknown. 
Previous retrospective studies yielded confl icting results concerning the association between 
platelet and plasma transfusions and outcome in cardiac surgery [7-13]. Th e purpose of this 
current analysis of the combined data from our two RCTs [5,6], is to investigate whether 
transfusion of platelet concentrates and FFP are independently associated with postoperative 
infection and mortality in cardiac surgery, aft er adjusting for the eff ect of the number of 
RBC transfusions and other confounders.
MATERIAL AND METHODS
Our two double-blinded RCTs had been conducted at two university hospitals in the 
Netherlands. Th e ethical review boards of the hospitals approved the trial protocols and 
informed consent was obtained from the patients. Th e design of these studies have been 
reported elsewhere in detail [5,6]. In summary, the fi rst study [5] was a single-center study 
conducted between 1992 and 1994. Patients undergoing coronary-artery-bypass-graft 
(CABG) or cardiac valve surgery or a combination of both, were randomised to receive, 
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when transfusion was necessary, BCD RBCs or LR RBCs (randomly assigned to receive 
either before storage from freshly drawn RBCs or fi ltered aft er storage before transfusion 
RBCs). For the current analysis we included only the patients who had received prestorage 
LR RBCs (n=305) and those who had received BCD RBCs (n=306), because these were the 
randomization arms also transfused in the second study. Th e second study [6] was conducted 
between 1999 and 2001 at two hospitals and included patients undergoing valve surgery 
with or without CABG. In this study BCD RBCs (n=237) were compared with pre-storage 
LR RBCs (n=237). In both studies oral anticoagulants and aspirin were stopped at least 
5 days before surgery. Heparin (3 mg/kg) was administered before initiation of bypass 
with a target activated clotting time of 400 seconds. Th e priming of the cardiopulmonary 
bypass circuit was comparable in both studies. Aft er termination of bypass, heparin was 
antagonized by protamine sulphate at a 1:1 ratio. In both studies, all patients received 
prophylactic antibiotics postoperatively for 24 hours (for subjects undergoing CABG) or 48 
hours (for subjects undergoing valve surgery). In the second study, only patients considered 
to be at high risk for bleeding received aprotinin at one hospital. Postoperatively, all patients 
were admitted to the intensive care unit (ICU) until they had been extubated and had no 
longer needed positive inotropes. In one hospital, in the second study, patients without 
complications were transferred to a medium care unit before they were transferred to the 
department of cardiothoracic surgery. 
Blood Products and Transfusions
Th e blood products in both studies were similar and fulfi lled the requirements and the 
specifi cations of the Dutch standards for Blood Banks. Platelet concentrates were prepared 
from fi ve pooled buff y coats and were prestorage LR by fi ltration. BCD RBCs were prepared 
by removal of the buff y coat and plasma, followed by reconstitution with 100 mL saline-
adenine-glucose-mannitol. Prestorage fi ltration of RBC units was performed within 24 
hours aft er whole-blood collection, by passage through a leuko-reduction fi lter (Cellselect-
Optima, NPBI International-Fresenius HemoCare, the Netherlands). FFP was prepared by 
separation from whole donor-blood by hard spin and freezing within 6 hours at < -23oC. 
Women with a history of pregnancy were excluded from plasma donations, except in one 
hospital in the second study. In both studies the precise number of transfused RBCs, plasma 
units and platelet concentrates was recorded. At the time of both studies no documented 
guidelines for blood transfusions were present. Th e decision to transfuse blood products was 
based on the hemoglobin level (less than 8-8.5 gr/dl), platelet count (less than 100 x 109/l), 
total amount of blood loss and/or presence of bleeding disorders. 
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Endpoints
In both studies, postoperative infections had been a secondary endpoint based on the criteria 
of Centers for Disease Control and Prevention [14] and were scored during the hospital stay 
of the patients. In both studies, the length of stay in the ICU had been recorded in days. 
Because respiratory failure was not documented in the fi rst study, length of ICU-stay for at 
least 4 days was considered to indicate need for prolonged mechanical ventilation. In the fi rst 
study, mortality was a secondary endpoint and it was registered until day 60 postoperatively. 
In the second study mortality at 90 days postoperatively was the primary endpoint, although 
60-days mortality was also recorded. 
Statistical Analysis
Breslow-Day and Tarone’s tests were used to examine whether the data from two RCTs were 
suffi  cient homogeneous to permit combined analyses of both studies. Data were expressed as 
mean ± SD, number or percentage as appropriate. For comparison of qualitative parameters, 
the Fisher’s exact test or chi-square test was used and for the comparison of quantitative 
parameters, the t-test or Mann-Whitney U test. To estimate risk factors for postoperative 
infection, ICU-stay for 4 or more days, overall mortality and mortality occurring in the 
presence or in the absence of postoperative infections known variables associated with these 
postoperative complications were included in a univariate analysis. Multivariate analysis of 
the risk factors was performed using a logistic regression enter/backward stepwise model 
to estimate independent predictors for postoperative complications. Th e following variables 
were eligible for inclusion in this model: study (our 1992-1994 versus our 1999-2001 RCT), 
age, gender, type of surgery (CABG, valve or the combination of both), cardiopulmonary 
bypass time, number of transfused RBC’s, randomization arm (BCD vs. LR RBCs) and 
number of transfused plasma units and number of transfused platelet units. Time on 
cardiopulmonary bypass was analyzed as a categorical variable (in hr). Th e number of 
transfused RBC units, transfused plasma units and transfused platelet units were forced into 
the multivariate analysis. Th e results of the univariate analysis are reported as p values and 
the results of the multivariate analysis as odds ratios (ORs) with 95% confi dence intervals 
(CIs). All p values are two tailed. Analyses were performed using the SPSS 17.0 (SPSS Inc, 
Chicago IL, USA). 
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RESULTS
Th e data from the two studies comprised 1.085 patients; 611 from the fi rst study and 474 
from the second study. Testing for homogeneity indicated that it was legitimate to pool 
the data from both studies. Only ICU-stay was diff erent between both studies which was 
due to the presence of a medium care in one hospital in the second study. In the combined 
population of 1.085 patients; 316 patients (29.1%) had developed postoperative infection 
and 80 patients (7.4%) had died. Of the patients who died, 41 patients (51.3%) died who 
had developed infections in the postoperative period, while 27 patients (33.8%) died from 
a cardiac cause without any postoperative infection. In total 12 patients (15.0%) died 
from other reasons (e.g., bleeding or multiple-organ-dysfunction-syndrome) without any 
postoperative infection. 
 In Table 1 the attributes of the patients are presented who developed postoperative 
infections and of the patients who died. Compared with patients who did not develop 
infections or patients who survived, patients who developed infections and patients who 
died were older, more oft en female; they had a longer duration of surgery and received more 
units RBCs and plasma and they had received platelet transfusion more oft en. Th e patients 
who received plasma and/or platelet transfusions were older, had a longer duration of 
surgery, and had received more RBC transfusions than patients who did not receive plasma 
or platelet transfusions. More infections and more deaths were observed in patients who 
received plasma or platelet transfusions (Table 2). As shown in Figures 1 and 2 patients who 
received more RBC units also received more plasma units (of 615 patients receiving 4 or 
more units RBCs, 403 patients [65.5%] had received 4 or more units plasma units as well) 
and patients who received more RBC units also received platelet transfusion more oft en (of 
615 patients receiving 4 or more units RBCs, 233 patients [37.9%] had received also platelet 
transfusions). 
 Table 3 shows the results of univariate analyses concerning risk factors for the 
development of postoperative infection, length of ICU-stay at least 4 days, overall 
mortality, mortality in the presence (and absence) of infections in the postoperative period. 
Multivariate analysis showed that study, age, and number of RBC units transfused were 
associated with both postoperative infection and ICU-stay for at least 4 days. In addition 
to these factors, randomization arm and sex were associated with postoperative infections 
and the time on cardiopulmonary bypass with ICU-stay for at least 4 days (Table 4). Plasma 
or platelet transfusions were not associated with postoperative infections or ICU-stay for at 
least 4 days. All-cause mortality was associated with age, time on cardiopulmonary bypass, 
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Figure 1 | Distribution of number of patients receiving red blood cell (RBCs) transfusions (0,1-3 
or >4 units) with plasma transfusions (0,1-3 or >4 units).
Figure 2 | Distribution of number of patients receiving red blood cell (RBCs) transfusions RBCs 
(0,1-3 or > 4 units) with (or without) platelet transfusions.
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Table 3 | Risk Factors for Postoperative Infections, ICU-stay >4 days, Overall Mortality and 
Deaths occurring in the Presence (or Absence) of Infections Based on Univariate Analyses
Risk factors Infections ICU-stay 
>4 days




Study (fi rst/second) <0.001 <0.001 <0.001 <0.001 <0.001
Age <0.001 <0.001 <0.001 <0.001 0.06
Gender (male/female) 0.001 <0.001 0.003 0.04 0.03
Type of surgery (CABG/valve/both) 0.39 <0.001 <0.001 <0.001 0.02
Cardiopulmonary bypass <0.001 <0.001 <0.001 <0.001 <0.001
Number of RBC transfusions <0.001 <0.001 <0.001 <0.001 0.003
Randomization (BCD/LR) <0.001 0.41 0.004 0.005 0.24
Platelet transfusions <0.001 <0.001 <0.001 <0.001 <0.001
Number of plasma transfusions <0.001 <0.001 <0.001 <0.001 <0.001
RBC=Red blood cells, BCD=Buff y-coat depleted, LR=Leukocyte-depleted
Table 4 | Results of Multivariate Analyses for Postoperative Infections and ICU-stay for >4 days.










Study (fi rst/second) 0.62 0.41-0.93 0.02 1.81 1.20-2.73 0.01
Age (years) 1.03 1.01-1.04 <0.001 1.02 1.01-1.03 0.01
Gender (male/female) 1.43 1.06-1.93 0.02 1.18 0.86-1.60 0.30
Type of surgery 0.97 0.75-1.25 0.80 1.16 0.89-1.52 0.27
Cardiopulmonary bypass time 
(hours)
1.08 0.91-1.28 0.38 1.21 1.01-1.44 0.04
Number of RBC transfusions 1.12 1.07-1.17 <0.001 1.21 1.15-1.28 <0.001
Randomization arm (BCD/LD) 1.67 1.25-2.23 <0.001 0.86 0.64-1.15 0.30
Number of platelet transfusions 1.05 0.89-1.24 0.54 1.16 0.76-1.76 0.50
Number of plasma transfusions 1.01 0.96-1.07 0.61 0.99 0.94-1.06 0.94
RBC=Red blood cells, BCD=Buff y-coat depleted, LR=Leukocyte-depleted
plasma transfusions, platelet transfusions and randomization arm, but not with the number 
of RBC units transfused (Table 5). Randomization arm, age, platelet transfusions and 
plasma transfusions were associated with deaths occurring in the presence of infections in the 
postoperative period. Time on cardiopulmonary bypass and number of transfused plasma 
units were associated with deaths without postoperative infections (Table 5).
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DISCUSSION
In this retrospective analysis of data from two randomized controlled trials [5,6], the number 
of transfused plasma units was independently associated with all-cause mortality. Although 
leukocyte-containing RBCs were associated with mortality, the number of transfused RBC 
units was not. Th e number of transfused RBC units, but not the number of transfused 
plasma units or the receipt of platelet transfusion, was associated with the development of 
postoperative infections and with the stay in the ICU for at least 4 days. Transfusion of 
platelet units was associated with mortality with postoperative infections developed during 
the hospital-stay. Because patients who receive RBC transfusions, receive also plasma and 
platelet transfusions, it is diffi  cult to determine whether plasma and platelet transfusions 
could be independently associated with postoperative complications. 
 Our results are consistent with those of several previous studies which reported that 
infections aft er cardiac surgery are associated (in a dose-dependent manner) with the number 
of RBC transfusions [1-4]. We previously reported that the excess mortality secondary 
to leukocyte-containing RBC transfusions was due to higher mortality associated with 
postoperative infections [15]. To identify other risk factors (or confounders) than RBCs, in 
the current analysis we distinguished between deaths occurring in the presence or absence 
of infections in the postoperative period. Because in our fi rst RCT [5] organ failure was not 
recorded, in this analysis we used ICU-stay for at least 4 days as parameter for prolonged 
mechanical ventilation (and thus for respiratory failure). In practice, aft er extubation almost 
all patients were transferred from the ICU to the ward within 24 hours. In agreement with 
other studies [16,17], we found in the multivariate analysis that the most important predictors 
of longer ICU-stay were the number of transfused RBCs and the patient’s age. However, in 
contrast to others [18-21], we found no association between prolonged mechanical ventilation 
and plasma or platelet transfusions. 
 Th e fi nding that plasma transfusions are associated with all-cause mortality, while 
leukocyte-containing RBC transfusions and platelet transfusions are associated only with 
deaths with postoperative infections in the postoperative period, were unanticipated. A 
predominant role of plasma transfusions on outcome aft er cardiac surgery is consistent 
with the results of Ranucci et al [22]. Other studies that focused on plasma transfusions 
reported contradictory fi ndings [7-9]. Similarly platelet transfusions were reported not to be 
associated with mortality [10,11], except in two studies that found an association with platelet 
transfusions and mortality in cardiac surgery; however, these studies applied no corrections 
for concomitant RBC or plasma transfusions [12,13]. 
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Plasma-containing blood products have been implicated in the pathogenesis of transfusion-
related acute lung injury (TRALI). Patients undergoing cardiac surgery are at higher risk 
to develop TRALI, even if leukocyte-reactive antibodies in transfused plasma are absent 
[23,24]. However, TRALI seems unlikely as a cause of enhanced mortality because parameter 
for respiratory failure (prolonged ICU-stay) was not associated with plasma transfusion 
in our study. On the other hand, in a laboratory analysis we found in patients with low 
mannose-binding lectin (MBL) levels is a risk factor in the development of multiple-organ-
dysfunction-syndrome (MODS), which may contribute to mortality [25]. Besides allogeneic 
leukocytes in RBC products inducing higher pro-infl ammatory cytokine levels aft er cardiac 
surgery associated with more postoperative infections and mortality [26], platelet units also 
contain bioactive mediators. Increased CD40 ligand (CD40L or CD154) present in platelet 
units can induce production and release of proinfl ammatory markers [27,28]. Both leukocyte-
containing RBCs and platelet transfusions could thus aggravate an existing infl ammatory 
reaction impairing the outcome aft er cardiac surgery. More investigations are needed on the 
possible causal roles of transfusion of diff erent blood components.
 Th is study has several limitations. First, this is an observational analysis, despite the 
fact that the data were extracted from two RCTs. Second, the combined studies had not 
been designed to investigate the eff ects of plasma and platelet transfusions. Evidence-based 
transfusion triggers for platelet and plasma transfusions had not been used in either of our 
RCTs. Instead, plasma and platelet transfusions were administered based on institutional 
habits and the preferences of the clinicians. In both studies, also information on blood loss 
was not adequately documented. Aprotinin to reduce the risk of bleeding was administered 
only in the second study and only for selected patients (16% of the current population). 
In an earlier study we found no eff ect of aprotinin in the development of postoperative 
complications [26]. Th erefore, the eff ects of aprotinin were not considered in this analysis. 
Finally, our two RCTs had been performed 7 years apart. Between the time periods that the 
two studies were conducted, surgical procedures and transfusion practices has changed, as 
refl ected in the diff erence in length of ICU-stay between the two studies. 
 Nowadays, more restrictive criteria for RBC transfusion are used. In the periods when 
our studies were performed no clear consensus on the indications for plasma and platelet 
transfusions in these patient populations was present. Nevertheless despite guidelines for 
blood transfusions, the patients that receive perioperative blood transfusions in cardiac surgery 
is still high [29]. As the use of antiplatelet agents increases, we expect that more patients will 
receive blood transfusions in the future. In conclusion, we found that the number of RBC 
transfusions was not associated with postoperative mortality, whereas plasma transfusions 
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were dose-dependently associated with all-cause mortality. Th e transfusion of platelets was 
associated with mortality in the presence of (leukocyte-containing) RBCs. However, only 
few retrospective studies have considered the eff ects of plasma and platelet transfusions, 
which predominantly are transfused to patients who also received RBC transfusions. Our 
fi ndings underscore the need for further studies to investigate the aggregate eff ects of all the 
various blood components transfused in cardiac surgery.
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Allogeneic (leukocyte-containing) red blood cell (RBC) transfusions have profound eff ects 
on the recipient’s immune system. Besides induction of allo-antibody formation, also 
immunomodulation occurs impairing the allograft  rejection aft er renal transplantation. Th is 
suppression of the renal allograft  rejection led to concern about deleterious eff ects of blood 
transfusions on cancer recurrence and susceptibility for postoperative infections [1,2]. Th is 
hypothesis resulted in several observational studies and a limited number of randomized 
controlled trials (RCTs), mainly investigating the eff ect of leukocyte-containing blood 
transfusions on postoperative infections. Only two RCTs investigated cancer recurrence. 
One study compared leukocyte-containing RBC with leukocyte-depleted fi ltered RBC 
transfusions and did not show a diff erence in distant metastasis nor local recurrence between 
the two groups at 2-years and 5-years follow-up [3,4]. Th e other RCT compared allogeneic 
versus autologous, both buff y-coat depleted, leukocyte-containing RBC transfusions, also 
without a diff erence between the two groups [5]. In contrast, controversial results in diff erent 
patient populations using diff erent study designs were found for an eff ect of leukocyte-
containing RBC transfusions on postoperative infections [6]. Our group conducted 
two RCTs on the role of leukocyte-containing RBC transfusions on the occurrence of 
postoperative infections in colorectal surgery. Two studies, one aforementioned in colorectal 
cancer surgery and one in miscellaneous gastro-intestinal and vascular surgery, found no 
evidence for increased susceptibility for postoperative infections aft er leukocyte-containing 
RBC transfusions [3,7].
 Th e possible adverse immunomodulatory eff ects of blood transfusions are referred to 
as transfusion-related immunomodulation (TRIM). Th e existence and possible mechanisms 
of TRIM are hitherto pure descriptive. Extensive animal and laboratory studies investigated 
the possible mechanisms of immunomodulatory eff ects of blood transfusions and their 
relationship with clinical manifestations. Several factors have been suggested to play a role. 
Most suspected are: allogeneic mononuclear and apoptotic cells, soluble biological response 
modifi ers circulating in plasma and leukocyte-derived cytokines and chemokines. Allogeneic 
leukocytes or soluble factors released by leukocytes during storage have been most extensively 
studied in the past years [8]. 
Clinical Eff ects of Allogeneic Leukocytes in Cardiac Surgery 
Compared with other adverse transfusion eff ects, the clinical eff ects of leukocyte-mediated 
TRIM on mortality aft er cardiac surgery is more excessive (Figure 1) [10]. In cardiac surgery 
strong and dose-dependent associations between blood transfusions and postoperative 
morbidity and mortality are present. However, it is obvious that patients with more 
Discussion and Future Perspectives | 151
preoperative risk factors and undergoing more complex surgery are at higher risk for the 
development of postoperative complications and these patients receive also more blood 
transfusions, as compared to patients undergoing to less complex surgery. RCTs, balancing 
such confounding factors, may help to distinguish between patient, surgery and transfusion 
factors aff ecting outcome. Because allogeneic leukocytes are the most important factor held 
responsible for the clinical eff ects of TRIM; RCTs investigating their role are indispensable. 
Figure 1 | Estimates of risk of death per unit transfused RBCs for several transfusion-related 
complications in patients undergoing cardiac surgery. (with permission, from Despotis et al. 
Transfusion 2008; 48:2S-30S)
Th e fi rst RCT in cardiac surgery was performed in the Netherlands [9]. Th is study comprising 
914 patients randomized to receive 3 diff erent RBC products; buff y-coat depleted RBCs 
were compared with either pre-storage fi ltered freshly drawn RBCs fi ltered aft er storage 
prior to transfusion, containing during storage accumulated leukocyte-derived soluble 
factors. An increase in postoperative infections between transfusion of buff y-coat depleted 
RBCs and the two types of leukocyte-depleted RBCs was only found in patients receiving 
more than 3 units of RBCs. Moreover a signifi cant higher 60-day mortality rate in patients 
receiving buff y-coat depleted RBCs compared with both types of leukocyte-depleted RBCs 
was found. Th is diff erence in mortality was mainly due to death with diagnosis of multiple-
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organ-dysfunction-syndrome (MODS) in the patients receiving buff y-coat depleted RBCs. 
In this study MODS was not scored as an endpoint.
 We performed a second randomized controlled trial in more complicated cardiac 
surgery associated with a higher probability of multiple RBC transfusions in order to explore 
the relationship between leukocyte-containing transfusions on MODS and mortality 
(Chapter 2). In this study mortality at 90 days aft er surgery was the primary endpoint and 
hospital mortality rate and the incidences of MODS and postoperative infections were the 
secondary endpoints. Th e 90-day mortality showed a non-signifi cant reduction of 40% and 
the hospital mortality was halved in the group that received pre-storage leukocyte-depleted 
RBCs, confi rming the results of the previous study. Th e diff erences between these endpoints 
were more pronounced in the patient groups who received more than 3 units of RBCs. Th e 
main cause of excess mortality was MODS; despite the incidence of MODS was similar 
in both patient groups. Furthermore the other endpoint (postoperative infections) was 
reduced signifi cantly in the group that received pre-storage leukocyte-depleted RBCs. Few 
RCTs followed to investigate the role of leukocyte-depleted RBCs in cardiac surgery [11-14]. 
Th e characteristics and results of these studies are presented in Table 1. A meta-analysis of 
these studies in cardiac surgery revealed an increased short-term mortality aft er transfusion 
of leukocyte-containing RBCs [15]. 
 Th is second RCT confi rmed the fi ndings of the previous study with respect to 
a role of leukocyte-containing RBC increasing postoperative infections and mortality. 
Surprisingly, the incidence of MODS was not aff ected by the type of RBCs, while MODS 
was dose-dependently associated with more transfusions in both groups. Apparently, a larger 
number of leukocyte-containing RBC units infl uence the course, although not the incidence 
of MODS. For further understanding, we analyzed in more detail the causes of death in 
the two randomized controlled trials in cardiac surgery from the Netherlands (Chapter 3). 
We found that patients who received standard buff y-coat-poor, leukocyte-containing RBCs, 
compared with leukocyte-depleted RBCs, excessively died with a combination of MODS 
and the presence of infection in the postoperative period. Other causes of death (i.e. cardiac 
reasons and bleeding) were not diff erent between both types of RBCs. Th ese results suggest 
an important role of allogeneic leukocytes in RBCs aggravating the clinical course of MODS 
by co-occurrence of infections. Th ese infections could precede or develop when MODS is 
already manifest. Possibly, transfusion of allogeneic leukocytes results in more postoperative 
infections, due to long-standing post-surgical immune suppression. However this hypothesis 
is not confi rmed by prospective designed studies.
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Analyses on the cost-eff ectiveness of leukodepletion are scarce and are mainly based on 
observational data. Th e cost-eff ectiveness of leukodepletion in cardiac surgery was analyzed 
based on data derived from our two studies. Th e results showed that RBC leukodepletion 
was cost eff ective. Th e benefi t of leukodepletion of RBCs was between $220-$310 US 
per life-year gained in CABG patients [16] and $214 US per cardiac valve surgery patient 
(Chapter 7). 
 Because in most well-resourced countries universal leukodepletion (leukoreduction) 
is implemented, no new randomized controlled trials in this fi eld are expected. We used 
collected blood samples from the participants of the randomized controlled trial described 
in Chapter 2, to perform some further analysis of increased postoperative mortality (due to 
a combination of MODS and infections) aft er transfusion of allogeneic leukocytes in RBCs. 
Laboratory Eff ects of Allogeneic Leukocytes in Cardiac Surgery
Cardiac surgery results in release of infl ammatory mediators, which are presumed to play 
a role in the development of postoperative complications such as systemic infl ammatory 
response syndrome (SIRS), multiple-organ-dysfunction-syndrome (MODS) and infections. 
High concentrations of pro-and anti-infl ammatory mediators are released during and 
aft er trauma or major surgery. Imbalance of the concentration of cytokines can play a 
pivotal role in a balanced equilibrium aft er cardiac surgery. Cytokines are low molecular 
weight polypeptides, which are produced by many cells, such as macrophages, monocytes, 
neutrophils and platelets. Th ey are divided into two groups with at one end of the spectrum 
pro-infl ammatory cytokines such as interleukin-1 (IL-1), IL-2, IL-8 and IL-12 and at the 
other end the anti-infl ammatory cytokines as IL-4, IL-5 and IL-10. While IL-6 has both 
pro-and anti-infl ammatory properties [17,18]. During and aft er cardiac surgery several both 
pro-and anti-infl ammatory cytokines are released. 
 Few studies investigated the eff ect of allogeneic (leukocyte-containing) blood 
products on the cytokine balance. Th ese studies compared cytokine profi les in patients 
receiving leukocyte-containing RBC transfusions with patients who did not receive any 
transfusions. In one study in 114 patients an association was found between allogeneic RBC 
transfusions and postoperative increase of bactericidal permeability increasing protein (BPI), 
a marker of neutrophil activation, and of the infl ammatory mediator IL-6 [19]. However 
there are no studies that investigated the possible diff erences between the type of blood 
products and the concentrations of infl ammatory mediators in relation with the outcome of 
the patients.
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We could investigate profi les of some infl ammatory mediators in 346 patients participating 
in our RCT of whom pre-and post-surgical blood samples were available (Chapter 5). We 
selected four key mediators that represent the infl ammatory response aft er surgery. IL-6 
has been shown to be an early predictor for mortality in cardiac surgery. IL-10, an anti-
infl ammatory cytokine, has been found to be increased aft er per-operative allogeneic 
blood transfusions in orthopedic surgery in association with prolonged hospital stay [20]. 
Pro-infl ammatory cytokine IL-12 refl ects activation and proliferation of lymphocytes and 
natural killer cells, which are relevant for the defense against nosocomial infections [21]. Th e 
concentration of procalcitonin on the fi rst postoperative day aft er cardiac surgery has been 
shown to be an early marker for organ dysfunction with severe outcome [22]. 
 In the analysis of the total patient population we found no diff erences between 
the two transfusion arms in the levels of the infl ammatory mediators upon arrival at the 
ICU. However, signifi cantly higher IL-6 levels at arrival at ICU were found in patients 
aft er transfusion of 3 or more units BCD-RBCs compared with LD-RBCs. Higher IL-6 
and IL-12 concentrations aft er leukocyte-containing transfusions were present in patients 
who developed infections and MODS respectively. IL-10 and procalcitonin concentrations 
were not associated with number and type of transfusions in patients with or without 
complications, although higher IL-10 concentrations were associated with hospital 
mortality in both randomisation arms. In a selected patient population staying longer than 2 
days at ICU (because of more postoperative complications) we found that the concentration 
of IL-10 had decreased already on arrival at ICU in both study arms. Th e increase of IL-6 
concentration peaked later and a higher peak level was measured in the group that had 
received leukocyte-containing RBCs than in the group that had received leukocyte-depleted 
RBCs (Chapter 5). 
 Our study is the fi rst showing higher initial pro- infl ammatory markers aft er leukocyte-
containing transfusions aft er cardiac surgery, in particular in multi-transfused subgroups later 
developing serious clinical complications. Th ese results suggest that leukocyte-containing 
blood transfusions contribute to an infl ammatory response, in addition to an ongoing 
systemic infl ammatory response induced by cardiac surgery. In order to explain increased 
susceptibility for infections, we presume that this may lead to a more profound counteractive 
anti-infl ammatory response. 
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Eff ects of Plasma and Platelet Transfusions in Cardiac Surgery
Cardiac surgery using cardiopulmonary bypass activates the infl ammatory, coagulation and 
the complement system. Th e complement system can be activated by three pathways: the 
classical, the alternative and the lectin pathway. While the classical pathway is activated 
by antibodies and immune complexes, the lectin pathway can be triggered by binding of 
carbohydrates exposed on a wide range of micro-organisms to mannose-binding lectin 
(MBL). Based on genetic variation the level of MBL is highly variable. MBL-defi ciency in 
combination with immune-compromising factors is associated with infections and with 
enhancement of the systemic infl ammatory response syndrome and with myocardial injury 
[23-25]. We investigated in patients participating in our RCT described in Chapter 2, the 
eff ects of the type of blood transfusions on post-surgical MBL concentrations. We found that 
cardiac surgery is associated with considerable MBL consumption, which was independent 
of leukocyte-containing or leukocyte-depleted RBCs. Furthermore no relation was found 
between MBL-defi ciency and postoperative infections or mortality. In contrast, none of 
the patients with MBL-defi ciency developed MODS, unless they had been transfused with 
plasma units (Chapter 6). Our fi ndings suggest that plasma transfusions in cardiac surgery 
can have deleterious clinical eff ects, at least for a particular patient subpopulation. 
 A substantial proportion of patients undergoing cardiac surgery receive plasma 
and platelet transfusions. Plasma-containing blood transfusions can contribute to adverse 
outcome by causing transfusion-related acute lung injury (TRALI), a serious life-threatening 
condition and an underreported complication of allogeneic blood transfusions. Whether 
allogeneic leukocytes in blood transfusions play a role in the development of TRALI is 
unclear [26]. Some observational studies suggested that plasma and platelet transfusions 
in cardiac surgery are associated with postoperative complications and infl uence the 
postoperative outcome [27-33]. However, plasma and platelet transfusions are predominantly 
transfused to patients who also receive large numbers of RBC transfusions. Th erefore it is 
diffi  cult to determine whether plasma and platelet transfusions are independent risk factors 
or are only confounders.
 Retrospective, multivariate analysis of our two RCTs revealed that plasma transfusions 
were independently associated with higher all cause mortality (independent of the existence 
of postoperative infections), while platelet transfusions were associated with mortality in 
combination with infections present in the postoperative period (Chapter 8). Th is suggests 
that, in addition to immunomodulatory eff ects of RBC transfusions, also plasma and 
platelet transfusions could play an important role in the outcome aft er cardiac surgery. Our 
fi ndings underscore the need for further studies to investigate the aggregate eff ects of all 
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the various blood components transfused in cardiac surgery, as well as diff erentiate between 
adverse eff ects possibly associated with a specifi c blood component(s). How plasma and 
platelet transfusions indeed contribute by distinct pathways to postoperative morbidity and 
mortality aft er cardiac surgery should be evaluated in further studies.
 
Allogeneic Leukocytes and the Enhancement of MODS aft er Cardiac Surgery
During cardiac surgery blood is exposed to the extra-corporeal circuit, hypothermia, ischemia/
reperfusion injury and many infl ammatory responses are activated. Th ese responses lead to 
post-perfusion systemic infl ammatory response syndrome (SIRS). SIRS is defi ned by a body 
temperature less than 36oC or more than 38oC, heart rate more than 90/min, tachypnea 
with breaths more than 20/min or pCO2 less than 4.4 kPa (32 mm Hg) and leukocyte count 
less than 4 x 109/l or above 12 x 109/l. SIRS can be diagnosed when two or more criteria are 
present [34]. SIRS is a subset of cytokine storm with an abnormal regulation of cytokines 
and is immediately counteracted by a compensatory anti-infl ammatory response syndrome 
(CARS) [35]. An overwhelming SIRS causes a dormant state of cell metabolism, referred to 
as MODS; SIRS usually resolves with adequate supportive therapy and most of the patients 
recover. However overwhelming SIRS can dominate CARS and progress to MODS, which 
may lead to mortality. We presume that leukocyte-containing RBC transfusions to patients 
with an activated infl ammatory response act as a second-hit and imbalances the postoperative 
SIRS-CARS equilibrium further enhancing of prolonging SIRS (Chapter 4).
 Both the infl ammatory response and the release of pro-infl ammatory cytokines lead 
to activation of the coagulation system and down-regulate the anticoagulant system [36]. 
Activation of the coagulation factors can in turn activate infl ammation. Th is may enhance 
the development of infections and microvascular thrombi [37]. Both thrombi and infection 
play a central role in the development and worse outcome of MODS [38]. Th is could occur 
by increasing the circulating RBC mass and vascular rheologic deformations by RBC 
transfusions. Activated platelets (during storage) may contribute to thrombosis in patients 
at risk. It has recently been shown that leukocyte-containing RBCs and platelets contain 
prothrombotic soluble mediators, which interact with leukocytes preceding the apoptosis 
and death of leukocytes, subsequently producing microparticles with procoagulant activity 
[39]. Leukocyte-containing RBCs contain prothrombotic soluble mediators, such as 
CD40L, which induce the synthesis of proinfl ammatory mediators that can further activate 
the coagulation system [40]. Recently one study found in the bronchoalveolar lavage fl uid 
besides an increase in proinfl ammatory mediators IL-8 and TNF-alpha also an increase in 
trombine-antithrombin complex (TATc), indicating activation of the coagulation system 
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in the lung [41]. Some observational studies showed an association between allogeneic 
blood transfusions and the development of venous thromboembolism [42-44]. Th e possible 
association between allogeneic blood transfusions and the formation of thrombosis, as a 
factor aggravating MODS and having a role in increased mortality due to MODS, is a new 
subject and should be investigated further. 
Th e Final 
Allogeneic blood transfusions are given at diff erent times during and aft er cardiac surgery. 
Any intervention by allogeneic RBC transfusions during an already existing infl ammatory 
cascade can be inappropriately timed and can induce a second-hit response. Th e presence 
of leukocytes in blood products induces the production and release of proinfl ammatory 
cytokines in the recipient, which can aggravate SIRS by both activation of the coagulation 
system and the infl ammatory response. Th is second-hit response induced by allogeneic 
leukocytes (and possibly by platelet transfusions as well) may be in combination with 












Figure 2 | Relation between allogeneic blood transfusions, infl ammation and coagulation.
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 To understand the differences between leukocyte-containing and leukocyte-depleted RBC 
transfusions we investigated several possible causal mechanisms. Soluble mediators derived 
from deteriorating leukocytes during storage of RBC are unlikely to play a role. This is 
demonstrated in the first RCT, which observed equal benefit of post- and prestorage filtered 
RBCs [9]. The complement activation by lectin pathway may be relevant to explore as a 
causal deleterious effect of plasma transfusions, although does not explain excess death by 
MODS in association with allogeneic leukocytes. An acute phase reaction represented by 
procalcitonin could be excluded as a mediator induced by allogeneic leukocytes. A difference 
in cytokine responses in the recipient was the only significant factor that could be identified 
as playing a possible causal role (Table 2). Effects of allogeneic leukocytes and also activated 
platelet transfusions could influence this difference by enhancing interaction between both 
inflammatory and coagulation systems. 
Table 2 | Factors Related with Outcome after Cardiac Surgery in Relation with Allogeneic 
Leukocytes
Possible factors Relation with allogeneic leukocytes
Effects of RBC storage lesions
Investigated by the storage time of RBCs (Chapter 5)
Not related
Effects of stored plasma-derived factors
Investigated by fresh-filtered and stored-filtered RBCs [9]
Not related
Activation of the complement system by lectin pathway
Investigated substrate: MBL (Chapter 6)
Not related
Activation of the inflammatory systems
Investigated substrates: IL-6,IL10 and IL-12 (Chapter 5)
Higher pro-inflammatory and lower anti-inflammatory 
cytokines
Acute phase reaction
Investigated substrate: procalcitonin (Chapter 6)
Not related
Activation of the coagulation system
Not investigated
???
The abundant presence of allogeneic leukocytes in blood products is history in the 
Netherlands and in many well-resourced countries. It seems that cardiac surgery patients 
are one of the minorities that benefit from this change intended to reduce transmission of 
vCJD. Donor lymphocytes and granulocyte transfusions are currently only used in special 
cases in the treatment of hematologic malignancies. Therefore this thesis may be considered 
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as the “Swan Song” of allogeneic leukocytes in blood products. However the debate about 
transfusion of (non)-leukoreduced blood products is still continuing [45]. Furthermore other 
factors, such as plasma and platelet transfusions (due to activation or storage lesions) and 
the (possible) activation of the coagulation system by the allogeneic blood transfusions, may 
remain to play important roles in the development of transfusion-associated complications 
and are issues for further research in cardiac surgery. Th us many residual questions have still 
to be answered in the future. 
Discussion and Future Perspectives | 161
REFERENCES
1. Opelz G, Sengar DDS, Mickey MR, et al. Eff ect of blood transfusions on subsequent kidney transplants. 
Transplant Proc 1973; 5:253-259.
2. Gantt CL. Red blood cells for cancer patients. Lancet 1981; 2:363.
3. Houbiers JGA, Brand A, van de Watering LMG, Hermans J, Verwey PI, Bijnen AB, van de Velde CHJ. A 
randomized controlled trial comparing the prognosis of colorectal cancer patients transfused with either 
leukocyte depleted or buff y coat depleted blood. Lancet 1994; 344:573-578.
4. van de Watering LM, Brand A, Houbiers JG, Klein Kranenberg WM, Hermans J, van de Velde C; Cancer 
Recurrence and Blood Transfusion study group. Perioperative blood transfusions, with or without 
allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001; 88:267-272.
5. Skanberg J, Lundholm K, Haglind H. Eff ects of blood transfusion with leucocyte depletion on length 
of hospital stay, respiratory assistance and survival aft er curative surgery for colorectal cancer. Acta 
Oncologica 2007; 46:1123-1130.
6. Vamvakas EC. Why have meta-analysis of randomised controlled trials of the association between non-
white-blood-cell-reduced allogeneic blood transfusion and postoperative infection produced discordant 
results? Vox Sang 2007; 93:196-207.
7. van Hilten JA, van de Watering LM, van Bockel JH, van de Velde CJ, Kievit J, Brand R, van den Hout 
WB, Geelkerken RH, Roumen RM, Wesselink RM, Koopman-van Gemert AW, Koning J, Brand A. 
Eff ects of transfusion with red cells fi ltered to remove leucocytes:randomised controlled trial in patients 
undergoing major surgery. BMJ 2004; 328:1281-1284. 
8. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood 
reviews 2007; 21:327-348.
9. van de Watering LMG, Hermans J, Houbiers JGA, van den Broek PJ, Bouter H, Boer F, Harvey MS, 
Huysmans HA, Brand A. Benefi cial eff ects of leukocyte depletion of transfused blood on postoperative 
complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 
97:562-568.
10. Despotis G, Eby, C, Lublin DM. A review of transfusion risks and optimal management of perioperative 
bleeding with cardiac surgery. Transfusion 2008; 48:2S-30S.
11. Bracey AW, Radovancevic R, Nussmeier NA. Leukocyte-depleted blood in open-heart surgery patients: 
eff ects on outcome. Transfusion 2002; 42(Suppl):5S (Abstract).
12. Wallis JP, Chapman CE, Orr KE, Clark SC, Forty JR. Eff ect of WBC reduction of transfused RBCs on 
postoperative infection rates in cardiac surgery. Transfusion 2002; 42:1127-1134.
13. Connery CP, Toumpoulis IK, Anagnostopoulis CE, Hillei Z, Rahman FG, Katritsis D, Swistel DG. Does 
leukofi ltration reduce pulmonary infections in CABG patients? A prospective, randomised study with 
early results and mid-term survival. Acta Cardiol 2005; 60:285-293.
14. Boshkov LK, Chien G, VanWinkle D, Furnary AP, Wu Y, Grunkemeirer GL, Morris CD. Prestorage 
leukoreduction of transfused packed red cells is associated with signifi cant ongoing 1-12 month survival 
benefi t cardiac surgery patients. Blood 2006; 108:578 (Abstract).
15. Vamvakas EC. White-blood-cell-containing alloegenic blood transfusions and postoperative infection 
and mortality: an updated meta-analysis. Vox Sang 2007; 92:224-232. 
162 | Chapter 9
16. Postma MJ, van de Watering LMG, de Vries R, Versmoren D, van Hulst M, Tobi H, van der Poel CL, 
Brand A. Cost-eff ectiveness of leucocyte depletion of red-cell transfusions for patients undergoing 
cardiac surgery. Vox Sang 2003; 84:65-67.
17. Dinarello CA. Proinfl ammatory cytokines. Chest 2000; 118:503-508.
18. Opal SM, DePalo VA. Anti-infl ammatory cytokines. Chest 2000; 117:1162-1172.
19. Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact of blood transfusions on infl ammatory 
mediator release in patients undergoing cardiac surgery. Chest 1999; 116:1233-1239.
20. Kirkley SA. Cowles J, Pellegrini VD, Harris CM, Boyd AD, Blumberg N. Blood transfusion and total 
joint replacement: T helper 2 cytokine secretion and clinical outcome. Transf Med 1998; 8:195-204.
21. Ertel W, Keel M, Neidhardt R, Steckholzer U, Kremer JP, Ungethuem U, Trentz O. Inhibition of 
the defence system stimulating IL-12 Interferon-gamma pathway during critical illness. Blood 1997; 
89:1612-1620.
22. Falcoz PE, Laluc F, Toubin MM, Puyraveau M, Clement F, Mercier M, Chocron S, Etievent JP. Usefulness 
of procalcitonin in the early detection of infection aft er thoracic surgery. Eur J Cardiothorac Surg 2005; 
27:1074-1078.
23. Fidler KJ, Wilson P, Davies JC, Turner MW, Peters MJ, Klein NJ. Increased incidence and severity of the 
systemic infl ammatory response syndrome in patients defi cient in mannose-binding lectin. Intensive Care 
Med 2004; 30:1438-45.
24. Garred PJ, Strom JJ, Quist L, Taaning E, Madsen HO. Association mannose-binding lectin polymorphisms 
with sepsis and fatal outcome in patients with systemic infl ammatory response syndrome. J Infect Dis 
2003; 188:1394-1403.
25. Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic 
myocardial reperfusion injury. Circulation 2001; 104:1413-8.
26. Blumberg N, Heal JM, Gettings KF, Phipps RP, Masel D, Refaai MA, Kirkley SA, Fialkow LB. An 
association between decreased cardiopulmonary complications (transfusion-related acute lung injury and 
transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood 
transfusions. Transfusion 2010; 50:2738-2744.
27. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, Murkin J, Nadel A. Platelet transfusions 
during CABG surgery are associated with serious adverse outcomes. Transfusion 2004; 44:1143-1148.
28. Khan H, Belsher J, Yilmaz M, Winters JL, Moore SB, Hubmayr RD, Gajic O. Fresh-frozen plasma are 
associated with development of acute lung injury in critically ill medical patients. Chest 2007;131:1308-
1314.
29. Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Meineri M, Wasowicz M, McCluskey SA, Beattie 
WS. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Can 
J Anesth 2006; 53:279-287. 
30. McGrath T, Koch CG, Xu M, Li L, Mihaljevic T, Figueroa P, Blackstone EH. Platelet transfusion in 
cardiac surgery does not confer increased risk for adverse morbid outcomes. Ann Th orac Surg 2008; 
86:543-553.
31. Banbury MK, Brizzio ME, Rajeswaran J, Lytle BW, Blackstone EH. Transfusion increases the risk of 
postoperative infection aft er cardiac surgery. J Am Coll Surg 2006;202:131-138.
32. Sreeram GM, Welsby IJ, Sharma AD, Philips-Bute B, Smith PK, Slaughter TF. Infectious complications 
aft er cardiac surgery: lack of association with FFP or platelet transfusions. J Cardiothoracic Vasc 
Anesthesia 2005;19:430-434.
Discussion and Future Perspectives | 163
33. Mangano DT, for the multicenter study of perioperative ischemia research group. Aspirin and mortality 
from coronary bypass surgery. N Engl J Med 2002; 347:1309-1317.
34. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Defi nitions 
for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Th e ACCP/SCCM 
Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care 
Medicine. Chest 1992; 101:1644-1655.
35. Bone RC. Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med 1996; 24:1125-1128.
36. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, Buller HR. Pharmacological 
strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant 
endpoints. Lancet 1999; 354:1940-1947.
37. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010; 38 
(Suppl):S35-S42.
38. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and infl ammation and the coagulation system. 
Cardiovasc Res 2003;60:23-39.
39. Keating FK, Butenas S, Fung MK, Schneider DJ. Platelet-white blood cell (WBC) interaction, WBC 
apoptosis and procoagulant activity in stored red blood cells. Transfusion 2011; 51:1086-1095.
40. Blumberg N, Gettings KF, Turner C, Heal JM, Phipps RP. An association of soluble CD40 ligand 
(CD154) with adverse reactions to platelet transfusions. Transfusion 2006; 46:1813-1821.
41. Tuinman PR, Vlaar AP, Cornet AD, Hofstra JJ, Levi M, Meijers JCM, Beishuizen A, Schultz MJ, 
Groeneveld ABJ, Juff ermans NP. Blood transfusion during cardiac surgery is associated with infl ammation 
and coagulation in the lung: a case control study. Crit Care 2011; 15:R59. 
42. Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between 
venous thromboembolism and perioperative allogeneic transfusion. Arch Surg 2007; 142:126-132.
43. Gangireddy C, Rectenwald JR, Upchurch GR, Wakefi eld TW, Khuri S, Henderson WG, Henke PK. Risk 
factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 
45:335-342. 
44. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, 
thrombosis and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168:2377-2381. 
45. Rosenbaum L, Tomasulo P, Lipton KS, Ness P. Th e reintroduction of nonleukoreduced blood: would 




166 | Chapter 10
SUMMARY 
Worldwide more than 800.000 patients undergo cardiac surgery annually, in the Netherlands 
this regards 1 of 1.000 inhibitants. To compensate blood loss during and aft er cardiac surgery 
a lot of allogeneic blood is oft en transfused. Blood transfusions can cause unexpected 
adverse reactions. In Chapter 1 we discuss immunologic and non-immunologic transfusions 
reactions. Th e association between blood transfusions and higher morbidity and mortality 
in patients who underwent cardiac surgery and in intensive-care-unit-(ICU)-patients is 
discussed in detail. Special attention is given to transfusion-related immunomodulation 
(TRIM). Th e exact mechanism of TRIM is not known, although it has been suggested 
that allogeneic leukocytes and leukocyte-derived mediators play a prominent role in the 
development of TRIM. By fi ltration the number of allogeneic leukocytes in donated blood 
can be reduced by more than 99.9%. In the past leukocyte-depleted (or leukocyte-reduced) 
red blood cells (RBCs) were transfused to selected patient populations. For the fi rst time 
the benefi cial eff ects of leukocyte-depleted red blood cells on postoperative mortality (due 
to multiple-organ-dysfunction-syndrome [MODS]) was shown in the Netherlands in a 
randomized controlled trial in patients who underwent cardiac surgery. 
 In Chapter 2 the results of a new randomized controlled trial in 474 patients 
undergoing cardiac valve surgery is presented. Patients receiving buff y-coat depleted (which 
contain 20-30% donor leukocytes) allogeneic RBC transfusions had a (dose-dependent) 
higher hospital-mortality and postoperative infection rates than patients receiving leukocyte-
depleted red blood cell transfusions. Th e incidences of 90-day mortality, multiple-organ-
dysfunction-syndrome, ICU-stay and hospital-stay were not diff erent between both groups. 
 To investigate the causes of these diff erences between leukocyte-containing allogeneic 
RBC transfusions and leukocyte-depleted RBC transfusions, data from two randomized 
controlled trials were pooled. In Chapter 3 the results of this re-analysis of 1.085 patients 
are presented. Th e results revealed that mortality associated with postoperative infections 
was higher in the patients receiving leukocyte-containing allogeneic RBC transfusions than 
leukocyte-depleted RBC transfusions. Although mortality not associated with postoperative 
infections was similar in both groups. Th e only cause of death that diff ered signifi cantly 
between both groups was the combination of multiple-organ-dysfunction-syndrome and 
infections. Th is re-analysis shows that allogeneic leukocytes transfused during cardiac 
surgery may be associated with more infections with fatal outcome. 
 Chapter 4 is a review of all randomized controlled trials investigating the eff ects 
of leukocyte-depleted RBC transfusions. Th e study conclusions are that in contrast to 
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confl icting outcomes in diff erent clinical studies, in cardiac surgery there is evidence that 
leukocyte-depleted RBC transfusions have benefi ts by lowering postoperative complications. 
As possible explanation for these results in cardiac surgery, we suggest that leukocyte-
containing blood transfusions act as a second insult to the development of surgery-induced 
systemic infl ammatory response.
 To investigate the role of allogeneic leukocytes on several mediators in relation with 
postoperative complications laboratory analyses were performed. Th erefore blood samples 
were taken in patients participating in the randomized controlled trial described in Chapter 
2. In Chapter 5 the eff ects of RBC transfusions on infl ammatory markers are presented. Th e 
results revealed that patients who received more than 3 red blood cell units had signifi cantly 
higher cytokine IL-6 concentrations aft er leukocyte-containing, buff y-coat depleted RBC as 
compared to patients who had received similar numbers of leukocyte-depleted RBC units. 
Patients who developed postoperative infections and multiple-organ-dysfunction-syndrome 
showed, respectively, increased concentrations of cytokines IL-6 and IL-12 in the group that 
received leukocyte-containing RBC units. Th is analysis suggests that leukocyte-containing 
RBC transfusions may aff ect the development of postoperative complications by modulation 
of the postoperative proinfl ammatory response aft er cardiac surgery. In Chapter 6 we present 
the eff ects of blood transfusions on mannose-binding lectin (MBL), a recognition molecule 
of the lectin pathway of the complement system, and the clinical role of MBL aft er cardiac 
surgery. Cardiac surgery was associated with MBL consumption, independent of transfusion 
of allogeneic leukocytes. Patients with MBL-defi ciency developed no MODS, unless they 
have been transfused with plasma units. Th is suggests that plasma transfusions is associated 
with MBL reconstitution and can have a deleterious eff ect in cardiac surgery. In Chapter 7 
the cost-eff ectiveness of transfusion of leukodepleted RBCs has been estimated. Th is analysis 
revealed that leukodepletion of RBCs is cost eff ective in cardiac valve surgery.
 In Chapter 8 the clinical eff ects of plasma and platelet transfusions during cardiac 
surgery are shown. Th ese additional analyses from data of the two randomized controlled 
trials revealed that plasma transfusions was associated with all-cause mortality, while (in 
particular leukocyte-containing) RBC and platelet transfusions are both independently 
associated with postoperative infections and longer ICU-stay. 
 In Chapter 9 we discuss all results of the studies described in this thesis in their 
current scientifi c perspective. Finally possible direction for future studies are provided.
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SAMENVATTING 
Wereldwijd ondergaan jaarlijks meer dan 800.000 patiënten een open-hart operatie; in 
Nederland wordt 1 op de 1.000 inwoners geopereerd. Om bloedverlies te compenseren wordt 
tijdens en na een open-hart operatie vaak allogeen bloed getransfundeerd. Bloedtransfusies 
kunnen verschillende onverwachte bijwerkingen veroorzaken. In Hoofdstuk 1 worden 
de meest klinisch relevante immunologische en non-immunologische transfusie reacties 
besproken. De associatie tussen bloedtransfusies en hogere morbiditeit en mortaliteit 
bij intensive-care (IC)-patiënten en patiënten die een hartoperatie ondergingen wordt 
uitvoerig bediscussieerd. Speciale aandacht wordt gegeven aan transfusie-gerelateerde 
immunomodulatie (TRIM). Het exacte mechanisme van TRIM is niet bekend, maar er 
wordt wel gesuggereerd dat allogene leukocyten en van leukocyten afgeleide mediatoren 
een prominente rol spelen in de ontwikkeling van TRIM. Door middel van fi ltratie 
kan het aantal leukocyten van het gedoneerde bloed met meer dan 99.9% gereduceerd 
worden. In het verleden werden leukocyten-gedepleteerde (leukocyten-gereduceerde) rode 
bloedcellen getransfundeerd aan geselecteerde patiëntenpopulaties. In een gerandomiseerde 
gecontroleerde trial uit Nederland werd voor het eerst de gunstige eff ecten van leukocyten-
gedepleteerde rode bloedcellen op postoperatieve infecties en mortaliteit (ten gevolge 
van multi-orgaan-dysfunctie-syndroom [MODS]) bij patiënten die een hartchirurgie 
ondergingen aangetoond. Deze patiënten hadden minder postoperatieve infecties en ook de 
sterft e na operatie was gereduceerd.
 In Hoofdstuk 2 worden de resultaten van een nieuwe gerandomiseerde gecontroleerde 
trial bij patiënten die een hartklep-operatie ondergingen gepresenteerd. Patiënten die allogene 
buff y-coat gedepleteerde (bevatten 20-30% donor leukocyten) rode bloedceltransfusies 
ontvingen, hadden een (dosisafh ankelijk) hogere ziekenhuissterft e en postoperatieve 
infecties dan bij patiënten die leukocyten-gedepleteerde rode bloed celtransfusies ontvingen. 
Terwijl de incidenties van 90-dagen mortaliteit, MODS, IC-verblijf en ziekenhuis-verblijf 
niet verschillend waren niet verschillend tussen de beide groepen.
 Om de oorzaken van deze verschillen tussen allogene leukocyten-bevattende rode 
bloed celtransfusies en leukocyten-gedepleteerde rode bloed celtransfusies te onderzoeken 
werden de gegevens van twee gerandomiseerde gecontroleerde studies samengevoegd. In 
Hoofdstuk 3 worden de resultaten van deze re-analyse van 1.085 patiënten gepresenteerd. 
Uit deze resultaten bleek dat de sterft e geassocieerd met postoperatieve infecties hoger was 
bij de patiënten die allogene leukocyten-bevattende rode bloed celtransfusies kregen dan 
bij patiënten die leukocyten-gedepleteerde rode bloed celtransfusies ontvingen; hoewel de 
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sterft e niet geassocieerd met postoperatieve infecties vergelijkbaar was in beide groepen. 
De enige doodsoorzaak die signifi cant verschilde tussen beide groepen was de sterft e ten 
gevolge van de combinatie van MODS en infecties. Deze re-analyse toont aan dat allogene 
leukocyten die tijdens hartchirurgie getransfundeerd worden, geassocieerd kunnen zijn met 
meer infecties met een fatale afl oop.
 In Hoofdstuk 4 wordt een overzicht van alle gerandomiseerde gecontroleerde studies 
die de eff ecten van leukocyt-gedepleteerde rode bloed celtransfusies hebben onderzocht 
weergegeven. We vonden dat in tegenstelling tot de tegenstrijdige resultaten in verschillende 
klinische studies, in hartchirurgie er weldegelijk bewijs is dat leukocyten-bevattende rode 
bloedceltransfusies nadelige eff ecten hebben op postoperatieve complicaties. Tevens 
bespreken we de mogelijke verklaringen voor deze resultaten in hartchirurgie. Wij suggereren 
dat leukocyten-bevattende rode bloedceltransfusies fungeren als een tweede insult voor de 
ontwikkeling van operatie-geïnduceerde systemische infl ammatoire respons.
 Om de rol van allogene leukocyten te onderzoeken in relatie met verschillende 
mediatoren met postoperatieve complicaties werden laboratorium analyses uitgevoerd. 
Hiervoor werden er bloedmonsters afgenomen bij patiënten die deelnamen aan de 
gerandomiseerde gecontroleerde studie beschreven in Hoofdstuk 2. In Hoofstuk 5 worden 
de eff ecten van bloedtransfusies op infl ammatoire markers gepresenteerd. De resultaten 
laten zien dat patiënten die 4 of meer eenheden rode bloedcellen ontvingen signifi cant 
hogere cytokine IL-6 concentraties hadden in de leukocyten-bevattende, buff y-coat-
gedepleteerde groep dan in de leukocyten-gedepleteerde groep. Patiënten die postoperatieve 
infecties en multiple-organ-dysfunctie-syndroom ontwikkelden hadden respectievelijk 
hogere concentraties cytokines IL-6 en IL-12 in de leukocyten-bevattende, buff y-coat-
gedepleteerde groep dan in de leukocyten-gedepleteerde groep. Uit deze analyse bleek dat 
transfusie van leukocyt-bevattende rode bloedcellen van invloed is op de ontwikkeling van 
postoperatieve complicaties door modulatie van het pro-infl ammatoire postoperatieve reactie 
na een hartoperatie. In Hoofdstuk 6 worden de eff ecten van bloedtransfusies op mannose-
binding lectine (MBL), een molecuul van de lectine-route van het complement systeem, en 
de klinische rol van MBL na hartchirurgie gepresenteerd. Hartchirurgie was geassocieerd 
met MBL consumptie, onafh ankelijk van de transfusie van allogene leukocyten. Patiënten 
met een MBL-defi ciëntie ontwikkelden geen MODS, tenzij zij getransfundeerd werden 
met plasma-eenheden. Dit suggereert dat transfusie van plasma-eenheden geassocieerd 
is met reconstitutie van MBL en schadelijke eff ecten kan hebben bij hartchirurgie. In 
Hoofdstuk 7 wordt een schatting gemaakt van de kosten-eff ectiviteit van transfusie van 
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leukocyten-gedepleteerde rode bloedcellen in hartklepchirurgie. Deze analyse toonde aan 
dat leukodepletie van rode bloedcellen kosten besparend is in hartklepchirurgie.
 In Hoofdstuk 8 worden de klinische eff ecten van transfusies van plasma en 
bloedplaatjes tijdens hartchirurgie getoond. Bij deze aanvullende analyse van data van 
de twee gerandomiseerde gecontroleerde studies is gebleken dat transfusie van plasma 
geassocieerd was met sterft e, terwijl transfusies van (in het bijzonder leukocyten-bevattende) 
rode bloedcellen en bloedplaatjes signifi cant geassocieerd waren met postoperatieve infecties 
en langer IC-verblijf.
 In Hoofdstuk 9 bespreken we alle resultaten van de studies beschreven in dit 
proefschrift  binnen hun huidige wetenschappelijke perspectieven. Ten slotte, worden 
mogelijke richtingen voor toekomstig onderzoek gegeven. 
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De zwanenzang is een verwijzing naar de mythe dat een zwaan als hij zijn einde voelt 
aankomen, uit blijdschap voor de weldaden die hem te wachten staat na de dood, nog 
eenmaal wonderschoon zingt. Toen ik dit las, dacht ik aan de allogene leukocyt die aanleiding 
gaf voor vele onderzoeken die mijn illustere voorgangers verrichten. Na een proefschrift  
volgeschreven te hebben verdwijnt de allogene leukocyt als wetenschappelijk object uit ons 
leven. Echter in mijn dagelijkse leven zal deze cel met een diameter van 0,000001 meter op 
allerlei manieren een rol blijven spelen! 
 In dit proefschrift  is veel over de witte bloedcel in transfusie-eenheden geschreven. 
Maar het onzichtbare is dat de veel analyses en schrijfwerk tijdens de nachtdiensten werd 
verricht. Daarom zou het toepasselijk geweest zijn als de verdediging ook ’s nachts kon 
plaatsvinden! 
 In deze zwanenzang van mijn proefschrift  zal ik nu aantal mensen proberen te 
bedanken. Allereerst dank ik Professor Brand, mijn promotor. Anneke, vanaf het begin van 
het promotie-traject kon ik altijd bij je aankloppen. Je inzet, suggesties en ideeën om van 
één studie een heel proefschrift  te maken verdient ontzag. Ook respecteer ik jouw oprechte 
interesse in de mensen die met jou werken. Wens je veel succes bij Europdonor en hoop dat 
ik nog altijd bij je kan aankloppen.
 Professor van Oers, Rien, mede-promotor. Ik heb in die korte periode met plezier 
met je samengewerkt. Bedankt voor de gelegenheid dat ik (uit Rotterdam) in Amsterdam 
de basis van het doen van wetenschappelijk onderzoek mocht leren en in de keuken van de 
hematologie mocht meekijken. Helaas is het contact daarna vooral via e-mail gebleven. Bij 
Leo van de Watering, illustere voorganger, was ik altijd welkom om een analyse uit te voeren 
of een manuscript te bespreken. Je hebt jezelf bewezen als co-promotor, bedankt! 
 De leden van de leescommissie, Professor Kluin-Nelemans en Professor Klautz, 
dank ik voor het kritisch lezen van het manuscript. I thank Professor Vamvakas for his 
contribution, it is a great honour that you can come to the defending of my thesis. 
 Mijn klinische loopbaan begon ooit in het Leyenburg-ziekenhuis. Daar ben ik 
door de bevlogenheid van de internisten aangestoken en heb ik besloten om internist te 
worden. Een speciale dank gaat naar Dr van der Vijver voor de vele leermomenten (van 
het nemen van een bloedkweek tot en met de betekenis van de zwanenzang). In Leiden 
kon ik verder mijn onderzoek uitwerken en verdiepen in de transfusie-geneeskunde op de 
afdeling Immunohematologie en Bloedtransfusie. Daarvoor dank ik Professor de Vries en 
alle medewerkers van het transfusie-lab, de hemaferese-afdeling en het stamcel-lab. 
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In het IJsselland-ziekenhuis begon ik dan uiteindelijk met de opleiding. Ik dank de opleiders 
Dr Fischer en Dr van der Wiel voor het vertrouwen die ik kreeg. En natuurlijk bedank ik alle 
andere internisten en de vele collega’s voor de vele leuke momenten.
 Uiteraard gaat mijn dank uit naar de hoofd-opleider, Professor van Saase, voor 
de kans om de opleiding in Rotterdam te starten en het onderzoek in Leiden te kunnen 
afmaken. Het was niet mijn bedoeling om tijdens mijn opleiding te verdiepen in een stukje 
neurologie, maar soms lopen de dingen eenmaal zo. Zal uw bezoek na mijn operatie nooit 
vergeten. Mijn dank is dan ook erg groot dat u als eerste aangaf plaats te willen nemen in de 
promotiecommissie. Tevens dank ik de vele collega’s in het Erasmus MC voor de grote steun. 
 Verder gaat mijn dank uit naar mijn opleiders in de hematologie voor het vertrouwen 
en de mogelijkheid om me verder te verdiepen in het mooiste deel-specialisme van de interne 
geneeskunde. Ik dank ook alle stafleden, chefs en junioren voor de prettige samenwerking. 
In het bijzonder noem ik Ward Libourel, al meer dan 10 jaar (met tussenpozen) collega. 
Ook Aysel Darbas, al meer dan 10 jaar goede vriendin, verdient een bijzondere vermelding. 
Speciaal dank gaat ook uit naar Nazik Rayman, meer dan 10 jaar vriendin. Uiteindelijk ben 
jij mij met 5 dagen voorgegaan met je promotie. Gefeliciteerd en bedankt dat je paranimf 
wilde worden. 
 Niet te vergeten wil ik de medewerkers van de afdelingen cardio-thoracale chirurgie 
en de IC’s van het AMC en het LUMC bedanken voor de bereidheid mee te werken aan ons 
project, vooral het AKC en het transfusie-lab van het AMC dank ik voor de gastvrijheid.  
De medewerkers van Sanquin O&O bedankt voor de steun, vooral Jos Lorinser. De man die 
nooit nee zegt, ook niet om paranimf te worden. Apart dient vermeld te worden Jean-Louis 
Kerkhoffs, al meer dan 10 jaar meerdere keren collega.
 Dan zijn er de vele co-auteurs. Michel Versteegh, bedankt voor de correcties. Anja 
Roos, Stefan Berger en Professor Daha bedankt voor de analyse en tekst beschreven in 
Hoofdstuk 6. Tevens bedank ik Professor Ronald Brand voor zijn voortreffelijke statische 
bijdragen. En Rene van Hulst en Professor Postma bedankt voor de kosteneffectiviteit-
analyse beschreven in Hoofdstuk 7.
 Mijn ouders en mijn zusje, Gülgün, zijn uiteraard het belangrijkste. Om hun te 
bedanken heb ik geen woorden voor, noch in het Nederlands en noch in het Turks. Toch 
maar een kleine poging. Sevgili ailem, yıllardan beri sabırla verdiğiniz desteğiniz ve güveniniz 
icin teşekkür eder, dualarınızın kabulünü niyaz ederim. Allah sizden razı olsun.
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CURRICULUM VITAE
De auteur van dit proefschrift werd op 5 maart 1970 geboren te Eindhoven. Hij behaalde 
in 1989 zijn VWO diploma aan de Gemeentelijke Scholengemeenschap Genderdal 
te Eindhoven. Nadien ging hij geneeskunde studeren aan de Erasmus Universiteit te 
Rotterdam (1989-1997). Na zijn studie werkte hij als arts-assistent niet in opleiding op de 
afdelingen Interne Geneeskunde en Cardiologie van het toenmalige Leyenburg-ziekenhuis 
(tegenwoordig Haga ziekenhuis) te Den Haag (1998-1999). Vanaf 2000 werkte hij als arts-
onderzoeker op de afdeling Hematologie aan het AMC te Amsterdam (Onder supervisie 
van Prof. Dr. M.H.J. van Oers), waar een begin aan dit proefschrift werd gemaakt. Vanaf 
2002 werkte hij als arts-assistent niet in opleiding bij de afdeling Immunohematologie en 
Bloedtransfusie van het Leids Universitair Medisch Centrum; dit proefschrift werd daar 
tevens verder uitgewerkt. In mei 2005 werd de opleiding tot internist gestart in het IJsselland 
ziekenhuis te Capelle aan den IJssel (Opleiders: Dr. H.R.A. Fischer en Dr. H.E. van der Wiel). 
De opleiding werd vanaf mei 2007 voortgezet in het Erasmus MC te Rotterdam (Opleider: 
Prof. Dr. J.L.C.M. van Saase). In september 2009 werd de opleiding tot hematoloog gestart 
eveneens in het Erasmus MC te Rotterdam (Opleiders: Prof. Dr. P. Sonneveld en Prof. Dr. J.J. 
Cornelissen). Vanaf augustus 2010 is de auteur geregistreerd als internist. Vanaf september 
2011 werkt hij als internist-hematoloog op de afdeling Hematologie van het Erasmus 
MC. In 2001 werd de Jaap Steenbergen Stipendium tijdens de najaarsvergadering van de 
Nederlandse Vereniging voor Haematologie voor de beste presentatie ontvangen en in 2003 
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